{"cbfcc8ef7d0b19fda8e3d2001b34744c303af83b": [["WHAT IS ALREADY KNOWN ON THIS TOPICThere are several reports about the serum antibodies against SARS-CoV-2.", [["serum", "ANATOMY", 71, 76], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["SARS-CoV-2", "ORGANISM", 96, 106], ["serum antibodies", "PROTEIN", 71, 87], ["SARS-CoV", "SPECIES", 96, 104], ["the serum antibodies", "TEST", 67, 87], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104]]], ["However, most of them evaluate diagnostic accuracy.", [["diagnostic accuracy", "TEST", 31, 50]]], ["Only two articles report dynamics of SARS-CoV-2 viral RNA and antibodies with serial samples, but the observation periods are within 30 days.", [["samples", "ANATOMY", 85, 92], ["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["SARS-CoV-2 viral RNA", "RNA", 37, 57], ["antibodies", "PROTEIN", 62, 72], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["2 viral RNA", "PROBLEM", 46, 57], ["serial samples", "TEST", 78, 92]]], ["None of the studies investigate the profiles of SARS-CoV-2 viral load and antibodies in a long period.", [["SARS-CoV-2", "ORGANISM", 48, 58], ["viral", "ORGANISM", 59, 64], ["antibodies", "PROTEIN", 74, 84], ["SARS-CoV", "SPECIES", 48, 56], ["the studies", "TEST", 8, 19], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["viral load", "TEST", 59, 69], ["antibodies", "TEST", 74, 84]]], ["Three reports investigate profiles in respiratory samples, but there are no reports on the dynamics of the viral load in stool samples.WHAT THIS STUDY ADDSIn both sputum and stool, SARS-CoV-2 RNA persists for a long time.", [["respiratory samples", "ANATOMY", 38, 57], ["stool samples", "ANATOMY", 121, 134], ["sputum", "ANATOMY", 163, 169], ["stool", "ANATOMY", 174, 179], ["stool samples", "ORGANISM_SUBSTANCE", 121, 134], ["sputum", "ORGANISM_SUBSTANCE", 163, 169], ["stool", "ORGANISM_SUBSTANCE", 174, 179], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 181, 191], ["SARS-CoV-2 RNA", "RNA", 181, 195], ["SARS-CoV", "SPECIES", 181, 189], ["respiratory samples", "TEST", 38, 57], ["the viral load in stool samples", "TEST", 103, 134], ["THIS STUDY", "TEST", 140, 150], ["sputum", "TEST", 163, 169], ["stool", "TEST", 174, 179], ["SARS", "TEST", 181, 185], ["CoV", "TEST", 186, 189], ["respiratory samples", "OBSERVATION", 38, 57], ["stool", "ANATOMY", 174, 179]]], ["The anti-RBD antibodies may involve in the clearance of SARS-CoV-2 infection.", [["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 67, 76], ["anti-RBD antibodies", "GENE_OR_GENE_PRODUCT", 4, 23], ["SARS-CoV-2", "ORGANISM", 56, 66], ["anti-RBD antibodies", "PROTEIN", 4, 23], ["SARS-CoV-2", "SPECIES", 56, 66], ["The anti-RBD antibodies", "TREATMENT", 0, 23], ["SARS", "PROBLEM", 56, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["infection", "OBSERVATION", 67, 76]]], ["After eight weeks from symptom onset, IgM were negative in many of the previously positive patients, and IgG levels remained less than 50% of the peak levels in more than 20% of the patients.", [["IgM", "GENE_OR_GENE_PRODUCT", 38, 41], ["patients", "ORGANISM", 91, 99], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["patients", "ORGANISM", 182, 190], ["IgM", "PROTEIN", 38, 41], ["IgG", "PROTEIN", 105, 108], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 182, 190], ["symptom onset", "TEST", 23, 36], ["IgM", "TEST", 38, 41], ["IgG levels", "TEST", 105, 115], ["the peak levels", "TEST", 142, 157]]], ["In about 40% of the patients, anti-RBD IgG levels increased 4-time higher in convalescence than in acute phase.", [["patients", "ORGANISM", 20, 28], ["anti-RBD IgG", "GENE_OR_GENE_PRODUCT", 30, 42], ["anti-RBD", "PROTEIN", 30, 38], ["IgG", "PROTEIN", 39, 42], ["patients", "SPECIES", 20, 28], ["anti-RBD IgG levels", "TEST", 30, 49]]], ["Long persistence of SARS-CoV-2 viral RNA in sputum and stool presents challenges for management of the infection.", [["sputum", "ANATOMY", 44, 50], ["stool", "ANATOMY", 55, 60], ["infection", "DISEASE", 103, 112], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["sputum", "ORGANISM_SUBSTANCE", 44, 50], ["stool", "ORGANISM_SUBSTANCE", 55, 60], ["SARS-CoV-2 viral RNA", "RNA", 20, 40], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["2 viral RNA in sputum", "PROBLEM", 29, 50], ["management", "TREATMENT", 85, 95], ["the infection", "PROBLEM", 99, 112], ["SARS", "OBSERVATION", 20, 24], ["CoV", "OBSERVATION_MODIFIER", 25, 28], ["viral RNA", "OBSERVATION", 31, 40], ["stool", "OBSERVATION", 55, 60], ["infection", "OBSERVATION", 103, 112]]], ["The IgM/IgG comb test is better than single IgM test as a supplement diagnostic tool.", [["IgM", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 8, 11], ["IgM", "PROTEIN", 4, 7], ["IgG", "PROTEIN", 8, 11], ["IgM", "PROTEIN", 44, 47], ["The IgM/IgG comb test", "TEST", 0, 21], ["single IgM test", "TEST", 37, 52]]], ["Anti-RBD may be a protective antibody, and is valuable for development of vaccines.WHAT THIS STUDY ADDSAll rights reserved.", [["RBD", "PROTEIN", 5, 8], ["a protective antibody", "TREATMENT", 16, 37], ["vaccines", "TREATMENT", 74, 82]]], ["No reuse allowed without permission.WHAT THIS STUDY ADDS(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.WHAT THIS STUDY ADDSThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["The copyright holder", "TREATMENT", 211, 231], ["med", "ANATOMY", 135, 138]]], ["22.20071258 doi: medRxiv preprint Introduction A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide.", [["coronavirus", "DISEASE", 55, 66], ["acute respiratory syndrome coronavirus", "DISEASE", 75, 113], ["SARS-CoV-2", "CHEMICAL", 117, 127], ["coronavirus", "ORGANISM", 55, 66], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 68, 115], ["SARS-CoV-2", "ORGANISM", 117, 127], ["coronavirus", "SPECIES", 55, 66], ["severe acute respiratory syndrome coronavirus", "SPECIES", 68, 113], ["SARS-CoV-2", "SPECIES", 117, 127], ["medRxiv", "TREATMENT", 17, 24], ["A novel coronavirus", "PROBLEM", 47, 66], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 68, 113], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome", "OBSERVATION", 81, 101], ["spread", "OBSERVATION_MODIFIER", 134, 140], ["worldwide", "OBSERVATION_MODIFIER", 141, 150]]], ["[1] [2] [3] As of April 18, 2020, more than 2,160,000 confirmed cases and more than 146,000 deaths have been reported.", [["deaths", "DISEASE", 92, 98]]], ["The clinical characteristics of SARS-CoV-2 pneumonia have been well defined.", [["SARS", "DISEASE", 32, 36], ["pneumonia", "DISEASE", 43, 52], ["SARS-CoV-2", "ORGANISM", 32, 42], ["CoV-2 pneumonia", "SPECIES", 37, 52], ["SARS-CoV-2", "SPECIES", 32, 42], ["SARS", "PROBLEM", 32, 36], ["CoV-2 pneumonia", "PROBLEM", 37, 52], ["SARS", "OBSERVATION", 32, 36], ["CoV", "OBSERVATION_MODIFIER", 37, 40], ["pneumonia", "OBSERVATION", 43, 52], ["well defined", "OBSERVATION_MODIFIER", 63, 75]]], ["According to a large-scale epidemiological study in China, among the confirmed cases, 86.6%WHAT THIS STUDY ADDSwere aged between 30-79 years, 63.8% were men, 80.9% were considered as mild pneumonia, and 2.3% have died.", [["pneumonia", "DISEASE", 188, 197], ["men", "ORGANISM", 153, 156], ["men", "SPECIES", 153, 156], ["mild pneumonia", "PROBLEM", 183, 197], ["mild", "OBSERVATION_MODIFIER", 183, 187], ["pneumonia", "OBSERVATION", 188, 197]]], ["4 Common symptoms include fever, cough, fatigue, and lymphopenia etc. [5] [6] [7] On admission, half of the patients present typical radiological ground-glass opacity on chest computed tomography (CT).", [["fever", "DISEASE", 26, 31], ["cough", "DISEASE", 33, 38], ["fatigue", "DISEASE", 40, 47], ["lymphopenia", "DISEASE", 53, 64], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["Common symptoms", "PROBLEM", 2, 17], ["fever", "PROBLEM", 26, 31], ["cough", "PROBLEM", 33, 38], ["fatigue", "PROBLEM", 40, 47], ["lymphopenia etc", "PROBLEM", 53, 68], ["typical radiological ground-glass opacity", "PROBLEM", 125, 166], ["chest computed tomography", "TEST", 170, 195], ["CT", "TEST", 197, 199], ["fever", "OBSERVATION", 26, 31], ["cough", "OBSERVATION", 33, 38], ["lymphopenia", "OBSERVATION", 53, 64], ["radiological", "OBSERVATION_MODIFIER", 133, 145], ["ground", "OBSERVATION_MODIFIER", 146, 152], ["glass opacity", "OBSERVATION", 153, 166], ["chest", "ANATOMY", 170, 175]]], ["8 Clearance of viral RNA and appearance of specific antibodies are essential for recovery from viral infection.", [["viral infection", "DISEASE", 95, 110], ["viral RNA", "RNA", 15, 24], ["specific antibodies", "PROTEIN", 43, 62], ["viral RNA", "PROBLEM", 15, 24], ["specific antibodies", "TEST", 43, 62], ["viral infection", "PROBLEM", 95, 110], ["viral RNA", "OBSERVATION", 15, 24], ["viral", "OBSERVATION_MODIFIER", 95, 100], ["infection", "OBSERVATION", 101, 110]]], ["SARS-CoV-2 viral load in respiratory samples rapidly increases soon after symptom onset and peaks at around 5-6 days.", [["respiratory samples", "ANATOMY", 25, 44], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["viral load", "TEST", 11, 21], ["respiratory samples", "TEST", 25, 44], ["symptom onset", "PROBLEM", 74, 87], ["respiratory", "ANATOMY", 25, 36]]], ["[9] [10] [11] During the convalescence period, the clearance of viral RNA in patients' stool is delayed compared to oropharyngeal swabs.", [["stool", "ANATOMY", 87, 92], ["oropharyngeal swabs", "ANATOMY", 116, 135], ["patients", "ORGANISM", 77, 85], ["stool", "ORGANISM_SUBSTANCE", 87, 92], ["oropharyngeal swabs", "PATHOLOGICAL_FORMATION", 116, 135], ["viral RNA", "RNA", 64, 73], ["patients", "SPECIES", 77, 85], ["viral RNA in patients' stool", "PROBLEM", 64, 92], ["oropharyngeal swabs", "TEST", 116, 135], ["viral RNA", "OBSERVATION", 64, 73]]], ["12 As recommended by the National Health Commission of the People's Republic of China, the criteria for discharge from the hospital are relieved symptoms and two successive negative viral nucleic acid results from respiratory samples separated by at least a 24 hour sampling interval.", [["respiratory samples", "ANATOMY", 214, 233], ["nucleic acid", "CHEMICAL", 188, 200], ["symptoms", "PROBLEM", 145, 153], ["two successive negative viral nucleic acid results", "PROBLEM", 158, 208], ["respiratory samples", "TEST", 214, 233]]], ["13 It has been reported that some patients have had a relapse of the viral RNA after discharge from the hospital.", [["patients", "ORGANISM", 34, 42], ["viral RNA", "RNA", 69, 78], ["patients", "SPECIES", 34, 42], ["the viral RNA", "PROBLEM", 65, 78], ["viral RNA", "OBSERVATION", 69, 78]]], ["14, 15 However, this report included only four patients, and thus cannot show a complete picture of the patients discharged from hospitals.", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 104, 112]]], ["At present, reports about the profile of SARS-CoV-2 viral load have been mainly focused on relatively short periods (less than one month).", [["SARS", "DISEASE", 41, 45], ["SARS-CoV-2", "ORGANISM", 41, 51], ["SARS-CoV", "SPECIES", 41, 49], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["viral load", "TEST", 52, 62]]], ["The long-term dynamics of the viral load remain unclear.WHAT THIS STUDY ADDSSerological responses in patients are essential for understanding the immunological mechanisms and the recovery process of viral infection.", [["viral infection", "DISEASE", 199, 214], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["the viral load", "TEST", 26, 40], ["the immunological mechanisms", "PROBLEM", 142, 170], ["viral infection", "PROBLEM", 199, 214], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["viral load", "OBSERVATION", 30, 40], ["viral", "OBSERVATION_MODIFIER", 199, 204], ["infection", "OBSERVATION", 205, 214]]], ["Several assays have been developed for the detection of specific IgM and IgG against SARS-CoV-2.", [["IgM", "GENE_OR_GENE_PRODUCT", 65, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 73, 76], ["SARS-CoV-2", "ORGANISM", 85, 95], ["IgM", "PROTEIN", 65, 68], ["IgG", "PROTEIN", 73, 76], ["SARS-CoV", "SPECIES", 85, 93], ["Several assays", "TEST", 0, 14], ["the detection", "TEST", 39, 52], ["specific IgM", "TEST", 56, 68], ["IgG", "TEST", 73, 76], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93]]], ["[16] [17] [18] These studies have focused either on the evaluation of detection methods, or the diagnostic value of IgM and IgG for SARS-CoV-2 infection.", [["infection", "DISEASE", 143, 152], ["IgM", "GENE_OR_GENE_PRODUCT", 116, 119], ["IgG", "GENE_OR_GENE_PRODUCT", 124, 127], ["SARS-CoV-2", "ORGANISM", 132, 142], ["IgM", "PROTEIN", 116, 119], ["IgG", "PROTEIN", 124, 127], ["SARS-CoV-2", "SPECIES", 132, 142], ["These studies", "TEST", 15, 28], ["the evaluation", "TEST", 52, 66], ["detection methods", "TEST", 70, 87], ["IgM", "TEST", 116, 119], ["IgG", "TEST", 124, 127], ["SARS", "PROBLEM", 132, 136], ["CoV", "PROBLEM", 137, 140], ["2 infection", "PROBLEM", 141, 152], ["infection", "OBSERVATION", 143, 152]]], ["16, 17 Only two studies investigated the dynamics of IgM and IgG.", [["IgM", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgM", "PROTEIN", 53, 56], ["IgG", "PROTEIN", 61, 64], ["two studies", "TEST", 12, 23], ["IgM", "TEST", 53, 56], ["IgG", "TEST", 61, 64]]], ["Those studies reported that the median seroconversion time of IgM and IgG was 12 and 14 days, respectively, and more patients had earlier seroconversion for IgG than IgM.", [["IgM", "GENE_OR_GENE_PRODUCT", 62, 65], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["patients", "ORGANISM", 117, 125], ["IgG", "GENE_OR_GENE_PRODUCT", 157, 160], ["IgM", "PROTEIN", 62, 65], ["IgG", "PROTEIN", 70, 73], ["IgG", "PROTEIN", 157, 160], ["patients", "SPECIES", 117, 125], ["Those studies", "TEST", 0, 13], ["IgM", "TEST", 62, 65], ["IgG", "TEST", 70, 73]]], ["18 Due to the lack of serial results from the same cohort of patients over a longer period, the profile of specific IgM and IgG against SARS-CoV-2 remains unclear.", [["SARS", "DISEASE", 136, 140], ["patients", "ORGANISM", 61, 69], ["IgM", "GENE_OR_GENE_PRODUCT", 116, 119], ["IgG", "GENE_OR_GENE_PRODUCT", 124, 127], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["IgM", "PROTEIN", 116, 119], ["IgG", "PROTEIN", 124, 127], ["patients", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 136, 144], ["specific IgM", "TEST", 107, 119], ["IgG", "TEST", 124, 127], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144]]], ["Until now, antibody persistence after patients have been discharged from the hospital has been rarely reported, though this information is All rights reserved.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["No reuse allowed without permission.WHAT THIS STUDY ADDS(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.WHAT THIS STUDY ADDSThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["The copyright holder", "TREATMENT", 211, 231], ["med", "ANATOMY", 135, 138]]], ["22.20071258 doi: medRxiv preprint crucial for evaluating the immune profile of the recovered patients.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["Thus, the relationship between viral clearance and serological response has not been well investigated.WHAT THIS STUDY ADDSIn this study, we investigated the profiles of viral RNA, IgM, and IgG in a group of patients with confirmed SARS-CoV-2 pneumonia over an 8-week period after symptom onset.", [["SARS-CoV-2 pneumonia", "DISEASE", 232, 252], ["IgM", "GENE_OR_GENE_PRODUCT", 181, 184], ["IgG", "GENE_OR_GENE_PRODUCT", 190, 193], ["patients", "ORGANISM", 208, 216], ["viral RNA", "RNA", 170, 179], ["IgM", "PROTEIN", 181, 184], ["IgG", "PROTEIN", 190, 193], ["patients", "SPECIES", 208, 216], ["CoV-2", "SPECIES", 237, 242], ["SARS-CoV-2", "SPECIES", 232, 242], ["viral clearance", "TEST", 31, 46], ["this study", "TEST", 126, 136], ["viral RNA", "PROBLEM", 170, 179], ["IgM", "TEST", 181, 184], ["IgG", "TEST", 190, 193], ["SARS", "PROBLEM", 232, 236], ["CoV", "PROBLEM", 237, 240], ["pneumonia", "PROBLEM", 243, 252], ["symptom onset", "PROBLEM", 281, 294], ["viral RNA", "OBSERVATION", 170, 179], ["pneumonia", "OBSERVATION", 243, 252]]], ["Baseline characteristics and serial results of viral RNA in throat swabs, sputum, and stool specimens were monitored.", [["throat swabs", "ANATOMY", 60, 72], ["sputum", "ANATOMY", 74, 80], ["stool specimens", "ANATOMY", 86, 101], ["throat swabs", "MULTI-TISSUE_STRUCTURE", 60, 72], ["sputum", "ORGANISM_SUBSTANCE", 74, 80], ["stool specimens", "CANCER", 86, 101], ["viral RNA", "RNA", 47, 56], ["viral RNA in throat swabs", "TEST", 47, 72], ["sputum", "TEST", 74, 80], ["stool specimens", "TEST", 86, 101], ["viral RNA", "OBSERVATION", 47, 56], ["throat", "ANATOMY", 60, 66]]], ["Specific IgM and IgG against spike protein (S), spike protein receptor binding domain (RBD), and nucleocapsid (N) were also measured.", [["IgM", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgG against spike protein", "GENE_OR_GENE_PRODUCT", 17, 42], ["spike protein receptor binding domain", "GENE_OR_GENE_PRODUCT", 48, 85], ["RBD", "GENE_OR_GENE_PRODUCT", 87, 90], ["IgM", "PROTEIN", 9, 12], ["IgG", "PROTEIN", 17, 20], ["spike protein", "PROTEIN", 29, 42], ["S", "PROTEIN", 44, 45], ["spike protein receptor binding domain", "PROTEIN", 48, 85], ["RBD", "PROTEIN", 87, 90], ["nucleocapsid (N)", "PROTEIN", 97, 113], ["Specific IgM", "TEST", 0, 12], ["IgG", "TEST", 17, 20], ["spike protein (S", "TEST", 29, 45], ["spike protein receptor binding domain (RBD)", "PROBLEM", 48, 91], ["nucleocapsid", "PROBLEM", 97, 109]]], ["In this way, the long-term relationship between viral RNA persistence and the dynamics of SARS-CoV-2 antibodies have been more clearly established.Study design and participantsThis retrospective study was completed in Wenzhou Sixth People's Hospital, Wenzhou Central Hospital Group, one of the designated hospitals to treat patients with SARS-CoV-2 pneumonia.", [["SARS-CoV-2 pneumonia", "DISEASE", 338, 358], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 90, 111], ["participants", "ORGANISM", 164, 176], ["patients", "ORGANISM", 324, 332], ["SARS-CoV-2 antibodies", "PROTEIN", 90, 111], ["participants", "SPECIES", 164, 176], ["patients", "SPECIES", 324, 332], ["SARS-CoV", "SPECIES", 90, 98], ["viral RNA persistence", "PROBLEM", 48, 69], ["SARS", "TEST", 90, 94], ["CoV-2 antibodies", "TEST", 95, 111], ["This retrospective study", "TEST", 176, 200], ["SARS", "PROBLEM", 338, 342], ["CoV", "PROBLEM", 343, 346], ["pneumonia", "PROBLEM", 349, 358], ["viral RNA persistence", "OBSERVATION", 48, 69], ["pneumonia", "OBSERVATION", 349, 358]]], ["A total of 33 patients admitted to Wenzhou Sixth People's Hospital, Wenzhou Central Hospital Group, from January 27 to February 13, 2020 were included in this study.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["this study", "TEST", 154, 164]]], ["Among the patients, 31 (93.9%) were moderate, and two were severe SARS-CoV-2 pneumonia according to interim guidance issued by the WHO 19 and National Health Commission of the People's Republic of China.", [["SARS", "DISEASE", 66, 70], ["pneumonia", "DISEASE", 77, 86], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["severe SARS", "PROBLEM", 59, 70], ["CoV-2 pneumonia", "PROBLEM", 71, 86], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["SARS", "OBSERVATION", 66, 70], ["pneumonia", "OBSERVATION", 77, 86]]], ["13 The patients were followed up for 12-38 days (median, 30 days) after discharge from the hospital.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["This study was approved by the Ethics Commission of Wenzhou Central Hospital (L2020-01-036).Study design and participantsPatient Consent Form was signed by patients themselves.Data collectionA team of trained physicians and medical students reviewed all available electronic medical records, radiological findings, and laboratory examinations for all hospitalized patients with confirmed SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 388, 408], ["participants", "ORGANISM", 109, 121], ["patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 364, 372], ["CoV-2", "ORGANISM", 393, 398], ["participants", "SPECIES", 109, 121], ["Patient", "SPECIES", 121, 128], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 364, 372], ["SARS-CoV-2", "SPECIES", 388, 398], ["This study", "TEST", 0, 10], ["radiological findings", "TEST", 292, 313], ["laboratory examinations", "TEST", 319, 342], ["SARS", "PROBLEM", 388, 392], ["CoV", "PROBLEM", 393, 396], ["2 infection", "PROBLEM", 397, 408], ["infection", "OBSERVATION", 399, 408]]], ["Data were recorded on a standardized data collection form.", [["a standardized data collection", "TEST", 22, 52]]], ["Demographic data, symptom onset time, clinical features, radiological findings, routine laboratory results, and the results of SARS-CoV-2 viral RNA in throat swabs, sputum, and stool samples were recorded during hospitalization and follow-up.", [["throat swabs", "ANATOMY", 151, 163], ["sputum", "ANATOMY", 165, 171], ["stool samples", "ANATOMY", 177, 190], ["SARS", "DISEASE", 127, 131], ["SARS-CoV-2", "ORGANISM", 127, 137], ["throat swabs", "ORGANISM_SUBSTANCE", 151, 163], ["sputum", "ORGANISM_SUBSTANCE", 165, 171], ["stool samples", "CANCER", 177, 190], ["viral RNA", "RNA", 138, 147], ["SARS-CoV", "SPECIES", 127, 135], ["Demographic data", "TEST", 0, 16], ["SARS", "TEST", 127, 131], ["CoV", "TEST", 132, 135], ["2 viral RNA", "PROBLEM", 136, 147], ["throat swabs", "TEST", 151, 163], ["sputum", "TEST", 165, 171], ["stool samples", "TEST", 177, 190], ["throat", "ANATOMY", 151, 157]]], ["Results of specific IgM and IgG antibodies against SARS-CoV-2 S, RBD, and N were measured during hospitalization and follow-up.", [["IgM", "GENE_OR_GENE_PRODUCT", 20, 23], ["SARS-CoV-2 S", "ORGANISM", 51, 63], ["IgM", "PROTEIN", 20, 23], ["IgG antibodies", "PROTEIN", 28, 42], ["RBD", "PROTEIN", 65, 68], ["SARS-CoV", "SPECIES", 51, 59], ["specific IgM", "TEST", 11, 23], ["IgG antibodies", "TEST", 28, 42], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["RBD", "TEST", 65, 68]]], ["Any missing or uncertain records were clarified through communication with the physicians responsible for the patients in question, or with the patients themselves.Data collectionAll rights reserved.", [["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 144, 152], ["Data collection", "TEST", 164, 179]]], ["No reuse allowed without permission.Data collection(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Statistical analysisContinuous variables were presented as medians with interquartile ranges (IQRs) and means with standard deviations (SD).", [["Data collection", "TEST", 36, 51], ["Statistical analysisContinuous variables", "PROBLEM", 186, 226], ["med", "ANATOMY", 130, 133]]], ["For categorical variables, percentages of patients in each category were analyzed.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["categorical variables", "TEST", 4, 25]]], ["Differences between patients with sputum viral RNA short-persistence (viral RNA undetectable within 22 days) and those with long-persistence (viral RNA persists more than 22 days)Statistical analysiswere assessed by two sample t test or the Wilcoxon ranks sum test, depending on parametric or nonparametric data for continuous variables.", [["patients", "ORGANISM", 20, 28], ["viral RNA", "RNA", 70, 79], ["viral RNA", "RNA", 142, 151], ["patients", "SPECIES", 20, 28], ["sputum viral RNA short-persistence (viral RNA", "PROBLEM", 34, 79], ["long-persistence (viral RNA", "PROBLEM", 124, 151], ["sample t test", "TEST", 220, 233], ["the Wilcoxon ranks sum test", "TEST", 237, 264], ["nonparametric data", "TEST", 293, 311], ["viral RNA", "OBSERVATION_MODIFIER", 142, 151]]], ["Spearman's correlation analysis was used to assess relationships between parameters.", [["Spearman's correlation analysis", "TEST", 0, 31]]], ["All analyses were done with SPSS version 24.0 (IBM, Armonk, NY, USA).", [["All analyses", "TEST", 0, 12], ["SPSS version", "TEST", 28, 40]]], ["Tests were two-sided with significance assessed at the 0.05 level.Role of the funding sourceThe funders had no role in this study.", [["Tests", "TEST", 0, 5], ["this study", "TEST", 119, 129], ["no role", "UNCERTAINTY", 108, 115]]], ["The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.ResultsA total of 33 patients admitted to Wenzhou Sixth People's Hospital, Wenzhou Central Hospital Group, from January 27 to February 13, 2020, were included in this study.", [["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["the study", "TEST", 60, 69], ["this study", "TEST", 304, 314]]], ["The median age of the patients was 47 years old (range, 2-84) and 29 (87.9%) of them were less than 60 years old.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["Among the patients, 17Results(51.5%) were men, and 12 (36.4%) had comorbid illness (Supplemental Table 1) The most common symptoms were fever (19, 57.6%), cough (17, 51.5%), expectoration (4, 12.1%), fatigue (3, 9.", [["illness", "DISEASE", 75, 82], ["fever", "DISEASE", 136, 141], ["cough", "DISEASE", 155, 160], ["expectoration", "DISEASE", 174, 187], ["fatigue", "DISEASE", 200, 207], ["patients", "ORGANISM", 10, 18], ["men", "ORGANISM", 42, 45], ["patients", "SPECIES", 10, 18], ["men", "SPECIES", 42, 45], ["17Results", "TEST", 20, 29], ["comorbid illness", "PROBLEM", 66, 82], ["The most common symptoms", "PROBLEM", 106, 130], ["fever", "PROBLEM", 136, 141], ["cough", "TEST", 155, 160], ["expectoration", "TEST", 174, 187], ["fatigue", "PROBLEM", 200, 207]]], ["1%), and diarrhea (3, 9.", [["diarrhea", "DISEASE", 9, 17], ["diarrhea", "PROBLEM", 9, 17], ["diarrhea", "OBSERVATION", 9, 17]]], ["Routine laboratory parameters at admission and the first return visit time were available for analysis.ResultsMost of the laboratory parameters at admission were normal in all of the patients.", [["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["Routine laboratory parameters", "TEST", 0, 29], ["analysis", "TEST", 94, 102], ["the laboratory parameters", "TEST", 118, 143], ["normal", "OBSERVATION", 162, 168]]], ["Abnormal parameters observed in the patients at admission were abnormal white blood cell count (9, 27.3%), neutrophil All rights reserved.", [["white blood cell", "ANATOMY", 72, 88], ["neutrophil", "ANATOMY", 107, 117], ["patients", "ORGANISM", 36, 44], ["blood cell", "CELL", 78, 88], ["neutrophil", "CELL", 107, 117], ["patients", "SPECIES", 36, 44], ["Abnormal parameters", "PROBLEM", 0, 19], ["abnormal", "PROBLEM", 63, 71], ["white blood cell count", "TEST", 72, 94], ["neutrophil", "TEST", 107, 117]]], ["No reuse allowed without permission.Results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 122, 125]]], ["22.20071258 doi: medRxiv preprint count (4, 12.1%), lymphocyte count (5, 15.2%), platelet count (1, 3.0%), C-reactive protein (CRP) (15, 45 .5%), creatinine kinase (CK) (2, 6.1%), lactate dehydrogenase (LDH) (10, 30.3%), blood urea nitrogen (BUN) (9, 27.3%), and blood creatinine (Cr) (8, 24 .2%).", [["lymphocyte", "ANATOMY", 52, 62], ["platelet", "ANATOMY", 81, 89], ["blood", "ANATOMY", 221, 226], ["blood", "ANATOMY", 263, 268], ["creatinine", "CHEMICAL", 146, 156], ["lactate", "CHEMICAL", 180, 187], ["blood urea nitrogen", "CHEMICAL", 221, 240], ["creatinine", "CHEMICAL", 269, 279], ["Cr", "CHEMICAL", 281, 283], ["creatinine", "CHEMICAL", 146, 156], ["lactate", "CHEMICAL", 180, 187], ["urea", "CHEMICAL", 227, 231], ["nitrogen", "CHEMICAL", 232, 240], ["creatinine", "CHEMICAL", 269, 279], ["Cr", "CHEMICAL", 281, 283], ["lymphocyte", "CELL", 52, 62], ["platelet", "CELL", 81, 89], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 107, 125], ["CRP", "GENE_OR_GENE_PRODUCT", 127, 130], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 146, 163], ["CK", "GENE_OR_GENE_PRODUCT", 165, 167], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 180, 201], ["LDH", "GENE_OR_GENE_PRODUCT", 203, 206], ["blood urea nitrogen", "SIMPLE_CHEMICAL", 221, 240], ["BUN", "SIMPLE_CHEMICAL", 242, 245], ["blood", "ORGANISM_SUBSTANCE", 263, 268], ["creatinine", "SIMPLE_CHEMICAL", 269, 279], ["Cr", "SIMPLE_CHEMICAL", 281, 283], ["C-reactive protein", "PROTEIN", 107, 125], ["CRP", "PROTEIN", 127, 130], ["creatinine kinase", "PROTEIN", 146, 163], ["CK", "PROTEIN", 165, 167], ["lactate dehydrogenase", "PROTEIN", 180, 201], ["LDH", "PROTEIN", 203, 206], ["medRxiv preprint count", "TEST", 17, 39], ["lymphocyte count", "TEST", 52, 68], ["platelet count", "TEST", 81, 95], ["C-reactive protein", "TEST", 107, 125], ["CRP", "TEST", 127, 130], ["creatinine kinase", "TEST", 146, 163], ["CK", "TEST", 165, 167], ["lactate dehydrogenase", "TEST", 180, 201], ["LDH", "TEST", 203, 206], ["blood urea nitrogen", "TEST", 221, 240], ["BUN", "TEST", 242, 245], ["blood creatinine", "TEST", 263, 279], ["Cr", "TEST", 281, 283]]], ["Almost all of the patients had normal laboratory parameters upon their return visit one week after discharge (Supplemental Table 2 ).ResultsAll of the patients received antiviral treatment during hospitalization.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 151, 159], ["antiviral treatment", "TREATMENT", 169, 188]]], ["Atomized interferon, lopinavir and ritonavir, arbidol, ribavirin, and Lianhuaqingwen (Chinese traditional medicine) were used in combination.", [["Atomized interferon", "CHEMICAL", 0, 19], ["lopinavir", "CHEMICAL", 21, 30], ["ritonavir", "CHEMICAL", 35, 44], ["arbidol", "CHEMICAL", 46, 53], ["ribavirin", "CHEMICAL", 55, 64], ["Lianhuaqingwen", "CHEMICAL", 70, 84], ["lopinavir", "CHEMICAL", 21, 30], ["ritonavir", "CHEMICAL", 35, 44], ["arbidol", "CHEMICAL", 46, 53], ["ribavirin", "CHEMICAL", 55, 64], ["interferon", "GENE_OR_GENE_PRODUCT", 9, 19], ["lopinavir", "SIMPLE_CHEMICAL", 21, 30], ["ritonavir", "SIMPLE_CHEMICAL", 35, 44], ["arbidol", "SIMPLE_CHEMICAL", 46, 53], ["ribavirin", "SIMPLE_CHEMICAL", 55, 64], ["Lianhuaqingwen", "SIMPLE_CHEMICAL", 70, 84], ["Atomized interferon", "TREATMENT", 0, 19], ["lopinavir", "TREATMENT", 21, 30], ["ritonavir", "TREATMENT", 35, 44], ["arbidol", "TREATMENT", 46, 53], ["ribavirin", "TREATMENT", 55, 64], ["Lianhuaqingwen", "TREATMENT", 70, 84], ["Chinese traditional medicine", "TREATMENT", 86, 114]]], ["Atomized interferon was used in all patients.", [["Atomized interferon", "GENE_OR_GENE_PRODUCT", 0, 19], ["patients", "ORGANISM", 36, 44], ["interferon", "PROTEIN", 9, 19], ["patients", "SPECIES", 36, 44], ["Atomized interferon", "TREATMENT", 0, 19]]], ["Lopinavir and ritonavir was used in 32 (97.0%) of the patients.", [["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 14, 23], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 14, 23], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 14, 23], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 14, 23]]], ["Lianhuaqingwen, which was believed to relieve fever and cough, was used in for more than 22 days.", [["Lianhuaqingwen", "CHEMICAL", 0, 14], ["fever", "DISEASE", 46, 51], ["cough", "DISEASE", 56, 61], ["Lianhuaqingwen", "SIMPLE_CHEMICAL", 0, 14], ["fever", "PROBLEM", 46, 51], ["cough", "PROBLEM", 56, 61], ["cough", "OBSERVATION", 56, 61]]], ["Three patients (9.1%) showed a detectable relapse of viral RNA in sputum when they were tested two weeks after discharge from the hospital.", [["sputum", "ANATOMY", 66, 72], ["patients", "ORGANISM", 6, 14], ["sputum", "ORGANISM_SUBSTANCE", 66, 72], ["viral RNA", "RNA", 53, 62], ["patients", "SPECIES", 6, 14], ["viral RNA in sputum", "PROBLEM", 53, 72], ["detectable", "OBSERVATION_MODIFIER", 31, 41], ["relapse", "OBSERVATION", 42, 49], ["viral RNA", "OBSERVATION", 53, 62]]], ["One patient had persistent viral RNA for 59 days or longer.", [["patient", "ORGANISM", 4, 11], ["viral RNA", "RNA", 27, 36], ["patient", "SPECIES", 4, 11], ["persistent viral RNA", "PROBLEM", 16, 36], ["persistent", "OBSERVATION_MODIFIER", 16, 26], ["viral RNA", "OBSERVATION", 27, 36]]], ["SARS-CoV-2 viral loads at the first detection after onset were not corelated with age All rights reserved.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["viral loads", "TEST", 11, 22]]], ["No reuse allowed without permission.Results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 122, 125]]], ["(Figures 2, 3, and 4) .", [["Figures", "TEST", 1, 8]]], ["When comparing the IgG levels between the acute and All rights reserved.", [["IgG", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "PROTEIN", 19, 22], ["the IgG levels", "TEST", 15, 29], ["acute", "OBSERVATION_MODIFIER", 42, 47]]], ["No reuse allowed without permission.Results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 122, 125]]], ["22.20071258 doi: medRxiv preprint convalescent phases, a 4-fold increase was observed in 6 patients (18.2%) for anti-S, 12 patients (36.4%) for anti-RBD, and 3 patients (9.1%) for anti-N, respectively.ResultsSince detection of SARS-CoV-2 RNA in sputum is a routine test during treatment, and is commonly used in clinical settings, the relationship between the persistence of sputum viral RNA and antibodies was analyzed (Figures 3, 4, and 5 ).", [["sputum", "ANATOMY", 245, 251], ["RBD", "DISEASE", 149, 152], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 160, 168], ["anti-N", "SIMPLE_CHEMICAL", 180, 186], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 227, 237], ["sputum", "ORGANISM_SUBSTANCE", 245, 251], ["RBD", "PROTEIN", 149, 152], ["SARS-CoV-2 RNA", "RNA", 227, 241], ["sputum viral RNA", "RNA", 375, 391], ["antibodies", "PROTEIN", 396, 406], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 160, 168], ["SARS-CoV", "SPECIES", 227, 235], ["a 4-fold increase", "PROBLEM", 55, 72], ["anti-S", "TEST", 112, 118], ["anti-RBD", "TEST", 144, 152], ["anti-N", "TREATMENT", 180, 186], ["SARS", "PROBLEM", 227, 231], ["CoV", "TEST", 232, 235], ["sputum", "TEST", 245, 251], ["a routine test", "TEST", 255, 269], ["treatment", "TREATMENT", 277, 286], ["sputum viral RNA", "PROBLEM", 375, 391], ["antibodies", "TEST", 396, 406], ["Figures", "TEST", 421, 428]]], ["Compared to the viral RNA long persistence group, patients in the short persistence group had higher anti-S Ig G (P=0.000), anti-RBD IgM (P=0.000), and anti-RBD IgG levels (P=0.043).", [["patients", "ORGANISM", 50, 58], ["-S Ig G", "GENE_OR_GENE_PRODUCT", 105, 112], ["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 124, 136], ["anti-RBD IgG", "GENE_OR_GENE_PRODUCT", 152, 164], ["anti-S Ig G", "PROTEIN", 101, 112], ["anti", "PROTEIN", 124, 128], ["RBD IgM", "PROTEIN", 129, 136], ["RBD", "PROTEIN", 157, 160], ["IgG", "PROTEIN", 161, 164], ["patients", "SPECIES", 50, 58], ["anti-RBD IgM", "TEST", 124, 136], ["P", "TEST", 138, 139], ["anti-RBD IgG levels", "TEST", 152, 171], ["P", "TEST", 173, 174]]], ["Anti-RBD IgM levels at seroconversion (P=0.019) and the peak level of anti-RBD IgM (P=0.037) were also significantly higher in the short persistence group.", [["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 70, 82], ["RBD", "PROTEIN", 5, 8], ["IgM", "PROTEIN", 9, 12], ["anti", "PROTEIN", 70, 74], ["RBD IgM", "PROTEIN", 75, 82], ["Anti-RBD IgM levels", "TEST", 0, 19], ["seroconversion", "TEST", 23, 37], ["P", "TEST", 39, 40], ["the peak level", "TEST", 52, 66], ["anti", "TEST", 70, 74], ["RBD IgM", "TEST", 75, 82], ["P", "TEST", 84, 85], ["higher", "OBSERVATION_MODIFIER", 117, 123], ["short persistence", "OBSERVATION_MODIFIER", 131, 148]]], ["It was also observed that the time from symptom onset to hospital admission was significantly different between the short persistence and long persistence groups (P=0.048).DiscussionWe investigated the serial viral load and dynamics of antibodies from patients infected with SARS-CoV-2 over an eight-week period following the onset of symptoms.", [["SARS", "DISEASE", 275, 279], ["patients", "ORGANISM", 252, 260], ["SARS-CoV-2", "ORGANISM", 275, 285], ["antibodies", "PROTEIN", 236, 246], ["patients", "SPECIES", 252, 260], ["SARS-CoV", "SPECIES", 275, 283], ["the short persistence", "PROBLEM", 112, 133], ["the serial viral load", "TEST", 198, 219], ["antibodies", "PROBLEM", 236, 246], ["SARS", "PROBLEM", 275, 279], ["CoV", "TEST", 280, 283], ["symptoms", "PROBLEM", 335, 343], ["short persistence", "OBSERVATION_MODIFIER", 116, 133]]], ["In throat swab specimens, the SARS-CoV-2 viral load was high at the beginning of infection but declined quickly.", [["throat swab specimens", "ANATOMY", 3, 24], ["SARS", "DISEASE", 30, 34], ["infection", "DISEASE", 81, 90], ["SARS-CoV-2", "ORGANISM", 30, 40], ["SARS-CoV", "SPECIES", 30, 38], ["throat swab specimens", "TEST", 3, 24], ["the SARS", "TEST", 26, 34], ["CoV", "TEST", 35, 38], ["viral load", "TEST", 41, 51], ["infection", "PROBLEM", 81, 90], ["throat", "ANATOMY", 3, 9], ["infection", "OBSERVATION", 81, 90]]], ["The viral load in stool samples was low in the initial period but declined slowly.", [["stool samples", "ANATOMY", 18, 31], ["stool samples", "ORGANISM_SUBSTANCE", 18, 31], ["The viral load in stool samples", "TEST", 0, 31], ["viral load", "OBSERVATION", 4, 14]]], ["In both sputum and stool, viral RNA persisted for a long time.", [["sputum", "ANATOMY", 8, 14], ["stool", "ANATOMY", 19, 24], ["stool", "ORGANISM_SUBSTANCE", 19, 24], ["viral RNA", "RNA", 26, 35], ["viral RNA", "PROBLEM", 26, 35], ["both", "OBSERVATION_MODIFIER", 3, 7], ["sputum", "OBSERVATION", 8, 14], ["stool", "OBSERVATION", 19, 24], ["viral RNA", "OBSERVATION", 26, 35]]], ["Simultaneous seroconversion of IgM and IgG was observed in most of the patients.", [["IgM", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["patients", "ORGANISM", 71, 79], ["IgM", "PROTEIN", 31, 34], ["IgG", "PROTEIN", 39, 42], ["patients", "SPECIES", 71, 79], ["Simultaneous seroconversion of IgM", "PROBLEM", 0, 34], ["IgG", "TREATMENT", 39, 42], ["seroconversion", "OBSERVATION", 13, 27]]], ["IgM peaked in the fourth week (except for anti-N IgM, which peaked in the second week), and IgG peaked between the fourth and fifth week after the onset of symptoms.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["anti-N IgM", "GENE_OR_GENE_PRODUCT", 42, 52], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["IgM", "PROTEIN", 0, 3], ["anti", "PROTEIN", 42, 46], ["N IgM", "PROTEIN", 47, 52], ["IgG", "PROTEIN", 92, 95], ["IgM", "TEST", 0, 3], ["anti-N IgM", "TEST", 42, 52], ["IgG", "TEST", 92, 95], ["symptoms", "PROBLEM", 156, 164]]], ["High anti-RBD antibody levels were associated with short persistence of SARS-CoV-2 RNA in sputum.DiscussionSARS-CoV-2 viral load varies across different types of specimens.", [["sputum", "ANATOMY", 90, 96], ["specimens", "ANATOMY", 162, 171], ["anti-RBD antibody", "GENE_OR_GENE_PRODUCT", 5, 22], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["sputum", "ORGANISM_SUBSTANCE", 90, 96], ["CoV-2", "ORGANISM", 112, 117], ["specimens", "CANCER", 162, 171], ["anti-RBD antibody", "PROTEIN", 5, 22], ["SARS-CoV-2 RNA", "RNA", 72, 86], ["High anti-RBD antibody levels", "TEST", 0, 29], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["2 RNA in sputum", "PROBLEM", 81, 96], ["DiscussionSARS", "TEST", 97, 111], ["CoV", "TEST", 112, 115], ["viral load", "TEST", 118, 128], ["specimens", "TEST", 162, 171], ["SARS", "OBSERVATION", 72, 76], ["sputum", "OBSERVATION", 90, 96]]], ["20 In this study, we observed that in throat swab samples, the viral load was high in the early stages of infection, but it became undetectable by three weeks following symptom onset.", [["throat swab samples", "ANATOMY", 38, 57], ["infection", "DISEASE", 106, 115], ["throat swab samples", "ORGANISM_SUBSTANCE", 38, 57], ["this study", "TEST", 6, 16], ["throat swab samples", "TEST", 38, 57], ["the viral load", "TEST", 59, 73], ["infection", "PROBLEM", 106, 115], ["symptom onset", "PROBLEM", 169, 182], ["viral load", "OBSERVATION", 63, 73], ["early stages", "OBSERVATION_MODIFIER", 90, 102], ["infection", "OBSERVATION", 106, 115]]], ["Pan et al previously reported the viral load in several types of specimens from two patients 10 , and To and colleagues have reported the viral load in posterior oropharyngeal saliva samples.", [["specimens", "ANATOMY", 65, 74], ["oropharyngeal saliva samples", "ANATOMY", 162, 190], ["specimens", "CANCER", 65, 74], ["patients", "ORGANISM", 84, 92], ["oropharyngeal saliva samples", "ORGANISM_SUBSTANCE", 162, 190], ["patients", "SPECIES", 84, 92], ["the viral load", "PROBLEM", 30, 44], ["specimens", "TEST", 65, 74], ["the viral load in posterior oropharyngeal saliva samples", "PROBLEM", 134, 190], ["viral load", "OBSERVATION", 34, 44], ["viral load", "OBSERVATION", 138, 148], ["posterior", "ANATOMY_MODIFIER", 152, 161], ["oropharyngeal saliva", "ANATOMY", 162, 182]]], ["11 Combining those studies with our own results here, we can conclude that in upper respiratory samples, SARS-CoV-2 viral load is high shortly after symptom onset but declines quickly.DiscussionThe detection of SARS-CoV-2 RNA in respiratory specimens is included in the guidelines for monitoring treatment.", [["upper respiratory samples", "ANATOMY", 78, 103], ["respiratory specimens", "ANATOMY", 229, 250], ["SARS-CoV-2", "ORGANISM", 105, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 211, 221], ["SARS-CoV-2 RNA", "RNA", 211, 225], ["SARS-CoV", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 211, 219], ["upper respiratory samples", "TEST", 78, 103], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["viral load", "TEST", 116, 126], ["symptom onset", "PROBLEM", 149, 162], ["SARS", "PROBLEM", 211, 215], ["CoV", "TEST", 216, 219], ["respiratory specimens", "TEST", 229, 250], ["monitoring treatment", "TREATMENT", 285, 305], ["upper", "ANATOMY_MODIFIER", 78, 83], ["respiratory", "ANATOMY", 84, 95], ["respiratory", "ANATOMY", 229, 240]]], ["According to these guidelines, patients will be discharged from hospitals if they have experienced relief of symptoms and had two successive negative viral RNA tests from respiratory All rights reserved.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["symptoms", "PROBLEM", 109, 117], ["two successive negative viral RNA tests", "PROBLEM", 126, 165], ["viral RNA", "OBSERVATION", 150, 159]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 125, 128]]], ["22.20071258 doi: medRxiv preprint specimens across at least a 24 h sampling interval.", [["specimens", "ANATOMY", 34, 43]]], ["13 We observed that in sputum, viral load declined with time, and most patients were undetectable by week 5 after the onset of symptoms.", [["sputum", "ANATOMY", 23, 29], ["sputum", "ORGANISM_SUBSTANCE", 23, 29], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["sputum", "TEST", 23, 29], ["viral load", "TEST", 31, 41], ["symptoms", "PROBLEM", 127, 135], ["viral load", "OBSERVATION", 31, 41]]], ["However, positive viral RNA was detected in about 10% of our patients two weeks after their discharge from the hospital.", [["patients", "ORGANISM", 61, 69], ["viral RNA", "RNA", 18, 27], ["patients", "SPECIES", 61, 69], ["positive viral RNA", "PROBLEM", 9, 27], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["viral RNA", "OBSERVATION", 18, 27]]], ["In addition, one patient in our cohort had positive viral RNA for 59 days after symptom onset and would go on to persist even longer.", [["patient", "ORGANISM", 17, 24], ["viral RNA", "RNA", 52, 61], ["patient", "SPECIES", 17, 24], ["positive viral RNA", "PROBLEM", 43, 61], ["symptom onset", "PROBLEM", 80, 93], ["viral RNA", "OBSERVATION", 52, 61]]], ["This means that SARS-CoV-2 may persist for a long time in some patients.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20]]], ["Whether \"relapsed patients\" are truly relapsed, or the result of false negative viral RNA tests, needs to be explored further.DiscussionOur study also investigated SARS-CoV-2 viral load in serial stool specimens.", [["stool specimens", "ANATOMY", 196, 211], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 164, 174], ["patients", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 164, 172], ["false negative viral RNA tests", "PROBLEM", 65, 95], ["DiscussionOur study", "TEST", 126, 145], ["SARS", "TEST", 164, 168], ["CoV", "TEST", 169, 172], ["viral load", "TEST", 175, 185], ["serial stool specimens", "TEST", 189, 211]]], ["The viral load in stool was lower than what was observed in throat swabs and sputum at the beginning of infection but declined slowly.", [["stool", "ANATOMY", 18, 23], ["throat swabs", "ANATOMY", 60, 72], ["sputum", "ANATOMY", 77, 83], ["infection", "DISEASE", 104, 113], ["stool", "ORGANISM_SUBSTANCE", 18, 23], ["throat swabs", "ORGANISM_SUBSTANCE", 60, 72], ["sputum", "ORGANISM_SUBSTANCE", 77, 83], ["The viral load in stool", "TEST", 0, 23], ["throat swabs", "PROBLEM", 60, 72], ["sputum", "PROBLEM", 77, 83], ["infection", "PROBLEM", 104, 113], ["viral load", "OBSERVATION", 4, 14], ["stool", "OBSERVATION", 18, 23], ["throat", "ANATOMY", 60, 66], ["infection", "OBSERVATION", 104, 113]]], ["Many patients had persistent viral RNA in stool for more than five weeks.", [["patients", "ORGANISM", 5, 13], ["stool", "ORGANISM_SUBSTANCE", 42, 47], ["viral RNA", "RNA", 29, 38], ["patients", "SPECIES", 5, 13], ["persistent viral RNA in stool", "PROBLEM", 18, 47], ["persistent", "OBSERVATION_MODIFIER", 18, 28], ["viral RNA", "OBSERVATION", 29, 38], ["stool", "OBSERVATION", 42, 47]]], ["Since fluctuations of viral RNA in respiratory specimens were observed in most of the patients, false negative results will be inevitable in such specimens.", [["respiratory specimens", "ANATOMY", 35, 56], ["specimens", "ANATOMY", 146, 155], ["patients", "ORGANISM", 86, 94], ["specimens", "CANCER", 146, 155], ["viral RNA", "RNA", 22, 31], ["patients", "SPECIES", 86, 94], ["viral RNA in respiratory specimens", "PROBLEM", 22, 56], ["viral RNA", "OBSERVATION", 22, 31]]], ["Detection of viral RNA in stool specimens may thus act as a useful complement for monitoring treatments.DiscussionCurrently, serological tests are widely used for diagnosis, and SARS-CoV-2 IgM or IgM/IgG tests have been approved under emergency use authorization (EUA) in many countries.", [["stool specimens", "ANATOMY", 26, 41], ["stool specimens", "ORGANISM_SUBSTANCE", 26, 41], ["SARS-CoV-2", "ORGANISM", 178, 188], ["IgM", "ORGANISM", 189, 192], ["IgM", "GENE_OR_GENE_PRODUCT", 196, 199], ["IgG", "GENE_OR_GENE_PRODUCT", 200, 203], ["viral RNA", "RNA", 13, 22], ["IgM", "PROTEIN", 189, 192], ["IgM", "PROTEIN", 196, 199], ["IgG", "PROTEIN", 200, 203], ["SARS-CoV", "SPECIES", 178, 186], ["viral RNA in stool specimens", "TEST", 13, 41], ["monitoring treatments", "TREATMENT", 82, 103], ["serological tests", "TEST", 125, 142], ["diagnosis", "TEST", 163, 172], ["SARS", "TEST", 178, 182], ["CoV", "TEST", 183, 186], ["IgM", "TEST", 189, 192], ["IgM/IgG tests", "TEST", 196, 209], ["viral RNA", "OBSERVATION", 13, 22]]], ["In most of the known viral infections, seroconversion of IgM occurs earlier than seroconversion of IgG.", [["viral infections", "DISEASE", 21, 37], ["IgM", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgG", "GENE_OR_GENE_PRODUCT", 99, 102], ["IgM", "PROTEIN", 57, 60], ["IgG", "PROTEIN", 99, 102], ["the known viral infections", "PROBLEM", 11, 37], ["seroconversion of IgM", "PROBLEM", 39, 60], ["viral", "OBSERVATION_MODIFIER", 21, 26], ["infections", "OBSERVATION", 27, 37]]], ["[21] [22] [23] [24] Hence, specific IgM is often used as a diagnostic marker for acute viral infection.", [["viral infection", "DISEASE", 87, 102], ["[21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 19], ["IgM", "GENE_OR_GENE_PRODUCT", 36, 39], ["IgM", "PROTEIN", 36, 39], ["specific IgM", "TEST", 27, 39], ["acute viral infection", "PROBLEM", 81, 102], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infection", "OBSERVATION", 93, 102]]], ["Our results indicate that in SARS-CoV-2 infected patients, simultaneous seroconversion of IgM and IgG was observed in 75% of the patients.", [["SARS-CoV-2 infected", "DISEASE", 29, 48], ["SARS-CoV-2", "ORGANISM", 29, 39], ["patients", "ORGANISM", 49, 57], ["IgM", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["patients", "ORGANISM", 129, 137], ["IgM", "PROTEIN", 90, 93], ["IgG", "PROTEIN", 98, 101], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["simultaneous seroconversion of IgM", "PROBLEM", 59, 93], ["IgG", "TEST", 98, 101]]], ["Almost no patient had earlier seroconversion of IgM than IgG.", [["patient", "ORGANISM", 10, 17], ["IgM", "GENE_OR_GENE_PRODUCT", 48, 51], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgM", "PROTEIN", 48, 51], ["IgG", "PROTEIN", 57, 60], ["patient", "SPECIES", 10, 17]]], ["Nearly 10% of the patients had negative IgM across the entire study period.", [["patients", "ORGANISM", 18, 26], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgM", "PROTEIN", 40, 43], ["patients", "SPECIES", 18, 26]]], ["To and colleagues also reported that in most of SARS-CoV-2 infected patients, seroconversion of IgG was earlier than IgM, and they thought that this might be due to low sensitivity of their IgM test.", [["SARS-CoV-2 infected", "DISEASE", 48, 67], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "ORGANISM", 68, 76], ["IgG", "GENE_OR_GENE_PRODUCT", 96, 99], ["IgM", "GENE_OR_GENE_PRODUCT", 117, 120], ["IgM", "GENE_OR_GENE_PRODUCT", 190, 193], ["IgG", "PROTEIN", 96, 99], ["IgM", "PROTEIN", 117, 120], ["IgM", "PROTEIN", 190, 193], ["patients", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["seroconversion of IgG", "PROBLEM", 78, 99], ["low sensitivity of their IgM test", "PROBLEM", 165, 198]]], ["11 Combining the results together, it appears that a single IgM test may not be a reliable index for an auxiliary diagnosis of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 127, 147], ["SARS-CoV-2", "ORGANISM", 127, 137], ["IgM", "PROTEIN", 60, 63], ["SARS-CoV-2", "SPECIES", 127, 137], ["a single IgM test", "TEST", 51, 68], ["SARS", "PROBLEM", 127, 131], ["CoV-2 infection", "PROBLEM", 132, 147], ["SARS", "OBSERVATION", 127, 131], ["infection", "OBSERVATION", 138, 147]]], ["Convalescent IgM/IgG testing will likely be better than single IgM for patients for whom nucleic acid tests are not available, or those who have typical SARS-CoV-2 symptoms but are negative for nucleic acid detection.DiscussionThe coexistence of SARS-CoV-2 viral RNA and specific antibodies has been reported by several studies, 11, 17, 18 and has been observed in patients with severe acute respiratory syndrome (SARS) and middle eastern respiratory syndrome (MERS).", [["nucleic acid", "CHEMICAL", 89, 101], ["nucleic acid", "CHEMICAL", 194, 206], ["SARS", "DISEASE", 246, 250], ["acute respiratory syndrome", "DISEASE", 386, 412], ["SARS", "DISEASE", 414, 418], ["middle eastern respiratory syndrome", "DISEASE", 424, 459], ["MERS", "DISEASE", 461, 465], ["IgM", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["patients", "ORGANISM", 71, 79], ["SARS-CoV-2", "ORGANISM", 153, 163], ["nucleic acid", "SIMPLE_CHEMICAL", 194, 206], ["SARS-CoV-2", "ORGANISM", 246, 256], ["patients", "ORGANISM", 365, 373], ["IgM", "PROTEIN", 13, 16], ["IgG", "PROTEIN", 17, 20], ["IgM", "PROTEIN", 63, 66], ["SARS-CoV-2 viral RNA", "RNA", 246, 266], ["specific antibodies", "PROTEIN", 271, 290], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 365, 373], ["SARS-CoV", "SPECIES", 246, 254], ["Convalescent IgM/IgG testing", "TEST", 0, 28], ["nucleic acid tests", "TEST", 89, 107], ["typical SARS-CoV-2 symptoms", "PROBLEM", 145, 172], ["nucleic acid detection", "PROBLEM", 194, 216], ["SARS", "PROBLEM", 246, 250], ["CoV", "TEST", 251, 254], ["2 viral RNA", "PROBLEM", 255, 266], ["specific antibodies", "TEST", 271, 290], ["severe acute respiratory syndrome", "PROBLEM", 379, 412], ["SARS", "PROBLEM", 414, 418], ["middle eastern respiratory syndrome", "PROBLEM", 424, 459], ["severe", "OBSERVATION_MODIFIER", 379, 385], ["acute", "OBSERVATION_MODIFIER", 386, 391], ["respiratory syndrome", "OBSERVATION", 392, 412], ["middle", "ANATOMY_MODIFIER", 424, 430], ["respiratory syndrome", "OBSERVATION", 439, 459]]], ["25, 26 Our results shown that in some patients, SARS-CoV-2 RNA coexisted with antibodies for more than 50 days.", [["patients", "ORGANISM", 38, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["SARS-CoV-2 RNA", "RNA", 48, 62], ["antibodies", "PROTEIN", 78, 88], ["patients", "SPECIES", 38, 46], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["antibodies", "TEST", 78, 88]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 125, 128]]], ["22.20071258 doi: medRxiv preprint the existence of protective antibodies against SARS-CoV-2, since one of the key roles of protective antibodies is to clear viral infection.", [["SARS", "DISEASE", 81, 85], ["viral infection", "DISEASE", 157, 172], ["SARS-CoV-2", "ORGANISM", 81, 91], ["protective antibodies", "PROTEIN", 51, 72], ["protective antibodies", "PROTEIN", 123, 144], ["SARS-CoV", "SPECIES", 81, 89], ["medRxiv", "TREATMENT", 17, 24], ["protective antibodies", "TREATMENT", 51, 72], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89], ["protective antibodies", "TREATMENT", 123, 144], ["clear viral infection", "PROBLEM", 151, 172], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["infection", "OBSERVATION", 163, 172]]], ["27 To and colleagues reported that anti-SARS-CoV-2-N or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralization titre.", [["anti-SARS-CoV-2-N", "SIMPLE_CHEMICAL", 35, 52], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 71], ["RBD", "ORGANISM", 72, 75], ["IgG", "GENE_OR_GENE_PRODUCT", 76, 79], ["anti-SARS", "PROTEIN", 35, 44], ["RBD IgG", "PROTEIN", 72, 79], ["anti-SARS", "TEST", 35, 44], ["CoV", "TEST", 45, 48], ["anti-SARS", "TEST", 56, 65], ["CoV", "TEST", 66, 69], ["RBD IgG levels", "TEST", 72, 86], ["virus neutralization titre", "TREATMENT", 103, 129]]], ["11 In this study, we found that anti-SARS-CoV-2 IgG peaked within about 30 days after symptom onset.", [["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 32, 51], ["anti-SARS-CoV-2 IgG", "PROTEIN", 32, 51], ["this study", "TEST", 6, 16], ["anti-SARS", "TEST", 32, 41], ["CoV", "TEST", 42, 45], ["symptom onset", "PROBLEM", 86, 99]]], ["In about 36% of the patients, anti-RBD IgG increased more than four-fold within one to two weeks after seroconversion and persisted for more than four weeks.", [["patients", "ORGANISM", 20, 28], ["anti-RBD IgG", "GENE_OR_GENE_PRODUCT", 30, 42], ["anti-RBD IgG", "PROTEIN", 30, 42], ["patients", "SPECIES", 20, 28], ["anti-RBD IgG", "TEST", 30, 42], ["seroconversion", "PROBLEM", 103, 117]]], ["We also found that anti-RBD IgM and IgG levels, including anti-RBD IgM levels at presentation and peak time, were significantly higher in patients showing viral RNA short persistence than in patients showing long persistence.", [["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 19, 31], ["IgG", "GENE_OR_GENE_PRODUCT", 36, 39], ["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 58, 70], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 191, 199], ["anti-RBD IgM", "PROTEIN", 19, 31], ["IgG", "PROTEIN", 36, 39], ["anti-RBD", "PROTEIN", 58, 66], ["IgM", "PROTEIN", 67, 70], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 191, 199], ["anti-RBD IgM", "TEST", 19, 31], ["IgG levels", "TEST", 36, 46], ["anti-RBD IgM levels", "TEST", 58, 77], ["viral RNA short persistence", "PROBLEM", 155, 182], ["viral RNA", "OBSERVATION", 155, 164], ["short persistence", "OBSERVATION_MODIFIER", 165, 182], ["long persistence", "OBSERVATION_MODIFIER", 208, 224]]], ["These data imply that the anti-RBD antibodies may be involved in the clearance of SARS-CoV-2 infection and would be potential candidates for a protective antibody.", [["infection", "DISEASE", 93, 102], ["anti-RBD antibodies", "GENE_OR_GENE_PRODUCT", 26, 45], ["SARS-CoV-2", "ORGANISM", 82, 92], ["anti-RBD antibodies", "PROTEIN", 26, 45], ["protective antibody", "PROTEIN", 143, 162], ["SARS-CoV-2", "SPECIES", 82, 92], ["the anti-RBD antibodies", "TREATMENT", 22, 45], ["SARS", "PROBLEM", 82, 86], ["CoV-2 infection", "PROBLEM", 87, 102], ["a protective antibody", "PROBLEM", 141, 162]]], ["Further studies are needed to identify whether RBD is a useful epitope for developing vaccines against SARS-CoV-2.DiscussionWe also observed that the length of time from symptom onset to hospital admission was associated with SARS-CoV-2 viral RNA clearance.", [["RBD", "DISEASE", 47, 50], ["SARS", "DISEASE", 103, 107], ["SARS-CoV-2", "ORGANISM", 103, 113], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 226, 236], ["RBD", "PROTEIN", 47, 50], ["SARS-CoV", "SPECIES", 103, 111], ["Further studies", "TEST", 0, 15], ["RBD", "PROBLEM", 47, 50], ["developing vaccines", "TREATMENT", 75, 94], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["SARS", "PROBLEM", 226, 230], ["CoV", "TEST", 231, 234]]], ["In addition, the seropositive rate for anti-S and anti-RBD IgM was significantly higher in viral RNA long persistence patients.", [["anti-S", "GENE_OR_GENE_PRODUCT", 39, 45], ["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 50, 62], ["patients", "ORGANISM", 118, 126], ["anti-S", "PROTEIN", 39, 45], ["anti-RBD", "PROTEIN", 50, 58], ["IgM", "PROTEIN", 59, 62], ["patients", "SPECIES", 118, 126], ["anti-RBD", "SPECIES", 50, 58], ["the seropositive rate", "TEST", 13, 34], ["anti-S", "TREATMENT", 39, 45], ["anti-RBD IgM", "TEST", 50, 62], ["viral RNA", "OBSERVATION", 91, 100], ["long persistence", "OBSERVATION_MODIFIER", 101, 117]]], ["Based on current evidence, the relationship between late treatment and seropositivity for anti-S or anti-RBD IgM is undetermined.", [["anti-S", "GENE_OR_GENE_PRODUCT", 90, 96], ["anti-RBD IgM", "GENE_OR_GENE_PRODUCT", 100, 112], ["anti-S", "PROTEIN", 90, 96], ["anti-RBD IgM", "PROTEIN", 100, 112], ["late treatment", "TREATMENT", 52, 66], ["anti-S", "TREATMENT", 90, 96], ["anti-RBD IgM", "TEST", 100, 112]]], ["It is possible that the higher seropositive rate is due to a longer infection time and delayed treatment.DiscussionHowever, our data imply that shorter delay is linked to better recovery.", [["infection", "DISEASE", 68, 77], ["the higher seropositive rate", "PROBLEM", 20, 48], ["a longer infection time", "PROBLEM", 59, 82], ["delayed treatment", "TREATMENT", 87, 104], ["infection", "OBSERVATION", 68, 77]]], ["\"Early identification, early hospitalization\" is thus likely to be an efficient strategy for the prevention and management of SARS-CoV-2 infection.DiscussionOur study has some limitations.", [["SARS-CoV-2 infection", "DISEASE", 126, 146], ["SARS-CoV-2", "ORGANISM", 126, 136], ["SARS-CoV-2", "SPECIES", 126, 136], ["an efficient strategy", "TREATMENT", 67, 88], ["management", "TREATMENT", 112, 122], ["SARS", "PROBLEM", 126, 130], ["CoV", "PROBLEM", 131, 134], ["2 infection", "PROBLEM", 135, 146], ["DiscussionOur study", "TEST", 147, 166], ["infection", "OBSERVATION", 137, 146]]], ["First, the patient number in our study is relatively small, and only 33 patients were included in this study.", [["patient", "ORGANISM", 11, 18], ["patients", "ORGANISM", 72, 80], ["patient", "SPECIES", 11, 18], ["patients", "SPECIES", 72, 80], ["our study", "TEST", 29, 38], ["this study", "TEST", 98, 108], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["This is, of course, a common weakness of studies of emerging infectious diseases.", [["infectious diseases", "DISEASE", 61, 80], ["a common weakness", "PROBLEM", 20, 37], ["emerging infectious diseases", "PROBLEM", 52, 80], ["infectious", "OBSERVATION", 61, 71]]], ["Second, samples for viral RNA and antibody detection were collected weekly and not on a daily basis.", [["samples", "ANATOMY", 8, 15], ["viral RNA", "RNA", 20, 29], ["viral RNA", "TEST", 20, 29], ["antibody detection", "TEST", 34, 52]]], ["It was also difficult to collect samples at exactly one-week intervals.", [["samples", "ANATOMY", 33, 40]]], ["In some patients, initial samples were even missed due to the emerging situation for SARS-CoV-2 infection.DiscussionIn conclusion, this study adds important new information about the features of viral load and antibody dynamics of SARS-CoV-2.", [["samples", "ANATOMY", 26, 33], ["SARS-CoV-2 infection", "DISEASE", 85, 105], ["SARS", "DISEASE", 231, 235], ["patients", "ORGANISM", 8, 16], ["SARS-CoV-2", "ORGANISM", 85, 95], ["SARS-CoV-2", "ORGANISM", 231, 241], ["patients", "SPECIES", 8, 16], ["SARS-CoV-2", "SPECIES", 85, 95], ["SARS-CoV", "SPECIES", 231, 239], ["initial samples", "TEST", 18, 33], ["SARS", "PROBLEM", 85, 89], ["CoV-2 infection", "PROBLEM", 90, 105], ["this study", "TEST", 131, 141], ["viral load", "TEST", 195, 205], ["antibody dynamics", "TEST", 210, 227], ["SARS", "PROBLEM", 231, 235], ["CoV", "TEST", 236, 239], ["infection", "OBSERVATION", 96, 105], ["viral load", "OBSERVATION", 195, 205]]], ["It is clear from these results that the viral RNA persists in sputum and stool specimens for a relatively long time in many patients.", [["sputum", "ANATOMY", 62, 68], ["stool specimens", "ANATOMY", 73, 88], ["sputum", "ORGANISM_SUBSTANCE", 62, 68], ["stool specimens", "ORGANISM_SUBSTANCE", 73, 88], ["patients", "ORGANISM", 124, 132], ["viral RNA", "RNA", 40, 49], ["patients", "SPECIES", 124, 132], ["the viral RNA", "PROBLEM", 36, 49], ["stool specimens", "TEST", 73, 88], ["clear", "OBSERVATION", 6, 11], ["viral RNA", "OBSERVATION", 40, 49]]], ["Anti-RBD may also serve as a potential protective antibody against SARS-CoV-2 infection, as viral persistence appears to be related to anti-RBD levels.", [["SARS-CoV-2 infection", "DISEASE", 67, 87], ["SARS-CoV-2", "ORGANISM", 67, 77], ["anti-RBD", "GENE_OR_GENE_PRODUCT", 135, 143], ["RBD", "PROTEIN", 5, 8], ["anti-RBD", "PROTEIN", 135, 143], ["CoV-2", "SPECIES", 72, 77], ["SARS-CoV-2", "SPECIES", 67, 77], ["SARS", "PROBLEM", 67, 71], ["CoV", "PROBLEM", 72, 75], ["2 infection", "PROBLEM", 76, 87], ["viral persistence", "PROBLEM", 92, 109], ["anti-RBD levels", "TEST", 135, 150], ["infection", "OBSERVATION", 78, 87]]], ["Earlier treatment intervention also appears to be a factor in viral persistence.", [["Earlier treatment intervention", "TREATMENT", 0, 30], ["viral persistence", "PROBLEM", 62, 79], ["viral persistence", "OBSERVATION", 62, 79]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 125, 128]]], ["22.20071258 doi: medRxiv preprint studies are needed to better understand the virological and immunological features of SARS-CoV-2 infection, which are important for the prevention, treatment and control of the spread of this disease.FootnotesContributors: SHT designed the study, and had full access to all data in the study.", [["SARS-CoV-2 infection", "DISEASE", 120, 140], ["SARS-CoV-2", "ORGANISM", 120, 130], ["CoV-2", "SPECIES", 125, 130], ["SARS-CoV-2", "SPECIES", 120, 130], ["medRxiv preprint studies", "TEST", 17, 41], ["SARS", "PROBLEM", 120, 124], ["CoV-2 infection", "PROBLEM", 125, 140], ["treatment", "TREATMENT", 182, 191], ["this disease", "PROBLEM", 221, 233], ["the study", "TEST", 270, 279], ["the study", "TEST", 316, 325], ["infection", "OBSERVATION", 131, 140]]], ["SHT Patient consent: Written informed consent was waived due to the emergency state of the disease.Data sharing:No additional data available.Transparency declaration:The lead author and the manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.", [["Patient", "SPECIES", 4, 11], ["the disease", "PROBLEM", 87, 98], ["the study", "TEST", 292, 301], ["the study", "TEST", 347, 356], ["the study", "TEST", 408, 417], ["disease", "OBSERVATION", 91, 98]]], ["A comparison of viral loads across different types of specimens is also shown (D).Figure 2.", [["specimens", "ANATOMY", 54, 63], ["specimens", "CANCER", 54, 63], ["viral loads", "PROBLEM", 16, 27], ["specimens", "TEST", 54, 63], ["viral loads", "OBSERVATION", 16, 27]]], ["Dynamics of antibodies against SARS-CoV-2 in patientsEach column represents the mean levels of the antibody in one week.", [["SARS-CoV-2", "ORGANISM", 31, 41], ["patients", "ORGANISM", 45, 53], ["antibodies", "PROTEIN", 12, 22], ["patients", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 31, 39], ["Dynamics of antibodies", "TEST", 0, 22], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39]]], ["Dynamics of antibodies against SARS-CoV-2 in patients(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 2.", [["SARS", "DISEASE", 31, 35], ["SARS-CoV-2", "ORGANISM", 31, 41], ["patients", "ORGANISM", 45, 53], ["antibodies", "PROTEIN", 12, 22], ["patients", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 31, 39], ["Dynamics of antibodies", "TEST", 0, 22], ["SARS", "PROBLEM", 31, 35], ["med", "ANATOMY", 132, 135]]], ["Dynamics of antibodies against SARS-CoV-2 in patientsThe copyright holder for this preprint this version posted April 27, 2020. . https://doi.org/10.1101/2020.04.", [["SARS-CoV-2", "ORGANISM", 31, 41], ["patients", "ORGANISM", 45, 53], ["antibodies", "PROTEIN", 12, 22], ["patients", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 31, 39], ["Dynamics of antibodies", "TEST", 0, 22], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["The copyright holder", "TREATMENT", 53, 73]]]], "6163faf31b5137cf6adbfe2d878f9b3cb73ece2a": [["These data are relevant for cancer institutions.", [["cancer", "ANATOMY", 28, 34], ["cancer", "DISEASE", 28, 34], ["cancer", "CANCER", 28, 34]]], ["In the COVID-19 scenario, and especially in low-and middleincome settings, prioritization of adequate pathways for these patients is critical.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129]]], ["Liang et al 1 described only 18 cases (1% of the entire COVID-19 population).", [["the entire COVID", "TREATMENT", 45, 61]]], ["We have limited data to make deeper conclusions, but in an attempt to help cancer centers in low-resource settings we have compiled [2] [3] [4] and created some adjusted recommendations:", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["cancer", "CANCER", 75, 81]]]], "PMC7254905": [["Theorem 1 ::: IntroductionUsing linear time in the in-place model, one can traverse the vertices of any graph in (un)ordered BFS and DFS manner,recognize bipartite graphs, and compute connected components,report the vertices of a DAG in topologically sorted order,obtain a maximum cardinality search ordering of any graph,output an st-numbering of given biconnected graph, given two vertices s and t,perform a chain decomposition of any undirected graph, anddetermine whether any given undirected graph G is biconnected (and/or 2-edge connected resp.) and if not, we can also compute and report all the cut vertices (bridges resp.) of G.", [["DAG", "CHEMICAL", 230, 233], ["DAG", "SIMPLE_CHEMICAL", 230, 233], ["G.", "SPECIES", 635, 637], ["the in-place model", "TREATMENT", 47, 65], ["bipartite graphs", "TEST", 154, 170], ["any graph", "TEST", 312, 321], ["biconnected graph", "TREATMENT", 354, 371], ["a chain decomposition", "TREATMENT", 408, 429]]]], "PMC7179519": [["IntroductionThe term \u201centeric viruses\u201d refers to an important but complex community of viruses found in the intestinal tract of humans and animals.", [["intestinal tract", "ANATOMY", 108, 124], ["intestinal tract", "ORGANISM_SUBDIVISION", 108, 124], ["humans", "ORGANISM", 128, 134], ["humans", "SPECIES", 128, 134], ["humans", "SPECIES", 128, 134], ["The term \u201centeric viruses", "TREATMENT", 12, 37], ["viruses", "PROBLEM", 87, 94], ["viruses", "OBSERVATION", 30, 37], ["viruses", "OBSERVATION", 87, 94], ["intestinal tract", "ANATOMY", 108, 124]]], ["Enteric viruses include more than 100 viral entities belonging to families such as Reoviridae, Caliciviridae, Astroviridae, Adenoviridae, and Picornaviridae and more rarely Coronaviridae and Picobirnaviridae.", [["Reoviridae", "GENE_OR_GENE_PRODUCT", 83, 93], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 95, 108], ["Astroviridae", "GENE_OR_GENE_PRODUCT", 110, 122], ["Adenoviridae", "GENE_OR_GENE_PRODUCT", 124, 136], ["Picobirnaviridae", "CANCER", 191, 207], ["Enteric viruses", "PROBLEM", 0, 15], ["Reoviridae", "TREATMENT", 83, 93], ["Caliciviridae", "TREATMENT", 95, 108], ["Astroviridae", "TREATMENT", 110, 122], ["Adenoviridae", "TREATMENT", 124, 136], ["Picornaviridae", "TREATMENT", 142, 156], ["Coronaviridae", "TREATMENT", 173, 186], ["Picobirnaviridae", "TREATMENT", 191, 207], ["viruses", "OBSERVATION", 8, 15]]], ["These agents are related to a broad range of clinical features including gastroenteritis mainly but also hepatitis, neurological manifestations, and others.", [["neurological", "ANATOMY", 116, 128], ["gastroenteritis", "DISEASE", 73, 88], ["hepatitis", "DISEASE", 105, 114], ["neurological manifestations", "DISEASE", 116, 143], ["gastroenteritis", "PROBLEM", 73, 88], ["hepatitis", "PROBLEM", 105, 114], ["neurological manifestations", "PROBLEM", 116, 143], ["gastroenteritis", "OBSERVATION", 73, 88], ["hepatitis", "OBSERVATION", 105, 114]]], ["The main representatives in humans are rotavirus, norovirus, astrovirus, adenovirus, enterovirus, hepatitis A virus (HAV), and hepatitis E virus (HEV) [1, 2, 3].IntroductionIndividuals infected with enteric viruses can excrete large amounts of viral particles in body secretions, especially feces, even beyond the stage of symptomatic illness.", [["body secretions", "ANATOMY", 263, 278], ["feces", "ANATOMY", 291, 296], ["rotavirus, norovirus, astrovirus, adenovirus, enterovirus, hepatitis A virus (HAV), and hepatitis E", "DISEASE", 39, 138], ["enteric viruses", "DISEASE", 199, 214], ["humans", "ORGANISM", 28, 34], ["rotavirus", "ORGANISM", 39, 48], ["norovirus", "ORGANISM", 50, 59], ["astrovirus", "ORGANISM", 61, 71], ["adenovirus", "ORGANISM", 73, 83], ["enterovirus,", "ORGANISM", 85, 97], ["hepatitis A virus", "ORGANISM", 98, 115], ["HAV", "ORGANISM", 117, 120], ["hepatitis E virus", "ORGANISM", 127, 144], ["HEV", "ORGANISM", 146, 149], ["body secretions", "ORGANISM_SUBSTANCE", 263, 278], ["feces", "ORGANISM_SUBDIVISION", 291, 296], ["humans", "SPECIES", 28, 34], ["rotavirus", "SPECIES", 39, 48], ["hepatitis A virus", "SPECIES", 98, 115], ["hepatitis E virus", "SPECIES", 127, 144], ["humans", "SPECIES", 28, 34], ["rotavirus", "SPECIES", 39, 48], ["hepatitis A virus", "SPECIES", 98, 115], ["HAV", "SPECIES", 117, 120], ["hepatitis E virus", "SPECIES", 127, 144], ["HEV", "SPECIES", 146, 149], ["rotavirus", "PROBLEM", 39, 48], ["norovirus", "PROBLEM", 50, 59], ["astrovirus", "PROBLEM", 61, 71], ["adenovirus", "PROBLEM", 73, 83], ["enterovirus", "PROBLEM", 85, 96], ["hepatitis A virus (HAV)", "PROBLEM", 98, 121], ["hepatitis E virus", "PROBLEM", 127, 144], ["enteric viruses", "PROBLEM", 199, 214], ["viral particles in body secretions", "PROBLEM", 244, 278], ["symptomatic illness", "PROBLEM", 323, 342], ["main", "OBSERVATION_MODIFIER", 4, 8], ["rotavirus", "OBSERVATION", 39, 48], ["large", "OBSERVATION_MODIFIER", 227, 232], ["amounts", "OBSERVATION_MODIFIER", 233, 240], ["viral particles", "OBSERVATION", 244, 259], ["body", "OBSERVATION_MODIFIER", 263, 267], ["secretions", "OBSERVATION", 268, 278], ["symptomatic", "OBSERVATION_MODIFIER", 323, 334], ["illness", "OBSERVATION", 335, 342]]], ["These nonenveloped viruses are very stable in the environment and they are transmitted via the fecal-oral route.", [["oral", "ANATOMY", 101, 105], ["fecal", "ORGANISM_SUBDIVISION", 95, 100], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["These nonenveloped viruses", "PROBLEM", 0, 26], ["nonenveloped", "OBSERVATION_MODIFIER", 6, 18], ["viruses", "OBSERVATION", 19, 26], ["very", "OBSERVATION_MODIFIER", 31, 35], ["stable", "OBSERVATION_MODIFIER", 36, 42], ["fecal", "ANATOMY", 95, 100]]], ["Most outbreaks of enteric viral disease have been associated with water- or foodborne transmission [4, 5].IntroductionHowever, contamination of environmental surfaces seems to play an important role in the spread of these infections, especially in indoor establishments such as hospitals, nurseries, day care centers, and institutions for the elderly.", [["enteric viral disease", "DISEASE", 18, 39], ["infections", "DISEASE", 222, 232], ["enteric viral disease", "PROBLEM", 18, 39], ["contamination of environmental surfaces", "PROBLEM", 127, 166], ["these infections", "PROBLEM", 216, 232], ["enteric", "ANATOMY", 18, 25], ["viral disease", "OBSERVATION", 26, 39], ["infections", "OBSERVATION", 222, 232]]], ["Many enteric viruses have been associated with nosocomial and health care-related infections via contaminated hands and surfaces [6].", [["enteric viruses", "DISEASE", 5, 20], ["infections", "DISEASE", 82, 92], ["hands", "ORGANISM_SUBDIVISION", 110, 115], ["Many enteric viruses", "PROBLEM", 0, 20], ["nosocomial", "PROBLEM", 47, 57], ["related infections", "PROBLEM", 74, 92], ["enteric", "ANATOMY", 5, 12], ["viruses", "OBSERVATION", 13, 20], ["associated with", "UNCERTAINTY", 31, 46], ["nosocomial", "OBSERVATION", 47, 57]]], ["Various surfaces such as door handles, clothes, telephones, toilet seats, walls, thermometers, gloves, and papers can be contaminated and serve as vehicles for the virus [7].IntroductionMost fomite contaminations occur through direct contact or deposition of aerosol particles containing the virus.", [["gloves", "TREATMENT", 95, 101], ["the virus", "PROBLEM", 160, 169], ["Most fomite contaminations", "PROBLEM", 186, 212], ["aerosol particles", "TREATMENT", 259, 276], ["the virus", "PROBLEM", 288, 297], ["surfaces", "OBSERVATION_MODIFIER", 8, 16]]], ["Aerosols can be produced for example by toilet flushing [8] or via vomiting, coughing, sneezing, or talking [7].", [["vomiting", "DISEASE", 67, 75], ["coughing", "DISEASE", 77, 85], ["sneezing", "DISEASE", 87, 95], ["Aerosols", "SIMPLE_CHEMICAL", 0, 8], ["Aerosols", "TREATMENT", 0, 8], ["vomiting", "PROBLEM", 67, 75], ["coughing", "PROBLEM", 77, 85], ["sneezing", "PROBLEM", 87, 95]]], ["Thereafter, the virus can be transferred easily to others fomites through interaction with individuals [7].IntroductionVirus transfer from hands to fomites and vice-versa is thought to play a significant role in the spreading of infection.", [["fomites", "ANATOMY", 148, 155], ["infection", "DISEASE", 229, 238], ["hands", "ORGANISM_SUBDIVISION", 139, 144], ["the virus", "PROBLEM", 12, 21], ["infection", "PROBLEM", 229, 238], ["infection", "OBSERVATION", 229, 238]]], ["It has been shown that hands can be easily contaminated with norovirus by transfer from fomites, and then the contaminated hands could cross-contaminate up to 7 other surfaces without any recontamination [9].IntroductionIn hospitals and others health care centers, further dissemination has been associated with parents and staff trafficking when hygiene measures such as hand washing before and after visiting a patient are not strictly respected [10].IntroductionThe prevention of enteric virus-related nosocomial infections or outbreaks requires a good understanding of virus persistence in the environment and of the role of contaminated surfaces and objects in virus transmission.IntroductionThe survival of main enteric viruses on fomites and its implication for virus transmission will be analyzed, and the major disinfection procedures and their impact will be described.Factors Involved in Virus Survival on FomitesThe resistance of viruses in the environment, which determines the risk of transmission, is multifactorial, depending not only on virus characteristics but also on fomite properties and extrinsic environmental factors (Fig. 1).Factors Involved in Virus Survival on FomitesThe virus type is determinant for survival on surfaces, as well as the initial inoculum.", [["hand", "ANATOMY", 372, 376], ["fomites", "ANATOMY", 737, 744], ["norovirus", "DISEASE", 61, 70], ["nosocomial infections", "DISEASE", 505, 526], ["norovirus", "ORGANISM", 61, 70], ["hand", "ORGANISM_SUBDIVISION", 372, 376], ["patient", "ORGANISM", 413, 420], ["enteric virus", "ORGANISM", 483, 496], ["fomites", "CANCER", 737, 744], ["Virus", "ORGANISM", 899, 904], ["Virus", "ORGANISM", 1171, 1176], ["extrinsic environmental factors", "PROTEIN", 1110, 1141], ["patient", "SPECIES", 413, 420], ["norovirus", "PROBLEM", 61, 70], ["the contaminated hands", "PROBLEM", 106, 128], ["hygiene measures", "TREATMENT", 347, 363], ["hand washing", "TREATMENT", 372, 384], ["enteric virus", "PROBLEM", 483, 496], ["nosocomial infections", "PROBLEM", 505, 526], ["outbreaks", "PROBLEM", 530, 539], ["virus persistence", "PROBLEM", 573, 590], ["main enteric viruses", "PROBLEM", 713, 733], ["virus transmission", "TREATMENT", 769, 787], ["the major disinfection procedures", "TREATMENT", 810, 843], ["norovirus", "OBSERVATION", 61, 70], ["enteric virus", "OBSERVATION", 483, 496], ["nosocomial", "OBSERVATION_MODIFIER", 505, 515], ["infections", "OBSERVATION", 516, 526], ["virus", "OBSERVATION", 573, 578], ["main", "OBSERVATION_MODIFIER", 713, 717], ["enteric", "OBSERVATION_MODIFIER", 718, 725], ["viruses", "OBSERVATION", 726, 733], ["resistance", "OBSERVATION_MODIFIER", 928, 938], ["viruses", "OBSERVATION", 942, 949], ["virus", "OBSERVATION", 1200, 1205], ["determinant for", "UNCERTAINTY", 1214, 1229], ["survival", "OBSERVATION_MODIFIER", 1230, 1238], ["surfaces", "OBSERVATION_MODIFIER", 1242, 1250], ["initial", "OBSERVATION_MODIFIER", 1267, 1274], ["inoculum", "OBSERVATION", 1275, 1283]]], ["Generally enteric viruses are resistant and have been reported to persist on fomites for several weeks to months, as compared for example to respiratory viruses which can only resist for a few hours or days [11].", [["enteric viruses", "DISEASE", 10, 25], ["respiratory viruses", "DISEASE", 141, 160], ["Generally enteric viruses", "PROBLEM", 0, 25], ["respiratory viruses", "PROBLEM", 141, 160], ["enteric", "ANATOMY", 10, 17], ["viruses", "OBSERVATION", 18, 25], ["resistant", "OBSERVATION", 30, 39], ["viruses", "OBSERVATION", 153, 160]]], ["The higher the contaminating viral titer is, the longer the persistence will be [7].", [["The higher the contaminating viral titer", "PROBLEM", 0, 40], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["viral titer", "OBSERVATION", 29, 40]]], ["Some differences between the groups of viruses involved in gastroenteritis have also been described.", [["gastroenteritis", "DISEASE", 59, 74], ["viruses", "PROBLEM", 39, 46], ["gastroenteritis", "PROBLEM", 59, 74], ["viruses", "OBSERVATION", 39, 46], ["gastroenteritis", "OBSERVATION", 59, 74]]], ["HAV and rotavirus have been shown to be more resistant than adenovirus and enterovirus [12].Factors Involved in Virus Survival on FomitesThe nature of fomites could influence the survival of viruses.", [["HAV", "ORGANISM", 0, 3], ["rotavirus", "ORGANISM", 8, 17], ["adenovirus", "ORGANISM", 60, 70], ["enterovirus", "ORGANISM", 75, 86], ["Virus", "ORGANISM", 112, 117], ["HAV", "SPECIES", 0, 3], ["rotavirus", "SPECIES", 8, 17], ["adenovirus", "SPECIES", 60, 70], ["HAV", "PROBLEM", 0, 3], ["rotavirus", "PROBLEM", 8, 17], ["adenovirus", "PROBLEM", 60, 70], ["enterovirus", "PROBLEM", 75, 86], ["fomites", "PROBLEM", 151, 158], ["viruses", "PROBLEM", 191, 198], ["rotavirus", "OBSERVATION", 8, 17], ["viruses", "OBSERVATION", 191, 198]]], ["Surfaces are generally classified as porous (e.g., papers and clothes) or nonporous (e.g., stainless steel, plastic, and glass).", [["nonporous (e.g., stainless steel, plastic, and glass", "PROBLEM", 74, 126], ["porous", "OBSERVATION_MODIFIER", 37, 43], ["nonporous", "OBSERVATION_MODIFIER", 74, 83], ["stainless steel", "OBSERVATION_MODIFIER", 91, 106]]], ["Available data suggest that the majority of viruses persist longer on nonporous surfaces [7]; however, results are sometimes conflicting, and the effect of fomite properties might also depend on the viral type.", [["Available data", "TEST", 0, 14], ["viruses", "PROBLEM", 44, 51], ["fomite properties", "PROBLEM", 156, 173], ["viruses", "OBSERVATION", 44, 51], ["viral type", "OBSERVATION", 199, 209]]], ["For example, rotavirus seem to survive very well on nonporous surfaces, while results are very variable for porous ones [13].", [["rotavirus", "ORGANISM", 13, 22], ["rotavirus", "SPECIES", 13, 22], ["rotavirus", "PROBLEM", 13, 22]]], ["Poliovirus has been shown to be particularly susceptible to aluminum.", [["aluminum", "CHEMICAL", 60, 68], ["aluminum", "CHEMICAL", 60, 68], ["Poliovirus", "ORGANISM", 0, 10], ["aluminum", "SIMPLE_CHEMICAL", 60, 68], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus", "PROBLEM", 0, 10]]], ["By comparing HAV and rotavirus, it has been shown that HAV is more resistant on nonporous materials, while rotavirus is more stable on porous surfaces such as paper [12].", [["HAV", "DISEASE", 55, 58], ["HAV", "ORGANISM", 13, 16], ["rotavirus", "ORGANISM", 21, 30], ["HAV", "ORGANISM", 55, 58], ["rotavirus", "ORGANISM", 107, 116], ["HAV", "SPECIES", 13, 16], ["rotavirus", "SPECIES", 21, 30], ["HAV", "SPECIES", 55, 58], ["rotavirus", "SPECIES", 107, 116], ["rotavirus", "PROBLEM", 21, 30], ["HAV", "PROBLEM", 55, 58], ["rotavirus", "PROBLEM", 107, 116], ["more resistant", "OBSERVATION_MODIFIER", 62, 76], ["nonporous materials", "OBSERVATION_MODIFIER", 80, 99], ["stable", "OBSERVATION_MODIFIER", 125, 131]]], ["In similar conditions, astroviruses are able to persist for up to 90 days on paper, while they survive for a maximum of 60 days on nonporous surfaces [14].Factors Involved in Virus Survival on FomitesThe environmental factors include mainly air temperature and humidity, but the length of virus viability may also depend on the cleanliness of the surface, which can be determined for example by the presence or not of fecal material or by the number of microbes on the surface.", [["surface", "ANATOMY", 347, 354], ["surface", "ANATOMY", 469, 476], ["Virus", "ORGANISM", 175, 180], ["surface", "CELLULAR_COMPONENT", 347, 354], ["surface", "CELLULAR_COMPONENT", 469, 476], ["astroviruses", "PROBLEM", 23, 35], ["mainly air temperature and humidity", "PROBLEM", 234, 269], ["virus viability", "PROBLEM", 289, 304], ["fecal material", "PROBLEM", 418, 432], ["air temperature", "OBSERVATION", 241, 256], ["surface", "OBSERVATION_MODIFIER", 347, 354], ["fecal material", "OBSERVATION", 418, 432], ["microbes", "OBSERVATION", 453, 461], ["surface", "OBSERVATION_MODIFIER", 469, 476]]], ["These factors largely affect the resistance to desiccation, which appears to be an important determinant of virus survival on fomites [5].", [["These factors", "PROBLEM", 0, 13], ["desiccation", "PROBLEM", 47, 58]]], ["For most enteric viruses, low temperatures have been reported to promote a longer persistence [11].", [["most enteric viruses", "PROBLEM", 4, 24], ["low temperatures", "PROBLEM", 26, 42], ["viruses", "OBSERVATION", 17, 24], ["low temperatures", "OBSERVATION_MODIFIER", 26, 42]]], ["The effect of humidity is less consistent.", [["humidity", "TREATMENT", 14, 22]]], ["It has been reported that decreases in humidity could affect the infectivity of HAV, rotavirus, and adenovirus [12].", [["HAV", "ORGANISM", 80, 83], ["rotavirus", "ORGANISM", 85, 94], ["adenovirus", "ORGANISM", 100, 110], ["HAV", "SPECIES", 80, 83], ["rotavirus", "SPECIES", 85, 94], ["adenovirus", "SPECIES", 100, 110], ["the infectivity of HAV", "PROBLEM", 61, 83], ["rotavirus", "PROBLEM", 85, 94], ["adenovirus", "PROBLEM", 100, 110], ["decreases", "OBSERVATION_MODIFIER", 26, 35]]], ["Another study found that HAV was further preserved at a low humidity [15].", [["HAV", "ORGANISM", 25, 28], ["HAV", "SPECIES", 25, 28], ["Another study", "TEST", 0, 13], ["HAV", "PROBLEM", 25, 28]]], ["Conflicting results have also been described for other enteric viruses [11].", [["other enteric viruses", "PROBLEM", 49, 70], ["viruses", "OBSERVATION", 63, 70]]], ["Indeed, it has been suggested that viruses have a better survival at both low and high humidity, while intermediate humidity (e.g., between 40 and 70%) is deleterious [16].", [["viruses", "PROBLEM", 35, 42], ["high humidity", "OBSERVATION_MODIFIER", 82, 95]]], ["Overall, the humidity level is thought to play an important role in virus persistence in the environment, and it has been suggested to explain the seasonality of rotavirus infections, for example [17].", [["rotavirus infections", "DISEASE", 162, 182], ["rotavirus", "ORGANISM", 162, 171], ["rotavirus", "SPECIES", 162, 171], ["the humidity level", "TEST", 9, 27], ["rotavirus infections", "PROBLEM", 162, 182], ["thought to play", "UNCERTAINTY", 31, 46], ["rotavirus", "OBSERVATION", 162, 171]]], ["Nevertheless, in most studies, relative humidity (temperature dependent) has been reported, while some authors have shown more recently that absolute humidity (temperature independent) rather than relative humidity could explain the seasonality of infections [18].", [["infections", "DISEASE", 248, 258], ["relative humidity (temperature dependent", "PROBLEM", 31, 71], ["infections", "PROBLEM", 248, 258]]], ["Absolute humidity shows a high correlation between indoor and outdoor conditions [19], and it could be more useful to explain infections occurring in closed environments, such as norovirus outbreaks [18].Evidence of the Role of Fomites in the Transmission of Enteric VirusesThe contamination and the survival of enteric viruses on surfaces and objects can undoubtedly explain a significant proportion of acute viral diarrhea.", [["infections", "DISEASE", 126, 136], ["norovirus", "DISEASE", 179, 188], ["Enteric Viruses", "DISEASE", 259, 274], ["viral diarrhea", "DISEASE", 410, 424], ["Absolute humidity", "TEST", 0, 17], ["infections", "PROBLEM", 126, 136], ["norovirus outbreaks", "PROBLEM", 179, 198], ["Fomites", "PROBLEM", 228, 235], ["Enteric Viruses", "PROBLEM", 259, 274], ["enteric viruses", "PROBLEM", 312, 327], ["acute viral diarrhea", "PROBLEM", 404, 424], ["infections", "OBSERVATION", 126, 136], ["Enteric", "ANATOMY", 259, 266], ["Viruses", "OBSERVATION", 267, 274], ["enteric", "OBSERVATION_MODIFIER", 312, 319], ["viruses", "OBSERVATION", 320, 327], ["significant", "OBSERVATION_MODIFIER", 378, 389], ["acute", "OBSERVATION_MODIFIER", 404, 409], ["viral diarrhea", "OBSERVATION", 410, 424]]], ["Direct evidence of virus transmission via fomites is difficult to obtain because others routes such as person-to-person transmission are also usually suspected.Evidence of the Role of Fomites in the Transmission of Enteric VirusesEnteric viruses have been detected frequently from naturally contaminated fomites in hospitals, houses, or others community facilities.", [["Enteric viruses", "DISEASE", 230, 245], ["Enteric Viruses", "ORGANISM", 215, 230], ["person", "SPECIES", 103, 109], ["person", "SPECIES", 113, 119], ["virus transmission via fomites", "PROBLEM", 19, 49], ["Enteric VirusesEnteric viruses", "PROBLEM", 215, 245], ["virus", "OBSERVATION", 19, 24], ["Enteric", "ANATOMY", 215, 222], ["Viruses", "OBSERVATION", 223, 230], ["viruses", "OBSERVATION", 238, 245]]], ["The early reported prevalence of rotaviruses on fomites was very high, especially in pediatric settings, ranging from 19 to 79% [20, 21, 22, 23].", [["rotaviruses", "DISEASE", 33, 44], ["rotaviruses", "ORGANISM", 33, 44], ["rotaviruses", "PROBLEM", 33, 44], ["rotaviruses", "OBSERVATION", 33, 44], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["In a more recent study, a significant rate (14%) was detected on environmental surfaces in a hospital intensive care unit [24].", [["a significant rate", "TEST", 24, 42], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["Toys were associated with a rotavirus outbreak in a pediatric oncology unit [25].", [["rotavirus", "SPECIES", 28, 37], ["a rotavirus outbreak", "PROBLEM", 26, 46]]], ["Beyond detection of viral RNA by RT-PCR, infectious particles have been reported in some cases [24].", [["viral RNA", "RNA", 20, 29], ["viral RNA", "PROBLEM", 20, 29], ["RT-PCR", "TEST", 33, 39], ["infectious particles", "PROBLEM", 41, 61], ["viral RNA", "OBSERVATION", 20, 29], ["infectious", "OBSERVATION", 41, 51]]], ["Noroviruses have been found on surfaces and objects around patients during outbreaks in hospitals, hotels, or cruise ships [7, 26, 27].", [["Noroviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Noroviruses", "PROBLEM", 0, 11], ["surfaces", "OBSERVATION_MODIFIER", 31, 39]]], ["The role of contamination of environmental surfaces such as dining room tables or elevator buttons used by staff has been reported in a norovirus outbreak in a long-term care center [28].", [["norovirus", "DISEASE", 136, 145], ["contamination of environmental surfaces", "TREATMENT", 12, 51]]], ["Touching a reusable grocery bag was linked to cases in a norovirus outbreak in a soccer team [29].", [["norovirus", "DISEASE", 57, 66], ["a reusable grocery bag", "TREATMENT", 9, 31]]], ["A high rate of norovirus contamination (58%) in environmental swabs has been observed during outbreaks [30].Evidence of the Role of Fomites in the Transmission of Enteric VirusesContamination of fomites by adenoviruses has been described [31, 32], including the presence of infectious particles [33].Evidence of the Role of Fomites in the Transmission of Enteric VirusesDetection of astroviruses on environment surfaces was also reported during a hospital outbreak [23, 34].", [["norovirus contamination", "DISEASE", 15, 38], ["Enteric Viruses", "DISEASE", 163, 178], ["norovirus", "ORGANISM", 15, 24], ["adenoviruses", "ORGANISM", 206, 218], ["norovirus", "SPECIES", 15, 24], ["A high rate of norovirus contamination", "PROBLEM", 0, 38], ["environmental swabs", "TEST", 48, 67], ["Fomites", "PROBLEM", 132, 139], ["Enteric Viruses", "PROBLEM", 163, 178], ["adenoviruses", "PROBLEM", 206, 218], ["infectious particles", "PROBLEM", 274, 294], ["astroviruses", "PROBLEM", 383, 395], ["high", "OBSERVATION_MODIFIER", 2, 6], ["norovirus", "OBSERVATION", 15, 24], ["Enteric", "ANATOMY", 163, 170], ["Viruses", "OBSERVATION", 171, 178], ["infectious", "OBSERVATION", 274, 284], ["Enteric", "OBSERVATION_MODIFIER", 355, 362], ["astroviruses", "OBSERVATION", 383, 395]]], ["Contamination of drinking glasses with HAV by a barman during incubation of the infection resulted in an outbreak of hepatitis A in a public house [35].Norovirus ::: Experimental Study of Virus Survival on FomitesNorovirus is a leading cause of sporadic and epidemic cases of acute gastroenteritis across all age groups worldwide [39].", [["HAV", "DISEASE", 39, 42], ["barman", "CHEMICAL", 48, 54], ["infection", "DISEASE", 80, 89], ["hepatitis A", "DISEASE", 117, 128], ["Norovirus", "DISEASE", 152, 161], ["Norovirus", "DISEASE", 213, 222], ["gastroenteritis", "DISEASE", 282, 297], ["HAV", "ORGANISM", 39, 42], ["Norovirus", "ORGANISM", 152, 161], ["Virus", "ORGANISM", 188, 193], ["HAV", "SPECIES", 39, 42], ["hepatitis A", "SPECIES", 117, 128], ["the infection", "PROBLEM", 76, 89], ["hepatitis A", "PROBLEM", 117, 128], ["Experimental Study", "TEST", 166, 184], ["FomitesNorovirus", "PROBLEM", 206, 222], ["sporadic", "PROBLEM", 245, 253], ["acute gastroenteritis", "PROBLEM", 276, 297], ["infection", "OBSERVATION", 80, 89], ["hepatitis", "OBSERVATION", 117, 126], ["acute", "OBSERVATION_MODIFIER", 276, 281], ["gastroenteritis", "OBSERVATION", 282, 297]]], ["The virus is highly infectious and 10-100 virions are enough to cause gastroenteritis.", [["gastroenteritis", "DISEASE", 70, 85], ["The virus", "PROBLEM", 0, 9], ["highly infectious", "PROBLEM", 13, 30], ["gastroenteritis", "PROBLEM", 70, 85], ["virus", "OBSERVATION", 4, 9], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["infectious", "OBSERVATION", 20, 30], ["gastroenteritis", "OBSERVATION", 70, 85]]], ["To date, human norovirus cannot be propagated in mammalian cell lines.", [["cell lines", "ANATOMY", 59, 69], ["human", "ORGANISM", 9, 14], ["norovirus", "ORGANISM", 15, 24], ["mammalian cell lines", "CELL", 49, 69], ["mammalian cell lines", "CELL_LINE", 49, 69], ["human", "SPECIES", 9, 14], ["human norovirus", "SPECIES", 9, 24], ["human norovirus", "PROBLEM", 9, 24], ["mammalian cell lines", "TREATMENT", 49, 69], ["norovirus", "OBSERVATION", 15, 24], ["mammalian cell lines", "OBSERVATION", 49, 69]]], ["Therefore, survival and inactivation studies are commonly conducted using cultivable surrogates such as feline calicivirus (FCV) or murine norovirus (MNV) [40].", [["feline calicivirus", "DISEASE", 104, 122], ["feline calicivirus", "ORGANISM", 104, 122], ["FCV", "ORGANISM", 124, 127], ["murine norovirus", "ORGANISM", 132, 148], ["MNV", "ORGANISM", 150, 153], ["feline calicivirus", "SPECIES", 104, 122], ["murine", "SPECIES", 132, 138], ["feline calicivirus", "SPECIES", 104, 122], ["FCV", "SPECIES", 124, 127], ["MNV", "SPECIES", 150, 153], ["inactivation studies", "TEST", 24, 44], ["cultivable surrogates", "TREATMENT", 74, 95], ["feline calicivirus (FCV", "TREATMENT", 104, 127]]], ["Doultree et al. [41] assessed FCV survival on glass and glass coverslips.", [["FCV", "ORGANISM", 30, 33], ["FCV", "SPECIES", 30, 33], ["glass and glass coverslips", "TREATMENT", 46, 72]]], ["The virus remained infectious for up to 57 days at 4\u00b0C and the resistance decreased significantly with higher temperatures.", [["C", "GENE_OR_GENE_PRODUCT", 53, 54], ["The virus", "PROBLEM", 0, 9], ["infectious", "PROBLEM", 19, 29], ["the resistance", "PROBLEM", 59, 73], ["higher temperatures", "PROBLEM", 103, 122], ["virus", "OBSERVATION", 4, 9], ["infectious", "OBSERVATION", 19, 29], ["resistance", "OBSERVATION_MODIFIER", 63, 73], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["higher temperatures", "OBSERVATION_MODIFIER", 103, 122]]], ["D'Souza et al. [42] also found that FCV survived for more than 7 days at room temperature on stainless steel, ceramic, and formica surfaces.", [["FCV", "ORGANISM", 36, 39], ["FCV", "SPECIES", 36, 39], ["stainless steel, ceramic", "TREATMENT", 93, 117], ["stainless steel", "OBSERVATION_MODIFIER", 93, 108], ["formica surfaces", "OBSERVATION", 123, 139]]], ["A shorter survival ranging from 8-12 h (keyboard keys and brass) to 2-3 days (telephone buttons and telephone receivers) was reported on uncommon fomites.", [["A shorter survival", "TREATMENT", 0, 18]]], ["Unlike norovirus, which is an enteric pathogen, FCV causes respiratory diseases in cats and is not an ideal surrogate.", [["respiratory", "ANATOMY", 59, 70], ["norovirus", "DISEASE", 7, 16], ["FCV", "DISEASE", 48, 51], ["respiratory diseases", "DISEASE", 59, 79], ["norovirus", "ORGANISM", 7, 16], ["FCV", "ORGANISM", 48, 51], ["cats", "ORGANISM", 83, 87], ["cats", "SPECIES", 83, 87], ["FCV", "SPECIES", 48, 51], ["norovirus", "PROBLEM", 7, 16], ["an enteric pathogen", "PROBLEM", 27, 46], ["respiratory diseases in cats", "PROBLEM", 59, 87], ["norovirus", "OBSERVATION", 7, 16], ["enteric", "OBSERVATION_MODIFIER", 30, 37], ["pathogen", "OBSERVATION", 38, 46], ["respiratory diseases", "OBSERVATION", 59, 79]]], ["MNV has been reported to be more applicable as a norovirus surrogate because it shows environmental stability and is genetically close to human norovirus [43].", [["norovirus", "DISEASE", 49, 58], ["norovirus", "DISEASE", 144, 153], ["MNV", "ORGANISM", 0, 3], ["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["MNV", "SPECIES", 0, 3], ["human norovirus", "SPECIES", 138, 153], ["a norovirus surrogate", "TEST", 47, 68], ["stability", "OBSERVATION", 100, 109]]], ["Kim et al. [40] investigated MNV survival on steel and wood, and a better resistance was shown on wood at lower temperature and higher relative humidity values.", [["wood", "ANATOMY", 55, 59], ["wood", "ANATOMY", 98, 102], ["MNV", "ORGANISM", 29, 32], ["wood", "ORGANISM_SUBDIVISION", 98, 102]]], ["In another study conducted at room temperature, the authors demonstrated that MNV could survive for up to 28 days on 6 different surfaces and the rank order of infectivity reduction from highest to lowest was stainless steel, plastic, rubber, glass, ceramic, and wood [44].", [["MNV", "ORGANISM", 78, 81], ["MNV", "SPECIES", 78, 81], ["another study", "TEST", 3, 16], ["MNV", "PROBLEM", 78, 81], ["infectivity reduction", "PROBLEM", 160, 181]]], ["Human norovirus, MNV, and FCV were found to remain infective beyond 70 days on stainless steel and plastic both at 7\u00b0C and at room temperature [45].Rotavirus ::: Experimental Study of Virus Survival on FomitesRotavirus is the leading cause of diarrhea-related illness worldwide among children aged <5 years, accounting for the majority of diarrhea-related deaths, especially in low-income countries [46].", [["Rotavirus", "DISEASE", 148, 157], ["FomitesRotavirus", "DISEASE", 202, 218], ["diarrhea", "DISEASE", 243, 251], ["illness", "DISEASE", 260, 267], ["diarrhea", "DISEASE", 339, 347], ["deaths", "DISEASE", 356, 362], ["Human", "ORGANISM", 0, 5], ["norovirus", "ORGANISM", 6, 15], ["MNV", "ORGANISM", 17, 20], ["FCV", "ORGANISM", 26, 29], ["Rotavirus", "ORGANISM", 148, 157], ["Virus", "ORGANISM", 184, 189], ["children", "ORGANISM", 284, 292], ["Human", "SPECIES", 0, 5], ["FCV", "SPECIES", 26, 29], ["children", "SPECIES", 284, 292], ["Human norovirus", "SPECIES", 0, 15], ["MNV", "SPECIES", 17, 20], ["FCV", "SPECIES", 26, 29], ["Human norovirus", "PROBLEM", 0, 15], ["FCV", "TREATMENT", 26, 29], ["infective", "PROBLEM", 51, 60], ["stainless steel", "TREATMENT", 79, 94], ["Experimental Study", "TEST", 162, 180], ["Rotavirus", "PROBLEM", 209, 218], ["diarrhea", "PROBLEM", 243, 251], ["diarrhea", "PROBLEM", 339, 347], ["infective", "OBSERVATION", 51, 60], ["diarrhea", "OBSERVATION", 243, 251]]], ["Rotavirus has displayed a good resistance in the environment.", [["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus", "SPECIES", 0, 9], ["Rotavirus", "PROBLEM", 0, 9], ["good resistance", "OBSERVATION", 26, 41]]], ["When rotavirus suspension in culture medium is applied on aluminum and paper, infectious particles can be detected for more than 2 months between 4 and 20\u00b0C at a high relative humidity.", [["aluminum", "CHEMICAL", 58, 66], ["aluminum", "CHEMICAL", 58, 66], ["rotavirus", "ORGANISM", 5, 14], ["aluminum", "SIMPLE_CHEMICAL", 58, 66], ["C", "GENE_OR_GENE_PRODUCT", 155, 156], ["rotavirus", "SPECIES", 5, 14], ["rotavirus suspension", "TREATMENT", 5, 25], ["culture medium", "TREATMENT", 29, 43], ["aluminum", "TREATMENT", 58, 66], ["infectious particles", "PROBLEM", 78, 98], ["infectious", "OBSERVATION", 78, 88]]], ["However, in a 20% fecal suspension, survival was better at 20\u00b0C [12].", [["fecal", "ORGANISM_SUBSTANCE", 18, 23], ["a 20% fecal suspension", "TREATMENT", 12, 34]]], ["The impact of relative humidity is not consistent throughout studies [13, 17].Adenovirus ::: Experimental Study of Virus Survival on FomitesHuman adenoviruses type 40/41, known as enteric adenoviruses, have been associated with sporadic acute diarrhea as well as outbreaks [47, 48].", [["enteric adenoviruses", "DISEASE", 180, 200], ["diarrhea", "DISEASE", 243, 251], ["Adenovirus", "ORGANISM", 78, 88], ["Virus", "ORGANISM", 115, 120], ["FomitesHuman adenoviruses type 40/41", "ORGANISM", 133, 169], ["adenoviruses", "ORGANISM", 188, 200], ["Adenovirus", "SPECIES", 78, 88], ["FomitesHuman adenoviruses type 40/41", "SPECIES", 133, 169], ["relative humidity", "TREATMENT", 14, 31], ["Experimental Study", "TEST", 93, 111], ["FomitesHuman adenoviruses type", "TREATMENT", 133, 163], ["enteric adenoviruses", "PROBLEM", 180, 200], ["sporadic acute diarrhea", "PROBLEM", 228, 251], ["relative humidity", "OBSERVATION", 14, 31], ["not consistent", "UNCERTAINTY", 35, 49], ["enteric", "ANATOMY", 180, 187], ["adenoviruses", "OBSERVATION", 188, 200], ["associated with", "UNCERTAINTY", 212, 227], ["sporadic", "OBSERVATION_MODIFIER", 228, 236], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["diarrhea", "OBSERVATION", 243, 251]]], ["Adenovirus 40 has been shown to resist for more than 1 month between 4 and 20\u00b0C. Survival is longer on paper than on aluminum [12].Astroviruses ::: Experimental Study of Virus Survival on FomitesHuman astroviruses are considered gastrointestinal pathogens that affect mainly children worldwide [49].", [["gastrointestinal", "ANATOMY", 229, 245], ["aluminum", "CHEMICAL", 117, 125], ["gastrointestinal pathogens", "DISEASE", 229, 255], ["aluminum", "CHEMICAL", 117, 125], ["Adenovirus 40", "ORGANISM", 0, 13], ["aluminum [12]", "SIMPLE_CHEMICAL", 117, 130], ["Virus", "ORGANISM", 170, 175], ["children", "ORGANISM", 275, 283], ["children", "SPECIES", 275, 283], ["Adenovirus 40", "SPECIES", 0, 13], ["Adenovirus", "TREATMENT", 0, 10], ["Experimental Study", "TEST", 148, 166], ["FomitesHuman astroviruses", "TREATMENT", 188, 213], ["gastrointestinal pathogens", "PROBLEM", 229, 255]]], ["The experimental survival of astroviruses has been poorly investigated.", [["astroviruses", "CANCER", 29, 41], ["astroviruses", "PROBLEM", 29, 41], ["survival", "OBSERVATION_MODIFIER", 17, 25], ["astroviruses", "OBSERVATION", 29, 41]]], ["It has been shown that the virus can survive for a long time on both porous and nonporous surfaces.", [["the virus", "PROBLEM", 23, 32], ["virus", "OBSERVATION", 27, 32], ["nonporous surfaces", "OBSERVATION", 80, 98]]], ["Resistance is better at low temperatures and on porous surfaces (up to 90 days at 4\u00b0C on paper) [14].Hepatitis A ::: Experimental Study of Virus Survival on FomitesViral hepatitis A is a global health problem that affects hundreds of millions of children and adults, especially in low-income countries where food and water hygiene may be of a low standard [50].", [["Hepatitis", "DISEASE", 101, 110], ["Viral hepatitis A", "DISEASE", 164, 181], ["Virus", "ORGANISM", 139, 144], ["children", "ORGANISM", 246, 254], ["children", "SPECIES", 246, 254], ["Viral hepatitis A", "SPECIES", 164, 181], ["Experimental Study", "TEST", 117, 135], ["Viral hepatitis", "PROBLEM", 164, 179], ["better", "OBSERVATION_MODIFIER", 14, 20], ["low temperatures", "OBSERVATION_MODIFIER", 24, 40], ["hepatitis", "OBSERVATION", 170, 179]]], ["The virus is primarily a human pathogen transmitted by person-to-person contact or ingestion of contaminated food or water, but contaminated fomites can play a role in transmission.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["person", "SPECIES", 55, 61], ["person", "SPECIES", 65, 71], ["human", "SPECIES", 25, 30], ["The virus", "PROBLEM", 0, 9], ["a human pathogen", "PROBLEM", 23, 39], ["virus", "OBSERVATION", 4, 9]]], ["HAV can survive for more than 2 months on fomites, and a better resistance has been observed on nonporous surfaces.", [["HAV", "ORGANISM", 0, 3], ["HAV", "SPECIES", 0, 3]]], ["Fecal suspension and a low temperature have been shown to have a positive effect on persistence [12], but the impact of the relative humidity level has not been confirmed [15].", [["Fecal", "ANATOMY", 0, 5], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["Fecal suspension", "TREATMENT", 0, 16], ["a low temperature", "PROBLEM", 21, 38], ["the relative humidity level", "TEST", 120, 147], ["suspension", "OBSERVATION_MODIFIER", 6, 16], ["low temperature", "OBSERVATION_MODIFIER", 23, 38], ["positive effect", "OBSERVATION_MODIFIER", 65, 80]]], ["A recent study found in similar conditions a better survival on wood [40].Enteroviruses ::: Experimental Study of Virus Survival on FomitesThe genus Enterovirus includes a great variety of human pathogens such as polioviruses, coxsackieviruses A and B, echovirus, and EV71.", [["Enterovirus", "DISEASE", 149, 160], ["echovirus", "DISEASE", 253, 262], ["EV71", "DISEASE", 268, 272], ["Virus", "ORGANISM", 114, 119], ["Enterovirus", "ORGANISM", 149, 160], ["human", "ORGANISM", 189, 194], ["coxsackieviruses A", "ORGANISM", 227, 245], ["B", "GENE_OR_GENE_PRODUCT", 250, 251], ["echovirus", "ORGANISM", 253, 262], ["EV71", "ORGANISM", 268, 272], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["EV71", "SPECIES", 268, 272], ["A recent study", "TEST", 0, 14], ["Experimental Study", "TEST", 92, 110], ["The genus Enterovirus", "PROBLEM", 139, 160], ["human pathogens", "PROBLEM", 189, 204], ["polioviruses", "PROBLEM", 213, 225], ["coxsackieviruses", "PROBLEM", 227, 243], ["echovirus", "PROBLEM", 253, 262], ["EV71", "PROBLEM", 268, 272], ["genus Enterovirus", "OBSERVATION", 143, 160]]], ["Enteroviruses can cause gastrointestinal symptoms; however, studies investigating the role of nonpolio enteroviruses in acute diarrhea are rare compared to those on major agents such as rotavirus [51].", [["gastrointestinal", "ANATOMY", 24, 40], ["Enteroviruses", "DISEASE", 0, 13], ["gastrointestinal symptoms", "DISEASE", 24, 49], ["enteroviruses", "DISEASE", 103, 116], ["diarrhea", "DISEASE", 126, 134], ["gastrointestinal", "ORGAN", 24, 40], ["nonpolio enteroviruses", "ORGANISM", 94, 116], ["Enteroviruses", "PROBLEM", 0, 13], ["gastrointestinal symptoms", "PROBLEM", 24, 49], ["studies", "TEST", 60, 67], ["nonpolio enteroviruses", "PROBLEM", 94, 116], ["acute diarrhea", "PROBLEM", 120, 134], ["rotavirus", "PROBLEM", 186, 195], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["diarrhea", "OBSERVATION", 126, 134]]], ["Enteroviruses are involved in various and numerous acute diseases, and their role in chronic cardiac diseases and type 1 diabetes is highly suspected [52].", [["cardiac", "ANATOMY", 93, 100], ["cardiac diseases", "DISEASE", 93, 109], ["type 1 diabetes", "DISEASE", 114, 129], ["Enteroviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["cardiac", "ORGAN", 93, 100], ["Enteroviruses", "PROBLEM", 0, 13], ["numerous acute diseases", "PROBLEM", 42, 65], ["chronic cardiac diseases", "PROBLEM", 85, 109], ["type 1 diabetes", "PROBLEM", 114, 129], ["numerous", "OBSERVATION_MODIFIER", 42, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["diseases", "OBSERVATION", 57, 65], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["cardiac", "ANATOMY", 93, 100], ["diseases", "OBSERVATION", 101, 109]]], ["Data on the survival of enteroviruses are scarce, with only few old data focusing on the poliovirus prototype.", [["enteroviruses", "DISEASE", 24, 37], ["enteroviruses", "ORGANISM", 24, 37], ["poliovirus", "ORGANISM", 89, 99], ["enteroviruses", "PROBLEM", 24, 37], ["the poliovirus prototype", "PROBLEM", 85, 109], ["enteroviruses", "OBSERVATION", 24, 37], ["few", "OBSERVATION_MODIFIER", 60, 63], ["poliovirus", "OBSERVATION", 89, 99]]], ["Poliovirus can survive for up to 1 month at 4\u00b0C. Feces increase survival, while a rapid decrease has been observed on aluminum surfaces [12].", [["Feces", "ANATOMY", 49, 54], ["aluminum", "CHEMICAL", 118, 126], ["aluminum", "CHEMICAL", 118, 126], ["Poliovirus", "ORGANISM", 0, 10], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus", "PROBLEM", 0, 10], ["a rapid decrease", "PROBLEM", 80, 96], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["survival", "OBSERVATION_MODIFIER", 64, 72]]], ["Recently our team investigated the survival of Coxsackievirus B4 on an inanimate surface.", [["surface", "ANATOMY", 81, 88], ["Coxsackievirus B4", "ORGANISM", 47, 64], ["Coxsackievirus B4", "SPECIES", 47, 64], ["Coxsackievirus B4", "PROBLEM", 47, 64], ["Coxsackievirus B4", "OBSERVATION", 47, 64]]], ["When the virus was dried on a petri dish lid at 20\u00b0C, infectious particles could be detected for up to 5 weeks.", [["the virus", "PROBLEM", 5, 14], ["a petri dish lid", "TREATMENT", 28, 44], ["infectious particles", "PROBLEM", 54, 74], ["virus", "OBSERVATION", 9, 14], ["infectious", "OBSERVATION", 54, 64]]], ["CVB4 was especially susceptible to repetitive cycles of drying and resuspension, with a significant decrease in the viral titer at each cycle.", [["CVB4", "GENE_OR_GENE_PRODUCT", 0, 4], ["CVB4", "SPECIES", 0, 4], ["repetitive cycles of drying", "TREATMENT", 35, 62], ["resuspension", "TREATMENT", 67, 79], ["a significant decrease in the viral titer", "PROBLEM", 86, 127], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["decrease", "OBSERVATION_MODIFIER", 100, 108], ["viral titer", "OBSERVATION", 116, 127]]], ["The viability of CVB4 was also highly reduced when the virus was dried in a protein-rich medium [53].Enteroviruses ::: Experimental Study of Virus Survival on FomitesSelected data on the survival of enteric viruses are shown in Table 1 [12, 14, 40, 41, 53].Thermal Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesTemperature is one of the major factors determining virus survival outside a cell.", [["cell", "ANATOMY", 422, 426], ["CVB4", "GENE_OR_GENE_PRODUCT", 17, 21], ["Virus", "ORGANISM", 141, 146], ["cell", "CELL", 422, 426], ["The viability of CVB4", "TEST", 0, 21], ["the virus", "PROBLEM", 51, 60], ["Experimental Study", "TEST", 119, 137], ["FomitesSelected data", "TEST", 159, 179], ["enteric viruses", "PROBLEM", 199, 214], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["reduced", "OBSERVATION_MODIFIER", 38, 45], ["enteric", "ANATOMY", 199, 206], ["viruses", "OBSERVATION", 207, 214], ["Enteric", "ANATOMY", 298, 305], ["Viruses", "OBSERVATION", 306, 313]]], ["Its effect on virus inactivation has been evaluated under different conditions, including wet and dry.", [["virus inactivation", "TREATMENT", 14, 32], ["virus inactivation", "OBSERVATION", 14, 32], ["dry", "OBSERVATION", 98, 101]]], ["The common mechanism reported for picornaviruses and caliciviruses is destabilization and disruption of the viral capsid leading to its breakdown and the release of viral RNA [54], while for rotaviruses heat treatment has been shown to primarily target viral transcription functions [55].Thermal Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesExperiments for evaluation of the long-term persistence of enteric viruses outside a cell have shown that, overall, enteric viruses have a long-term survival in suspension at environmental temperatures (e.g., up to 25\u00b0C) [56, 57, 58].Thermal Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesThermal inactivation is principally used for enteric viruses in suspension and in food samples and less often for fomites.", [["cell", "ANATOMY", 461, 465], ["food samples", "ANATOMY", 780, 792], ["rotaviruses", "ORGANISM", 191, 202], ["cell", "CELL", 461, 465], ["enteric viruses", "ORGANISM", 492, 507], ["viral capsid", "PROTEIN", 108, 120], ["viral RNA", "RNA", 165, 174], ["picornaviruses", "PROBLEM", 34, 48], ["caliciviruses", "PROBLEM", 53, 66], ["destabilization", "PROBLEM", 70, 85], ["the viral capsid", "PROBLEM", 104, 120], ["its breakdown", "PROBLEM", 132, 145], ["viral RNA", "PROBLEM", 165, 174], ["rotaviruses heat treatment", "TREATMENT", 191, 217], ["evaluation", "TEST", 392, 402], ["enteric viruses", "PROBLEM", 435, 450], ["a long-term survival", "TREATMENT", 513, 533], ["Thermal inactivation", "TREATMENT", 698, 718], ["enteric viruses in suspension", "TREATMENT", 743, 772], ["picornaviruses", "OBSERVATION", 34, 48], ["caliciviruses", "OBSERVATION", 53, 66], ["viral capsid", "OBSERVATION", 108, 120], ["Enteric", "ANATOMY", 329, 336], ["Viruses", "OBSERVATION", 337, 344], ["enteric", "ANATOMY", 435, 442], ["viruses", "OBSERVATION", 443, 450], ["Enteric", "ANATOMY", 651, 658], ["Viruses", "OBSERVATION", 659, 666], ["viruses", "OBSERVATION", 751, 758]]], ["Two temperatures have been commonly applied: 63\u00b0C, recommended for pasteurization and, 72\u00b0C, recommended for sterilization, with an exposure time of 30 and 2 min, respectively.", [["Two temperatures", "TEST", 0, 16], ["pasteurization", "TREATMENT", 67, 81], ["sterilization", "TREATMENT", 109, 122]]], ["Under experimental conditions these two temperatures would most likely result in efficient virus inactivation.Thermal Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesResistance on warmed surfaces of MNV and CVB4 contained in droplets has been studied [59].", [["CVB4", "CHEMICAL", 239, 243], ["MNV", "ORGANISM", 231, 234], ["CVB4", "SIMPLE_CHEMICAL", 239, 243], ["MNV", "SPECIES", 231, 234], ["efficient virus inactivation", "PROBLEM", 81, 109], ["virus", "OBSERVATION", 91, 96], ["Enteric", "ANATOMY", 151, 158], ["Viruses", "OBSERVATION", 159, 166]]], ["CVB4 was inactivated in 5 s at 70\u00b0C, while 90 min were necessary to inactivate MNV at 80\u00b0C.UV Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesUV irradiations are commonly used for viral inactivation in food, in water, on food preparation surfaces, and in microbiology laboratories [60, 61].", [["CVB4", "GENE_OR_GENE_PRODUCT", 0, 4], ["MNV", "ORGANISM", 79, 82], ["CVB4", "PROTEIN", 0, 4], ["CVB4", "SPECIES", 0, 4], ["Physical ApproachesUV irradiations", "TREATMENT", 155, 189], ["viral inactivation in food", "PROBLEM", 212, 238], ["Enteric", "ANATOMY", 127, 134], ["Viruses", "OBSERVATION", 135, 142]]], ["UV-C radiation at wavelengths of 250-280 nm has been approved for disinfection purposes by the US Food and Drug Administration (FDA).", [["UV-C", "CHEMICAL", 0, 4], ["UV-C", "SIMPLE_CHEMICAL", 0, 4], ["UV", "TREATMENT", 0, 2], ["C radiation", "TREATMENT", 3, 14], ["disinfection purposes", "TREATMENT", 66, 87]]], ["Its antiviral activity is well known and can be applied to food, water, and surfaces [60, 62].UV Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesSusceptibility may vary between viruses.", [["antiviral activity", "OBSERVATION", 4, 22], ["Enteric", "ANATOMY", 130, 137], ["Viruses", "OBSERVATION", 138, 145], ["viruses", "OBSERVATION", 209, 216]]], ["Enteroviruses have been inactivated with commonly recommended UV-C doses, while adenoviruses have been reported to be more resistant [63, 64].UV Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesPark and al. [62] evaluated the effect of continuous UV-C treatment on stainless steel experimentally contaminated with MNV and HAV.", [["Enteric Viruses", "DISEASE", 178, 193], ["UV-C", "CHEMICAL", 278, 282], ["UV-C", "SIMPLE_CHEMICAL", 62, 66], ["adenoviruses", "ORGANISM", 80, 92], ["UV-C", "SIMPLE_CHEMICAL", 278, 282], ["MNV", "ORGANISM", 345, 348], ["HAV", "ORGANISM", 353, 356], ["MNV", "SPECIES", 345, 348], ["HAV", "SPECIES", 353, 356], ["Enteroviruses", "TREATMENT", 0, 13], ["UV-C doses", "TREATMENT", 62, 72], ["adenoviruses", "PROBLEM", 80, 92], ["continuous UV-C treatment on stainless steel", "TREATMENT", 267, 311], ["HAV", "PROBLEM", 353, 356], ["Enteric", "ANATOMY", 178, 185], ["Viruses", "OBSERVATION", 186, 193]]], ["Their data showed that HAV was more resistant to UV-C radiation than to MNV.", [["UV-C", "CHEMICAL", 49, 53], ["HAV", "ORGANISM", 23, 26], ["UV-C", "SIMPLE_CHEMICAL", 49, 53], ["MNV", "ORGANISM", 72, 75], ["HAV", "SPECIES", 23, 26], ["MNV", "SPECIES", 72, 75], ["Their data", "TEST", 0, 10], ["HAV", "PROBLEM", 23, 26], ["UV-C radiation", "TREATMENT", 49, 63]]], ["Using various UV-C dosages, they concluded that only 40 mW/cm2 was needed to reduce MNV infectivity by 2 logs, while this result was achieved beyond 180 mW/cm2 for HAV [62].UV Inactivation ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesPulsed UV light has been reported to be more effective than conventional (continuous) UV light, inducing a more rapid inactivation of infectious agents.", [["UV-C", "SIMPLE_CHEMICAL", 14, 18], ["MNV", "ORGANISM", 84, 87], ["MNV", "SPECIES", 84, 87], ["HAV", "SPECIES", 164, 167], ["various UV-C dosages", "TREATMENT", 6, 26], ["MNV infectivity", "PROBLEM", 84, 99], ["HAV", "PROBLEM", 164, 167], ["conventional (continuous) UV light", "TREATMENT", 316, 350], ["infectious agents", "TREATMENT", 390, 407], ["Enteric", "ANATOMY", 209, 216], ["Viruses", "OBSERVATION", 217, 224], ["infectious", "OBSERVATION", 390, 400]]], ["One 2-s treatment (6 pulses) can result in a 5-log decrease in the viral load for both MNV and HAV.", [["HAV", "DISEASE", 95, 98], ["MNV", "ORGANISM", 87, 90], ["HAV", "ORGANISM", 95, 98], ["MNV", "SPECIES", 87, 90], ["HAV", "SPECIES", 95, 98], ["the viral load", "TEST", 63, 77], ["HAV", "PROBLEM", 95, 98], ["viral load", "OBSERVATION", 67, 77]]], ["Effectiveness is reduced in the presence of organic matter (fetal bovine serum) [61].", [["fetal", "ANATOMY", 60, 65], ["serum", "ANATOMY", 73, 78], ["bovine", "ORGANISM", 66, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["bovine", "SPECIES", 66, 72], ["organic matter", "PROBLEM", 44, 58], ["fetal bovine serum", "TEST", 60, 78], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["organic matter", "OBSERVATION", 44, 58]]], ["The effects of UV inactivation have been observed at the protein and RNA levels.", [["UV inactivation", "TREATMENT", 15, 30], ["UV inactivation", "OBSERVATION", 15, 30]]], ["It has been shown that UV disrupts the MNV-1 structure and degrades both viral protein and RNA [65].Heavy Metal-Impregnated Surfaces ::: Inactivation of Enteric Viruses on Fomites: Physical ApproachesCertain heavy metals have been shown to have intrinsic antimicrobial effects.", [["UV", "CHEMICAL", 23, 25], ["Metal", "CHEMICAL", 106, 111], ["MNV-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["viral protein", "PROTEIN", 73, 86], ["intrinsic antimicrobial effects", "PROBLEM", 245, 276], ["UV", "OBSERVATION", 23, 25], ["viral protein", "OBSERVATION", 73, 86], ["Enteric", "ANATOMY", 153, 160], ["Viruses", "OBSERVATION", 161, 168], ["antimicrobial effects", "OBSERVATION", 255, 276]]], ["The most known include copper and gold.", [["copper", "CHEMICAL", 23, 29], ["copper", "CHEMICAL", 23, 29], ["copper", "SIMPLE_CHEMICAL", 23, 29], ["gold", "SIMPLE_CHEMICAL", 34, 38]]], ["The effect of copper and copper alloy surfaces has been extensively investigated [66, 67].", [["copper", "CHEMICAL", 14, 20], ["copper", "CHEMICAL", 25, 31], ["copper", "CHEMICAL", 14, 20], ["copper", "CHEMICAL", 25, 31], ["copper", "SIMPLE_CHEMICAL", 14, 20], ["copper", "SIMPLE_CHEMICAL", 25, 31], ["copper and copper alloy surfaces", "TREATMENT", 14, 46]]], ["Studies have shown a rapid inactivation of bacterial, fungal, and viral pathogens on copper and copper alloy surfaces, and these have led to clinical trials and real strategies for reduction of the microbial burden in some health settings [68, 69].", [["copper", "CHEMICAL", 85, 91], ["copper", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 85, 91], ["copper", "CHEMICAL", 96, 102], ["copper", "SIMPLE_CHEMICAL", 85, 91], ["copper", "SIMPLE_CHEMICAL", 96, 102], ["a rapid inactivation of bacterial, fungal", "PROBLEM", 19, 60], ["viral pathogens", "PROBLEM", 66, 81], ["copper and copper alloy surfaces", "TREATMENT", 85, 117], ["the microbial burden", "PROBLEM", 194, 214], ["rapid", "OBSERVATION_MODIFIER", 21, 26], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["fungal", "OBSERVATION", 54, 60], ["microbial", "OBSERVATION_MODIFIER", 198, 207], ["burden", "OBSERVATION_MODIFIER", 208, 214]]], ["Reports on enteric viruses have focused on noroviruses.", [["noroviruses", "ORGANISM", 43, 54], ["enteric viruses", "PROBLEM", 11, 26], ["noroviruses", "PROBLEM", 43, 54], ["enteric", "ANATOMY", 11, 18], ["viruses", "OBSERVATION", 19, 26], ["noroviruses", "OBSERVATION", 43, 54]]], ["MNV has been rapidly inactivated on copper and copper alloys containing over 60% of copper in both simulated wet fomite and dry touch contamination, while no reduction of infectivity has been observed on stainless steel.", [["copper", "CHEMICAL", 36, 42], ["copper", "CHEMICAL", 47, 53], ["copper", "CHEMICAL", 84, 90], ["copper", "CHEMICAL", 36, 42], ["copper", "CHEMICAL", 47, 53], ["copper", "CHEMICAL", 84, 90], ["MNV", "ORGANISM", 0, 3], ["copper", "SIMPLE_CHEMICAL", 36, 42], ["copper alloys", "SIMPLE_CHEMICAL", 47, 60], ["copper", "SIMPLE_CHEMICAL", 84, 90], ["MNV", "SPECIES", 0, 3], ["copper and copper alloys", "TREATMENT", 36, 60], ["dry touch contamination", "PROBLEM", 124, 147], ["infectivity", "PROBLEM", 171, 182], ["rapidly", "OBSERVATION_MODIFIER", 13, 20], ["infectivity", "OBSERVATION", 171, 182]]], ["MNV is completely inactivated within 30 min on copper.", [["copper", "CHEMICAL", 47, 53], ["copper", "CHEMICAL", 47, 53], ["MNV", "ORGANISM", 0, 3], ["copper", "SIMPLE_CHEMICAL", 47, 53], ["MNV", "SPECIES", 0, 3]]], ["The highest rate of inactivation occurs upon immediate contact and is proportional to the copper content of alloys.", [["copper", "CHEMICAL", 90, 96], ["copper", "CHEMICAL", 90, 96], ["copper", "SIMPLE_CHEMICAL", 90, 96], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["inactivation", "OBSERVATION", 20, 32]]], ["It has also been shown that Cu2+ and Cu+ ions but not superoxide and hydroxyl radicals are the primary effectors of toxicity, and the targets are both viral capsid and RNA [70, 71].", [["Cu2", "CHEMICAL", 28, 31], ["Cu", "CHEMICAL", 37, 39], ["superoxide", "CHEMICAL", 54, 64], ["hydroxyl", "CHEMICAL", 69, 77], ["toxicity", "DISEASE", 116, 124], ["Cu2+", "CHEMICAL", 28, 32], ["Cu+", "CHEMICAL", 37, 40], ["superoxide", "CHEMICAL", 54, 64], ["hydroxyl", "CHEMICAL", 69, 77], ["Cu2+", "SIMPLE_CHEMICAL", 28, 32], ["Cu+ ions", "SIMPLE_CHEMICAL", 37, 45], ["superoxide", "SIMPLE_CHEMICAL", 54, 64], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 69, 86], ["Cu2", "TEST", 28, 31], ["Cu+ ions", "PROBLEM", 37, 45], ["superoxide", "TREATMENT", 54, 64], ["hydroxyl radicals", "TREATMENT", 69, 86], ["toxicity", "PROBLEM", 116, 124]]], ["Similar findings have also been reported for human norovirus [72].Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsDisinfectants are commonly used for virus inactivation, especially in the health care settings and the food industry, to prevent outbreaks due to enteric viruses.Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsThe most popular disinfectants are ethanol, peroxyacids, chlorine, and quaternary ammonium.", [["norovirus", "DISEASE", 51, 60], ["enteric viruses", "DISEASE", 278, 293], ["ethanol", "CHEMICAL", 395, 402], ["peroxyacids", "CHEMICAL", 404, 415], ["chlorine", "CHEMICAL", 417, 425], ["quaternary ammonium", "CHEMICAL", 431, 450], ["ethanol", "CHEMICAL", 395, 402], ["peroxyacids", "CHEMICAL", 404, 415], ["chlorine", "CHEMICAL", 417, 425], ["quaternary ammonium", "CHEMICAL", 431, 450], ["human", "ORGANISM", 45, 50], ["Fomites", "SIMPLE_CHEMICAL", 329, 336], ["ethanol", "SIMPLE_CHEMICAL", 395, 402], ["peroxyacids", "SIMPLE_CHEMICAL", 404, 415], ["chlorine", "SIMPLE_CHEMICAL", 417, 425], ["quaternary ammonium", "SIMPLE_CHEMICAL", 431, 450], ["human", "SPECIES", 45, 50], ["human norovirus", "SPECIES", 45, 60], ["human norovirus", "PROBLEM", 45, 60], ["Chemical DisinfectantsDisinfectants", "TREATMENT", 110, 145], ["virus inactivation", "PROBLEM", 168, 186], ["enteric viruses", "PROBLEM", 278, 293], ["Chemical Disinfectants", "TREATMENT", 338, 360], ["ethanol", "TREATMENT", 395, 402], ["peroxyacids", "TREATMENT", 404, 415], ["chlorine", "TREATMENT", 417, 425], ["quaternary ammonium", "TREATMENT", 431, 450], ["Enteric", "ANATOMY", 82, 89], ["Viruses", "OBSERVATION", 90, 97], ["enteric", "ANATOMY", 278, 285], ["viruses", "OBSERVATION", 286, 293], ["Enteric", "ANATOMY", 310, 317], ["Viruses", "OBSERVATION", 318, 325]]], ["Laboratory or field investigations have evaluated the efficacy of these disinfectants for the inactivation of enteric viruses [5, 73].", [["enteric viruses", "DISEASE", 110, 125], ["Laboratory or field investigations", "TEST", 0, 34], ["these disinfectants", "TREATMENT", 66, 85], ["the inactivation of enteric viruses", "PROBLEM", 90, 125]]], ["However, most of these studies have focused on human norovirus and cultivable surrogates as enteric virus models because human norovirus combines many of the epidemiological characteristics of enteric viruses [74].Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsMNV and FCV are to date the most common surrogates and the latter is still considered the gold standard by the US Environmental Protection Agency for evaluating the antinoroviral activity of new products.", [["norovirus", "DISEASE", 127, 136], ["enteric viruses", "DISEASE", 193, 208], ["human", "ORGANISM", 47, 52], ["enteric virus", "ORGANISM", 92, 105], ["human", "ORGANISM", 121, 126], ["norovirus", "ORGANISM", 127, 136], ["Chemical DisinfectantsMNV", "ORGANISM", 258, 283], ["FCV", "ORGANISM", 288, 291], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 121, 126], ["human norovirus", "SPECIES", 47, 62], ["human", "SPECIES", 121, 126], ["FCV", "SPECIES", 288, 291], ["these studies", "TEST", 17, 30], ["human norovirus", "PROBLEM", 47, 62], ["enteric virus models", "TREATMENT", 92, 112], ["human norovirus", "PROBLEM", 121, 136], ["enteric viruses", "PROBLEM", 193, 208], ["Chemical DisinfectantsMNV", "TREATMENT", 258, 283], ["new products", "TREATMENT", 471, 483], ["enteric viruses", "OBSERVATION", 193, 208], ["Enteric", "ANATOMY", 230, 237], ["Viruses", "OBSERVATION", 238, 245]]], ["However, the use of multiple surrogate viruses rather than one is more judicious and recommended to obtain more reliable information on the effectiveness of disinfectants and this has been well documented in some studies [73, 75].", [["multiple surrogate viruses", "PROBLEM", 20, 46], ["disinfectants", "TREATMENT", 157, 170], ["viruses", "OBSERVATION", 39, 46]]], ["Indeed, differences in the sensitivity of the surrogates to experimental conditions and inactivation treatments have been reported.", [["experimental conditions", "PROBLEM", 60, 83], ["inactivation treatments", "TREATMENT", 88, 111]]], ["Some studies have shown that MNV is more susceptible to alcohols than FCV, whereas FCV is more susceptible to chlorine [76, 77].", [["alcohols", "CHEMICAL", 56, 64], ["chlorine", "CHEMICAL", 110, 118], ["alcohols", "CHEMICAL", 56, 64], ["chlorine", "CHEMICAL", 110, 118], ["MNV", "ORGANISM", 29, 32], ["alcohols", "SIMPLE_CHEMICAL", 56, 64], ["FCV", "ORGANISM", 70, 73], ["FCV", "ORGANISM", 83, 86], ["chlorine", "SIMPLE_CHEMICAL", 110, 118], ["MNV", "SPECIES", 29, 32], ["FCV", "SPECIES", 70, 73], ["FCV", "SPECIES", 83, 86], ["Some studies", "TEST", 0, 12], ["MNV", "PROBLEM", 29, 32]]], ["In a systematic meta-analysis, Hoelzer et al. [73] showed that HAV and MNV were significantly more resistant to disinfection than FCV, even if the differences in viral titer reduction appeared to be modest (i.e., 1.5 log PFU) [73].Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsOther studies have compared the efficacy of 3 commonly used active agents (ethanol, chlorine, and quaternary ammonium) at different concentrations against 2 human norovirus strains and 2 surrogates (MNV and FCV).", [["ethanol", "CHEMICAL", 372, 379], ["chlorine", "CHEMICAL", 381, 389], ["quaternary ammonium", "CHEMICAL", 395, 414], ["ethanol", "CHEMICAL", 372, 379], ["chlorine", "CHEMICAL", 381, 389], ["quaternary ammonium", "CHEMICAL", 395, 414], ["HAV", "ORGANISM", 63, 66], ["MNV", "ORGANISM", 71, 74], ["FCV", "ORGANISM", 130, 133], ["ethanol", "SIMPLE_CHEMICAL", 372, 379], ["chlorine", "SIMPLE_CHEMICAL", 381, 389], ["quaternary ammonium", "SIMPLE_CHEMICAL", 395, 414], ["human", "ORGANISM", 454, 459], ["MNV", "ORGANISM", 496, 499], ["FCV", "ORGANISM", 504, 507], ["human", "SPECIES", 454, 459], ["HAV", "SPECIES", 63, 66], ["MNV", "SPECIES", 71, 74], ["FCV", "SPECIES", 130, 133], ["human", "SPECIES", 454, 459], ["MNV", "SPECIES", 496, 499], ["FCV", "SPECIES", 504, 507], ["HAV and MNV", "PROBLEM", 63, 74], ["viral titer reduction", "PROBLEM", 162, 183], ["Chemical Disinfectants", "TREATMENT", 275, 297], ["active agents", "TREATMENT", 357, 370], ["ethanol", "TREATMENT", 372, 379], ["chlorine", "TREATMENT", 381, 389], ["quaternary ammonium)", "TREATMENT", 395, 415], ["2 human norovirus strains", "TREATMENT", 452, 477], ["Enteric", "ANATOMY", 247, 254], ["Viruses", "OBSERVATION", 255, 262]]], ["Data from these studies revealed a complete or relative lack of efficacy of quaternary ammonium against all of the viruses tested [76, 78, 79].", [["quaternary ammonium", "CHEMICAL", 76, 95], ["quaternary ammonium", "CHEMICAL", 76, 95], ["quaternary ammonium", "SIMPLE_CHEMICAL", 76, 95], ["these studies", "TEST", 10, 23], ["quaternary ammonium", "TREATMENT", 76, 95], ["viruses", "OBSERVATION", 115, 122]]], ["In another study FCV applied on a surface, but not in suspension, was effectively inactivated by a quaternary ammonium-based disinfectant, while CVB4, an enterovirus, was resistant [80].", [["surface", "ANATOMY", 34, 41], ["quaternary ammonium", "CHEMICAL", 99, 118], ["CVB4", "CHEMICAL", 145, 149], ["ammonium", "CHEMICAL", 110, 118], ["FCV", "ORGANISM", 17, 20], ["ammonium", "SIMPLE_CHEMICAL", 110, 118], ["CVB4", "SIMPLE_CHEMICAL", 145, 149], ["enterovirus", "ORGANISM", 154, 165], ["FCV", "SPECIES", 17, 20], ["a quaternary ammonium", "TREATMENT", 97, 118], ["CVB4", "TEST", 145, 149], ["an enterovirus", "PROBLEM", 151, 165], ["enterovirus", "OBSERVATION", 154, 165]]], ["Ethanol has shown minimal efficacy against human norovirus and FCV, but it is active against MNV, with a clear dose-dependent impact [76, 81, 82, 83].", [["Ethanol", "CHEMICAL", 0, 7], ["MNV", "DISEASE", 93, 96], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["human", "ORGANISM", 43, 48], ["FCV", "ORGANISM", 63, 66], ["MNV", "ORGANISM", 93, 96], ["human", "SPECIES", 43, 48], ["human norovirus", "SPECIES", 43, 58], ["FCV", "SPECIES", 63, 66], ["MNV", "SPECIES", 93, 96], ["human norovirus and FCV", "PROBLEM", 43, 66], ["minimal", "OBSERVATION_MODIFIER", 18, 25], ["active", "OBSERVATION_MODIFIER", 78, 84]]], ["Very high concentrations of hypochlorite (\u2265500 ppm) are necessary to inactivate human norovirus and MNV; FCV has been shown to be more susceptible to hypochlorite than human noroviruses [76, 79, 81].Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsChlorine dioxide (ClO2) represents a strong alternative to chlorine, with an increased ability to reduce or inactivate enteric viruses in the environment.", [["hypochlorite", "CHEMICAL", 28, 40], ["norovirus", "DISEASE", 86, 95], ["FCV", "CHEMICAL", 105, 108], ["hypochlorite", "CHEMICAL", 150, 162], ["noroviruses", "DISEASE", 174, 185], ["Chlorine dioxide", "CHEMICAL", 265, 281], ["ClO2", "CHEMICAL", 283, 287], ["chlorine", "CHEMICAL", 324, 332], ["hypochlorite", "CHEMICAL", 28, 40], ["hypochlorite", "CHEMICAL", 150, 162], ["Chlorine dioxide", "CHEMICAL", 265, 281], ["ClO2", "CHEMICAL", 283, 287], ["chlorine", "CHEMICAL", 324, 332], ["hypochlorite", "SIMPLE_CHEMICAL", 28, 40], ["human", "ORGANISM", 80, 85], ["norovirus", "ORGANISM", 86, 95], ["MNV", "ORGANISM", 100, 103], ["FCV", "ORGANISM", 105, 108], ["hypochlorite", "SIMPLE_CHEMICAL", 150, 162], ["human", "ORGANISM", 168, 173], ["Fomites", "SIMPLE_CHEMICAL", 234, 241], ["Chlorine dioxide", "SIMPLE_CHEMICAL", 265, 281], ["ClO2", "SIMPLE_CHEMICAL", 283, 287], ["chlorine", "SIMPLE_CHEMICAL", 324, 332], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 168, 173], ["human norovirus", "SPECIES", 80, 95], ["MNV", "SPECIES", 100, 103], ["FCV", "SPECIES", 105, 108], ["human", "SPECIES", 168, 173], ["hypochlorite", "TREATMENT", 28, 40], ["human norovirus", "PROBLEM", 80, 95], ["FCV", "PROBLEM", 105, 108], ["Enteric Viruses", "PROBLEM", 215, 230], ["Chemical DisinfectantsChlorine dioxide", "TREATMENT", 243, 281], ["chlorine", "TREATMENT", 324, 332], ["an increased ability", "PROBLEM", 339, 359], ["high", "OBSERVATION_MODIFIER", 5, 9], ["concentrations", "OBSERVATION_MODIFIER", 10, 24], ["Enteric Viruses", "OBSERVATION", 215, 230], ["viruses", "OBSERVATION", 392, 399]]], ["ClO2 is very attractive compared to chlorine because it has been shown to be less affected by pH conditions than chlorine and very effective even at low concentrations [84, 85].", [["ClO2", "CHEMICAL", 0, 4], ["chlorine", "CHEMICAL", 36, 44], ["chlorine", "CHEMICAL", 113, 121], ["ClO2", "CHEMICAL", 0, 4], ["chlorine", "CHEMICAL", 36, 44], ["chlorine", "CHEMICAL", 113, 121], ["ClO2", "SIMPLE_CHEMICAL", 0, 4], ["chlorine", "SIMPLE_CHEMICAL", 36, 44], ["chlorine", "SIMPLE_CHEMICAL", 113, 121], ["chlorine", "TREATMENT", 36, 44], ["chlorine", "TREATMENT", 113, 121]]], ["Indeed, several studies have shown that the disinfection efficacy of ClO2 is higher than that of chlorine when tested on enteric viruses, including human rotavirus, enteric adenoviruses, caliciviruses, and enteroviruses [84, 85, 86].", [["ClO2", "CHEMICAL", 69, 73], ["chlorine", "CHEMICAL", 97, 105], ["enteric adenoviruses, caliciviruses", "DISEASE", 165, 200], ["enteroviruses", "DISEASE", 206, 219], ["ClO2", "CHEMICAL", 69, 73], ["chlorine", "CHEMICAL", 97, 105], ["ClO2", "SIMPLE_CHEMICAL", 69, 73], ["chlorine", "SIMPLE_CHEMICAL", 97, 105], ["enteric viruses", "ORGANISM", 121, 136], ["human", "ORGANISM", 148, 153], ["rotavirus", "ORGANISM", 154, 163], ["enteric adenoviruses", "ORGANISM", 165, 185], ["caliciviruses", "CANCER", 187, 200], ["human", "SPECIES", 148, 153], ["human rotavirus", "SPECIES", 148, 163], ["several studies", "TEST", 8, 23], ["the disinfection efficacy of ClO2", "PROBLEM", 40, 73], ["chlorine", "TREATMENT", 97, 105], ["enteric viruses", "PROBLEM", 121, 136], ["human rotavirus", "PROBLEM", 148, 163], ["enteric adenoviruses", "PROBLEM", 165, 185], ["caliciviruses", "PROBLEM", 187, 200], ["enteroviruses", "PROBLEM", 206, 219], ["ClO2", "OBSERVATION", 69, 73], ["enteric adenoviruses", "ANATOMY", 165, 185]]], ["However, commonly active doses of chlorine dioxide against these viruses have been shown to have some, albeit limited, activity against human norovirus [87, 88].Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsTaken together, all of these studies have highlighted the fact that human noroviruses are much less sensitive to commonly used disinfectants than surrogate viruses, and one might pay attention to and integrate several parameters when extrapolating data between surrogate viruses and human noroviruses.Inactivation of Enteric Viruses on Fomites: Chemical DisinfectantsDifferent peroxyacids, including peracetic, perpropionic, perlactic, and percitric, have been assessed for norovirus inactivation on stainless steel and polyvinyl chloride surfaces.", [["chlorine dioxide", "CHEMICAL", 34, 50], ["norovirus", "DISEASE", 142, 151], ["peroxyacids", "CHEMICAL", 604, 615], ["peracetic, perpropionic, perlactic", "CHEMICAL", 627, 661], ["percitric", "CHEMICAL", 667, 676], ["polyvinyl chloride", "CHEMICAL", 747, 765], ["chlorine dioxide", "CHEMICAL", 34, 50], ["peroxyacids", "CHEMICAL", 604, 615], ["peracetic", "CHEMICAL", 627, 636], ["perpropionic", "CHEMICAL", 638, 650], ["stainless steel", "CHEMICAL", 727, 742], ["polyvinyl chloride", "CHEMICAL", 747, 765], ["chlorine dioxide", "SIMPLE_CHEMICAL", 34, 50], ["human", "ORGANISM", 136, 141], ["human", "ORGANISM", 295, 300], ["human", "ORGANISM", 510, 515], ["peroxyacids", "SIMPLE_CHEMICAL", 604, 615], ["peracetic", "SIMPLE_CHEMICAL", 627, 636], ["perpropionic", "SIMPLE_CHEMICAL", 638, 650], ["perlactic", "SIMPLE_CHEMICAL", 652, 661], ["percitric", "SIMPLE_CHEMICAL", 667, 676], ["norovirus", "ORGANISM", 701, 710], ["polyvinyl chloride surfaces", "SIMPLE_CHEMICAL", 747, 774], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 295, 300], ["human", "SPECIES", 510, 515], ["human norovirus", "SPECIES", 136, 151], ["human", "SPECIES", 295, 300], ["human", "SPECIES", 510, 515], ["chlorine dioxide", "TREATMENT", 34, 50], ["these viruses", "PROBLEM", 59, 72], ["human norovirus", "PROBLEM", 136, 151], ["Chemical Disinfectants", "TREATMENT", 205, 227], ["these studies", "TEST", 250, 263], ["human noroviruses", "PROBLEM", 295, 312], ["extrapolating data", "TEST", 461, 479], ["human noroviruses", "PROBLEM", 510, 527], ["Chemical Disinfectants", "TREATMENT", 572, 594], ["Different peroxyacids", "TREATMENT", 594, 615], ["peracetic", "TREATMENT", 627, 636], ["perpropionic", "TREATMENT", 638, 650], ["perlactic", "TREATMENT", 652, 661], ["percitric", "TREATMENT", 667, 676], ["norovirus inactivation", "PROBLEM", 701, 723], ["stainless steel and polyvinyl chloride surfaces", "TREATMENT", 727, 774], ["Enteric", "ANATOMY", 177, 184], ["Viruses", "OBSERVATION", 185, 192], ["noroviruses", "OBSERVATION", 301, 312], ["Enteric Viruses", "OBSERVATION", 544, 559]]], ["Peracetic acid and perpropionic acid have been found to be the most effective.", [["Peracetic acid", "CHEMICAL", 0, 14], ["perpropionic acid", "CHEMICAL", 19, 36], ["Peracetic acid", "CHEMICAL", 0, 14], ["perpropionic acid", "CHEMICAL", 19, 36], ["Peracetic acid", "SIMPLE_CHEMICAL", 0, 14], ["perpropionic acid", "SIMPLE_CHEMICAL", 19, 36], ["Peracetic acid", "TREATMENT", 0, 14], ["perpropionic acid", "TREATMENT", 19, 36], ["most effective", "OBSERVATION_MODIFIER", 63, 77]]], ["Exposure to a solution at 50 mg/mL for 5 min resulted in a 3-log reduction of the viral titer in all of the conditions tested [89].", [["a solution", "TREATMENT", 12, 22], ["the viral titer", "PROBLEM", 78, 93], ["viral titer", "OBSERVATION", 82, 93]]], ["Interestingly, peracetic acid airborne disinfectant was reported by our team to be very efficient in inactivating poliovirus applied on stainless steel carriers [90].ConclusionEnteric viruses represent an important public health issue both in developed and in developing countries.", [["peracetic acid", "CHEMICAL", 15, 29], ["Enteric viruses", "DISEASE", 176, 191], ["peracetic acid", "CHEMICAL", 15, 29], ["stainless steel", "CHEMICAL", 136, 151], ["peracetic acid", "SIMPLE_CHEMICAL", 15, 29], ["poliovirus", "ORGANISM", 114, 124], ["poliovirus", "SPECIES", 114, 124], ["peracetic acid airborne disinfectant", "TREATMENT", 15, 51], ["inactivating poliovirus", "PROBLEM", 101, 124], ["stainless steel carriers", "TREATMENT", 136, 160], ["Enteric", "ANATOMY", 176, 183], ["viruses", "OBSERVATION", 184, 191]]], ["These nonenveloped viruses have shown a high level of resistance in the environment.", [["These nonenveloped viruses", "PROBLEM", 0, 26], ["viruses", "OBSERVATION", 19, 26], ["high level of resistance", "OBSERVATION_MODIFIER", 40, 64]]], ["They can survive for a long time on animate and inanimate surfaces and be easily transferred to hands when hygiene measures are lacking.", [["hygiene measures", "TREATMENT", 107, 123]]], ["The role of fomites has been shown in the transmission of these viruses and the occurrence of outbreaks, especially in closed environments.", [["fomites", "CANCER", 12, 19], ["these viruses", "PROBLEM", 58, 71], ["outbreaks", "PROBLEM", 94, 103], ["viruses", "OBSERVATION", 64, 71]]], ["Several factors impact the survival of viruses on fomites, and detailed experimental studies comparing all of the main enteric viruses are scarce.", [["viruses on fomites", "PROBLEM", 39, 57], ["detailed experimental studies", "TEST", 63, 92], ["viruses", "OBSERVATION", 39, 46], ["viruses", "OBSERVATION", 127, 134]]], ["The implication of this strong resistance is the implementation of adequate disinfection strategies in health care centers and the food industry.", [["adequate disinfection strategies", "TREATMENT", 67, 99]]], ["Chemical disinfection is currently the most used in these settings, and great differences have been shown in the effects of various compounds on enteric viruses.", [["enteric viruses", "ORGANISM", 145, 160], ["Chemical disinfection", "TREATMENT", 0, 21], ["various compounds", "PROBLEM", 124, 141], ["enteric viruses", "PROBLEM", 145, 160], ["disinfection", "OBSERVATION", 9, 21], ["enteric viruses", "OBSERVATION", 145, 160]]]], "PMC7501511": [["The approach taken in this paperBusinesses exist in a turbulent environment and to survive must adjust and adapt to changing circumstances.", [["The approach", "TREATMENT", 0, 12]]], ["This situation is heightened presently by the challenge\u2019s resultant upon the drastic measures that have been taken Nationally (and internationally) to lessen the impact of Covid-19.", [["the drastic measures", "TREATMENT", 73, 93], ["Covid", "TEST", 172, 177]]], ["For example, an average of 46% of the working population across the UK have been working from home (ONS April 2020).", [["average", "OBSERVATION_MODIFIER", 16, 23]]], ["It seems likely that that many would like to continue with this practice.", [["this practice", "TREATMENT", 59, 72], ["seems likely", "UNCERTAINTY", 3, 15]]], ["At the time of writing it is not yet clear what the long-term effects will be upon the operational process of organizations, but there is likely to be re-structuring and the introduction of new working practices and the loss of employment for many.", [["new working practices", "TREATMENT", 190, 211], ["likely to be", "UNCERTAINTY", 138, 150], ["re-structuring", "OBSERVATION", 151, 165]]], ["These are significant changes and for those that remain there will be a feeling of insecurity and loss of confidence.", [["loss of confidence", "DISEASE", 98, 116], ["loss of confidence", "PROBLEM", 98, 116], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["changes", "OBSERVATION", 22, 29]]], ["Past examples of such major changes to working practices suggest that this will result in some form of resistance from those most affected.", [["resistance", "PROBLEM", 103, 113], ["resistance", "OBSERVATION", 103, 113]]], ["To this end I will also describe one way that these ideas could be put into action by calling upon the mnemonic PEArL (Champion and Stowell 2001).IntroductionIn 2020 the world experienced a devastating pandemic that has and is changing interactions both within and between nations.", [["devastating", "OBSERVATION_MODIFIER", 190, 201], ["pandemic", "OBSERVATION", 202, 210]]], ["The Globalization of economies and businesses that support them have had to find new ways of adapting if they are to survive.", [["economies", "OBSERVATION_MODIFIER", 21, 30]]], ["Change brings with it insecurity which often manifests in some form of resistance and the employment of \u2018power\u2019 by those affected in an attempt to adjust the situation into one where they feel less threatened.IntroductionThere is no universal and accepted definition of organisational power in the literature.", [["no", "UNCERTAINTY", 230, 232]]], ["The study of power is not the neat incision into society that a model implies, it is much more involved than that.", [["The study", "TEST", 0, 9], ["the neat incision", "TREATMENT", 26, 43]]], ["He recognized that human beings are unavoidably different and in any social grouping different interests will be being pursued. (e.g. Aristotle 1981, p.108, Checkland and Scholes 1990, p.50).", [["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["Furthermore, the development and ubiquity of ICT has acted to change the notion of \u2018organization\u2019.", [["\u2018organization", "PROBLEM", 83, 96]]], ["These teams are geographically and culturally dispersed and are important mechanisms for business organizations seeking to leverage scarce resources across geographic and other boundaries (Ebrahim et al. 2009).", [["business organizations", "TREATMENT", 89, 111]]], ["A \u2018working from home\u2019 pattern grown out of measures arising from containing the spread of the virus has created a new dynamic in the way an organisation operates.", [["the virus", "PROBLEM", 90, 99]]], ["When I refer to organisation here it is non-specific and should be thought of as a \u2018System\u2019.4 I will begin this paper with a summary of what I deem to be an organisation and then on to the core of this paper \u2018organisational\u2019 Power.The difficulty of defining \u2018Organization\u2019The difficulty of defining an organisation is not new.", [["not", "UNCERTAINTY", 318, 321], ["new", "OBSERVATION_MODIFIER", 322, 325]]], ["An organisation is an abstraction, an intellectual construct and as a consequence difficult to produce a once and for all definition because everyone has a general uninspected idea of what it is.", [["an abstraction", "PROBLEM", 19, 33], ["an intellectual construct", "PROBLEM", 35, 60], ["abstraction", "OBSERVATION", 22, 33]]], ["For example, a simple, but vacuous, definition of organisation is, it is an organisation because we say it is.", [["simple", "OBSERVATION_MODIFIER", 15, 21]]], ["This is no trivial undertaking as the way in which it functions has many dimensions so thinking in terms of a fixed model or a \u2018solution\u2019 based upon an \u2018ideal\u2019 case from past success is deficient.5 One valuable source of information comes from the programme of action research undertaken at the University of Lancaster6 that lasted for over three decades.", [["a fixed model", "TREATMENT", 108, 121], ["a \u2018solution", "TREATMENT", 125, 136], ["no", "UNCERTAINTY", 8, 10], ["trivial", "OBSERVATION", 11, 18], ["dimensions", "OBSERVATION_MODIFIER", 73, 83]]], ["The relationships between those that manage an organisation and those that undertake its operations define its character and resilience, which makes a sharp definition exceptionally difficult to pin down and yet to the observer it is a tangible entity.", [["its operations", "TREATMENT", 85, 99], ["a sharp definition", "PROBLEM", 149, 167]]], ["Individuals are there for different reasons, which are, as Vickers7observed, constantly revised or confirmed and as such will have different meanings for each person.", [["person", "SPECIES", 159, 165]]], ["But change brings with it the threat of the reallocation of resources, delegated power, changes to organizational boundaries and a change in group relationships.", [["organizational boundaries", "TREATMENT", 99, 124]]], ["It threatens on the one hand a defence of territory and on the other opportunities to make territorial gains.", [["territory", "OBSERVATION", 42, 51], ["territorial gains", "OBSERVATION", 91, 108]]], ["Zaleznik points out \u2018...the problems of organizational life involve the dangers associated with the losses of power; the uncertainties are legion especially in the recognition that there is no one best way to organize and distribute power, and yet any individual must make a commitment to some form of organisation\u20199(ibid, 1970).\u2018Organisational\u2019 InsecurityChange upsets the mutual security experienced by each agency and their acceptance of unwritten rules is disrupted, disturbing the \u2018balance\u2019 between the way these networks operate.", [["Zaleznik", "TREATMENT", 0, 8], ["organizational life", "TREATMENT", 40, 59], ["the losses of power", "PROBLEM", 96, 115]]], ["As each boundary alters it brings a feeling of insecurity and may lead to a breakdown of the mutual understanding existing between the various individuals and groups within.", [["a breakdown", "PROBLEM", 74, 85]]], ["A breakdown in trust is exemplified when staff work to rule, often creating a major disruption to the operation of the enterprise, sometimes bringing it to a halt.10\u2018Organisational\u2019 InsecurityUnderstanding of such complex relationships is no trivial undertaking.", [["A breakdown in trust", "PROBLEM", 0, 20], ["breakdown", "OBSERVATION_MODIFIER", 2, 11], ["no", "UNCERTAINTY", 239, 241]]], ["Not all those that work there will share the same targets but accede to its strictures all the time it suits their main, and often undisclosed purpose.", [["strictures", "PATHOLOGICAL_FORMATION", 76, 86], ["its strictures", "PROBLEM", 72, 86], ["strictures", "OBSERVATION", 76, 86]]], ["Experience of the real world suggest that harmony within any community rarely exists in perpetuity, an \u2018organisation\u2019 is no exception.", [["no exception", "UNCERTAINTY", 121, 133]]], ["The turbulent environment experienced by each organisation suggests stability to be a transient condition (Vickers 1983b, C.9).", [["a transient condition", "PROBLEM", 84, 105], ["Vickers", "TEST", 107, 114], ["turbulent", "OBSERVATION_MODIFIER", 4, 13], ["environment", "OBSERVATION", 14, 25], ["stability", "OBSERVATION", 68, 77]]], ["To accept this view, and experience proposes it has some credibility, I suggest it better assume that whilst its members appear to willingly agree with a management strategy this may be only when it serves their particular ends.Turbulent EnvironmentA business \u2018system\u2019 exists in a turbulent environment and those that manage it have to deal with conflicting demands, including utilizing existing assets such as infrastructures, resources, expertise and personal loyalties.11 These relationships can be troubled when new policies, working procedures or the introduction of technology act to disrupt the concord existing between the infrastructures.", [["a management strategy", "TREATMENT", 152, 173], ["working procedures", "TREATMENT", 530, 548]]], ["This can create anxiety as it may seem to those involved that what is taking place is more than changes to operating procedures, it also signals some form of revision of rules.", [["anxiety", "DISEASE", 16, 23], ["anxiety", "PROBLEM", 16, 23], ["operating procedures", "TREATMENT", 107, 127], ["revision of rules", "TREATMENT", 158, 175], ["revision", "OBSERVATION", 158, 166]]], ["The dispute affected not just the way newspapers are printed but, some commentators maintained, the erosion of civil liberties.", [["the erosion of civil liberties", "PROBLEM", 96, 126], ["erosion", "OBSERVATION_MODIFIER", 100, 107], ["civil liberties", "OBSERVATION", 111, 126]]], ["There were 1260 people arrested and severe restrictions on travel in the Wapping area and a significant cost to the taxpayers.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["severe restrictions", "PROBLEM", 36, 55], ["the Wapping area", "PROBLEM", 69, 85], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["restrictions", "OBSERVATION", 43, 55], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["cost", "OBSERVATION", 104, 108]]], ["There were many twists and turns in this affair, some confrontational, some underhand and some an outright struggle for power.", [["some underhand", "PROBLEM", 71, 85], ["many", "OBSERVATION_MODIFIER", 11, 15], ["twists", "OBSERVATION_MODIFIER", 16, 22]]], ["It is not possible in this brief reference to do justice to them all and a reader interested in a systemic account of the use and abuse of power (on both sides) might find some satisfaction in Stowell\u2019s account.Turbulent EnvironmentA more recent example of the effect of changing the policy was the junior doctors13 industrial action with the NHS between 2015 and 2016.", [["not possible", "UNCERTAINTY", 6, 18]]], ["The new contracts (new rules) were partly designed to make it cheaper to roster extra doctors on at weekends.", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The dispute dragged on for some months with periodic stoppages and some medical procedures halted.", [["periodic stoppages", "TREATMENT", 44, 62], ["some medical procedures", "TREATMENT", 67, 90]]], ["There was little dialogue between ministers and the union and the dispute generated ill feeling within the profession with each side blaming the other for the failure to reach an agreement.", [["the failure", "PROBLEM", 155, 166], ["failure", "OBSERVATION", 159, 166]]], ["Mark Britnell, head of global health for KPMG after working for the NHS for 20 years, is on record of saying \u2018\u2026It makes no sense, Junior doctors will be crucial in making the changes the NHS needs to cope with all the challenges it faces, but they will be demoralised.", [["KPMG", "CHEMICAL", 41, 45], ["head", "ORGANISM_SUBDIVISION", 15, 19], ["head", "ANATOMY", 15, 19], ["no", "UNCERTAINTY", 120, 122]]], ["An objective analysis from the literature, especially after so long, is unlikely to provide a satisfactory explanation as the disputes were so emotionally charged.", [["An objective analysis", "TEST", 0, 21]]], ["I acknowledge that a positivist approach could help shed light of some of the functional issues such as the law, the opportunity costs of installing the technology (in the case of the print dispute) and the cost of an all-out strike.", [["a positivist approach", "TREATMENT", 19, 40], ["strike", "PROBLEM", 226, 232]]], ["But closer involvement will reveal that there were various strategies employed by each side of the argument.", [["various strategies", "TREATMENT", 51, 69]]], ["A closer inspection of each of these disputes suggest it was unlikely to have produced an amicable settlement because the changes represented a new set of rules and de facto a new \u2018system\u2019.", [["A closer inspection", "TEST", 0, 19], ["an amicable settlement", "PROBLEM", 87, 109], ["new", "OBSERVATION_MODIFIER", 144, 147]]], ["To satisfy the aspirations of the staff and management there needs to be an interchange of information between its membership, to enable some degree of self-determination.", [["management", "TREATMENT", 44, 54]]], ["Organisational power can no longer be framed by the measures once taken for granted.The Organisation and the Consequences of Changing the RulesOne area of agreement that all commentators share is that the introduction of a change in working practices or in the structure of the organisation, both commonplace today, may cause the \u2018community\u2019 to react, either to comply or resist the proposals.", [["a change in working practices", "TREATMENT", 221, 250], ["no longer", "UNCERTAINTY", 25, 34]]], ["Those affected will accept or adopt strategies to overcome or resist the change.", [["adopt strategies", "TREATMENT", 30, 46]]], ["Rather than risk challenging formal power individuals may choose to use their soft power to try to modify these policies if they threaten the status quo.The Organisation and the Consequences of Changing the RulesEven a cursory examination of the News International and the NHS disputes show that there is a myriad of reasons standing behind the confrontations.", [["a cursory examination", "TEST", 217, 238]]], ["These range from loss of income to loss of face but at its base was the change of rules.", [["loss of face", "PROBLEM", 35, 47], ["loss", "OBSERVATION_MODIFIER", 17, 21], ["face", "ANATOMY", 43, 47], ["base", "ANATOMY_MODIFIER", 59, 63]]], ["The established \u2018systems\u2019 of the past that relied upon the tacit agreement between participants was thrown into disarray.", [["participants", "SPECIES", 83, 95]]], ["All the time this structure is stable then the player is contented with letting things stand.", [["stable", "OBSERVATION_MODIFIER", 31, 37]]], ["To this end I have adopted Gadamer\u2019s concept of play (Gadamer 2004, p.102\u2013109) as a metaphor for the way that participants, or players, interact within the system.The Organisation and the Consequences of Changing the RulesWhilst Gadamer begins by writing of \u2018play\u2019 as a representation of a form of art he develops the idea further describing playing as being a natural process.", [["participants", "SPECIES", 110, 122]]], ["Individuals joining the organization are often willing to accommodate the \u2018rules of the game\u2019 as it saves them taking responsibility, particularly when it satisfies their needs.The Organisation and the Consequences of Changing the RulesThe rules of the game can be compared to the operational procedures, the formal rules of the organisation and the way that the rules are interpreted are responsible for the character of the game itself.", [["the operational procedures", "TEST", 277, 303]]], ["The ambiance that exists is created from the experience and trust that the participants have for each other.", [["participants", "SPECIES", 75, 87]]], ["For those within, any change in the rules of the game can shake their very existence, so a sort of cat and mouse game ensues.The Organisation and the Consequences of Changing the RulesGadamer says that in order for there to be a game there has to be something, someone, others with which the \u2018player\u2019 responds with a countermove.", [["cat", "ORGANISM", 99, 102], ["mouse", "ORGANISM", 107, 112], ["mouse", "SPECIES", 107, 112], ["mouse", "SPECIES", 107, 112]]], ["The \u2018participants\u2019 in the \u2018game\u2019 particularly if known to each other, may anticipate the way in which the rules will be applied and consequently determine the atmosphere of the game, or working environment.", [["participants", "SPECIES", 5, 17]]], ["But within any organization there are power structures and groups that combine for a variety of reasons and when threatened by change, resist.", [["power", "OBSERVATION_MODIFIER", 38, 43]]], ["A change in \u2018team\u2019 (community) membership means participants may no longer be able to anticipate how the rules might be applied or what strategies they might introduce.", [["participants", "SPECIES", 48, 60], ["change", "OBSERVATION_MODIFIER", 2, 8]]], ["Coping with change, \u2018\u2026represents either an adjustment to the situation or an adjustment of the situation\u2019 (Cox 1987, p.7).The Organisation and the Consequences of Changing the RulesAn incautious shift in practices may break the harmony that exists between the activities that are designed to achieve a specific purpose and the social systems within the communities that enable them.", [["Changing the RulesAn", "TREATMENT", 163, 183]]], ["Our understanding of the \u2018world\u2019 is in respect of our surrounding world or culture, our consciousness of the world is created by and from \u2018things\u2019 which are around us.", [["culture", "TEST", 75, 82]]], ["Changes to the formal and informal structures of that community creates a feeling of insecurity.", [["insecurity", "PROBLEM", 85, 95]]], ["Changing the rules may be interpreted as a strategy to enable a particular aspiration such as personal gain, or simply survival to manifest, it changes the dynamic of the community.", [["a particular aspiration", "PROBLEM", 62, 85]]], ["Until a new relationship has been built up it is reasonable to suppose that participants will adopt a defensive stance until they can establish or preserve their position.", [["participants", "SPECIES", 76, 88]]], ["In other words, if management policies are to be implemented control has to be exercised.", [["management policies", "TREATMENT", 19, 38]]], ["This implies some form of power being applied to counter unwanted circumstances.Disharmony and Organisational PowerThe literature on power has many different forms and one issue that emerges is its importance upon decision-making.", [["Organisational Power", "OBSERVATION", 95, 115]]], ["Marx and Engels described theories of power as a \u2018trick in three acts\u2019, theorists, ideologists and philosophers\u2019 who provided the ruling classes with a self-serving belief in them.16 In the influential text \u2018The Anatomy of Power\u2019 (1983) Galbraith describes organisational power as a conduit for the submission of workers.", [["a conduit", "TREATMENT", 281, 290]]], ["Capra defines an organization as one that is designed specifically to organize the distribution of power, (Capra and Luisi 2014, p.313), implying that within its structure exists an in-built set of covenants to ensure compliance.Disharmony and Organisational PowerIn the 1980\u2019s Pfeffer suggested that power is neglected because the concept itself is problematic and troublesome, he went on to say that \u2018\u2026organizations are systems in which influence processes play an important part...\u2019", [["Capra", "SPECIES", 0, 5], ["Capra", "SPECIES", 107, 112], ["distribution", "OBSERVATION_MODIFIER", 83, 95], ["power", "OBSERVATION_MODIFIER", 99, 104]]], ["But I think that Pfeffer is more interested in outcomes and the attributes that he associates with success (observed from a particular point of reference) of these strategies.", [["these strategies", "TREATMENT", 158, 174]]], ["What we understand is based upon our own experience of the world which may be at variance with what the \u2018other\u2019 meant to convey; there is room for misinterpretation and the possibility of unintended consequences.Organisational Power in an Intangible worldI have suggested power is a neglected concept with no universally agreed definition.", [["unintended consequences", "PROBLEM", 188, 211]]], ["An examination of the literature does little to satisfy a researcher looking for a tangible model in an intangible world.", [["An examination", "TEST", 0, 14]]], ["It reveals a mixture of views, that includes management science, social science, psychology, anthropology and politics, much is based upon a reductionist belief in objectivity and facts.Organisational Power in an Intangible worldI believe that it is also a mistake to assume a binary perspective about the way that people interact.", [["people", "ORGANISM", 315, 321], ["people", "SPECIES", 315, 321]]], ["As Zaleznik pointed out that a \u2018\u2026realistic coalition matches formal authority and competence with the emotional commitments necessary to establish and maintain the coalition\u2019 (ibid, 1970, p.7).", [["Zaleznik", "TREATMENT", 3, 11]]], ["This kind of \u2018real world\u2019 relationship requires constant negotiation and compromise between members of the community.", [["constant negotiation", "TREATMENT", 48, 68]]], ["It is not a fixed entity but something that can be called upon when needed.", [["a fixed entity", "PROBLEM", 10, 24]]], ["This kind of power cannot be stored.Organisational Power in an Intangible worldLatour, something of a polymath, is generally thought of as philosopher, anthropologist and sociologist but thinking of some of Latour\u2019s ideas as transcendental has merit.", [["Power", "OBSERVATION_MODIFIER", 51, 56], ["Intangible worldLatour", "OBSERVATION", 63, 85]]], ["Examples include such resources as flags, colours, tattoos and so on.", [["tattoos", "TREATMENT", 51, 58]]], ["The use of power is relational and not necessarily shared by all because, \u2018\u2026 The obedience to an order given by someone would require the alignment of all people concerned by it who would assent faithfully without adding or subtracting anything.", [["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161]]], ["The chances are that the order has been modified and composed by many different people who slowly turned it into something completely different as they sought to achieve their own goals.\u2019", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["From this perspective power is contextual and temporal and becomes less useful as power increases or decreases (ibid, date? p265).", [["temporal", "OBSERVATION_MODIFIER", 46, 54], ["decreases", "OBSERVATION_MODIFIER", 101, 110]]], ["Primary mechanism as a composition made by other people and secondary mechanism attributed by another.Organisational Power in an Intangible worldLatour\u2019s argument is persuasive, but I find myself questioning if it fully explains the ebb and flow of influences that emerge in any social \u2018hub\u2019.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55]]], ["A key feature of ANT is that it is based upon \u2018objects\u2019 as \u2018vessels of power\u2019, yet there are instances where power is exercised with no apparent tangible item.", [["\u2018vessels", "ANATOMY", 59, 67], ["ANT", "SIMPLE_CHEMICAL", 17, 20], ["vessels", "MULTI-TISSUE_STRUCTURE", 60, 67], ["vessels", "ANATOMY", 60, 67], ["no apparent", "UNCERTAINTY", 133, 144]]], ["For example, for some an arachnid represents the evolution of one of nature\u2019s creatures to be admired, for others it is regarded as a threat.", [["arachnid", "CANCER", 25, 33]]], ["As Gadamer reminds me, \u2018\u2026power cannot be known or measured in terms of its expressions, but only experienced as an indwelling\u2019 (ibid, 2004, p.202).Organisational Power in an Intangible worldPower is more than its expression, power possesses potentiality.", [["indwelling", "OBSERVATION", 115, 125], ["Power", "OBSERVATION_MODIFIER", 162, 167]]], ["Fully understanding either or both of these is subjective and I feel it is a mistake for an observer to attribute \u2018power\u2019 to an object because what we see and hear is understood by each observer in terms of their experience of something they consider to be similar; it is noetic.19 I believe that there is a kind of power that cannot easily be defined but it is readily experienced,20 it is a form of power, a soft power, a force that is something existing \u2018within\u2019.", [["soft power", "OBSERVATION_MODIFIER", 410, 420]]], ["In this sense it seems clear to me that this, soft power, is best understood by each of those who experience it in action and who are aware of its consequences.Soft Power and when we use itAny form of power that is perceived as being used outside the accepted value systems of the community will be seen as illegitimate and invoke a reaction.", [["a reaction", "PROBLEM", 331, 341], ["clear", "OBSERVATION", 23, 28], ["Power", "OBSERVATION", 165, 170]]], ["As Capra points out \u2018\u2026people do not resist change; they resist having change imposed\u2026\u2019 (ibid 2003, p.87).", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28], ["Capra", "SPECIES", 3, 8]]], ["This I call soft power.Soft Power and when we use itSoft power, relies upon a shared, often unstated, understanding between those involved that such a \u2018force\u2019 exists, and it is only by experience do we gain an idea of this kind of power.", [["soft power", "OBSERVATION_MODIFIER", 12, 22], ["Power", "OBSERVATION", 28, 33]]], ["Soft power is associated with an individual rather than the role they may or may not occupy.", [["power", "OBSERVATION", 5, 10]]], ["This power is derived from a personal attribute that is conferred upon someone by a third person and is subjective (similar to Latours secondary mechanism).", [["person", "SPECIES", 90, 96]]], ["Its use can be significant and as researchers have observed, \u2018\u2026the use of soft power in social groups is often used to great effect in discussions and it at times \u2018trumps\u2019 that of formal power\u2019 (e.g. See Cooray 2010; Hart 2014).", [["soft power in social groups", "TREATMENT", 74, 101]]], ["It is not possible to define what it is in such a way that it can be applied to another situation.", [["not possible", "UNCERTAINTY", 6, 18]]], ["It relies upon the acknowledgement and agreement of the community in which it is exercised.Soft Power and when we use itPutting to one side examples that rely upon the indoctrination of individuals into a particular world view, such as blind support for a football team or to an ideology (this is a topic requiring a paper of its own), what remains seems to be another sort of power.", [["Power", "OBSERVATION_MODIFIER", 96, 101]]], ["But power need not be used as a force for suppression and coercion it can be used in a supportive way for an individual or group.", [["coercion", "TREATMENT", 58, 66]]], ["As Jary and Jary observed, \u2018Although power \u2026is often seen in negative terms, as involving coercion and conflicts of interest...\u2018power\u2019 can also be seen in more positive terms, as enabling.\u2019 (ibid, 1995, p.513).", [["negative terms", "OBSERVATION_MODIFIER", 61, 75]]], ["This flies in the face of the notion of soft power.", [["soft power", "OBSERVATION", 40, 50]]], ["Soft power is based upon things that mean something to the \u2018community\u2019 and accepted by them at that time and in that context.", [["power", "OBSERVATION", 5, 10]]], ["To understand how \u2018soft\u2019 power is used and what value it has within any group situation requires a subjective appreciation of what is taking place and not one constrained by the need to \u2018prove the model22\u2018.Soft Power and when we use itWe all possess \u2018soft\u2019 power and soon learn surreptitious ways to \u2018get our own way\u2019.", [["model22", "PROTEIN", 197, 204], ["Power", "OBSERVATION", 211, 216]]], ["We learn to apply unobtrusive strategies in order to find ways to help us \u2018cope\u2019 with our situation including calling upon personal attributes such as reputation, personality, esteem to help us to be accepted within our community (e.g. see Zaleznik 1970; Stowell 1989a, 2018; Checkland and Poulter 2006).Soft Power and when we use itWhilst there is some form of continuity as we transfer from one familiar community to another eventually, we join an alien \u2018domain\u2019.", [["unobtrusive strategies", "TREATMENT", 18, 40], ["Power", "OBSERVATION", 309, 314]]], ["Joining a new community opens up a new set of circumstances and we enter a community with little knowledge of others or the norms within that community.", [["new", "OBSERVATION_MODIFIER", 10, 13]]], ["We develop a way of coping and either fit in or try to change things to make us feel more secure, a sort of transformation of intent takes place as individuals and groups attempt to gain a greater amount of control.", [["a greater amount of control", "TREATMENT", 187, 214]]], ["I suggest thinking of soft power in terms of a metaphor23 reflects its abstruse nature and might prove useful.A Metaphor for soft PowerA simple definition of the use of power adopted in this paper is \u2018The ability to \u2018convert\u2019 someone to adopt a course of action at variance with their original inclination\u2019.", [["metaphor23", "GENE_OR_GENE_PRODUCT", 47, 57], ["metaphor23", "PROTEIN", 47, 57], ["soft power", "OBSERVATION_MODIFIER", 22, 32]]], ["Whilst \u2018hard\u2019 power can be seen in action e.g. orders or sanctions soft power can only be gauged by its effect.", [["sanctions soft power", "TREATMENT", 57, 77]]], ["Soft power is intangible, and it is its effect that gives the impression of power, which leaves an observer unable to \u2018put their finger\u2019 on what it was that changed the direction.", [["finger", "ANATOMY", 129, 135], ["finger", "ORGANISM_SUBDIVISION", 129, 135], ["power", "OBSERVATION_MODIFIER", 5, 10], ["intangible", "OBSERVATION", 14, 24]]], ["I have proposed using this metaphor as a way of offering a neutral account of the perceived inputs (soft power) of individuals and groups in which attempts are made to translate a situation into something else.A Metaphor for soft PowerReferring to soft power as a commodity facilitates free discussion in the spirit of Gadamer\u2019s \u2018Fusion of Horizons\u201924 where participants work to exchange knowledge rather than seek to impose a particular opinion, (Gadamer 2004, p.304; Stowell and Welch 2012, pp.147\u2013148).", [["participants", "SPECIES", 358, 370]]], ["Champion and Stowell say that by \u2018Applying the \u2018power as a commodity\u2019 the metaphor facilitates asking how power has been expressed within the situation and how people intend to use and maintain these \u2018commodities\u2019 (ibid, 2001, p.9).", [["people", "ORGANISM", 160, 166], ["people", "SPECIES", 160, 166]]], ["As Gadamer reminds us, \u2018A man who is disguised does not want to be recognised, but instead to appear as someone else\u2026we merely pretend, act a part, and create an impression.\u2019 (ibid, 2004, p.111).A Metaphor for soft PowerRecognizing the use of a \u2018commodity\u2019 (or commodities) provides an opportunity of giving weight to the opinion within the context of the way in which this \u2018commodity\u2019 has been expressed.", [["man", "ORGANISM", 26, 29], ["man", "SPECIES", 26, 29]]], ["It is this idea that underpins the Analysis One, Two and Three stages incorporated within SSM.", [["the Analysis", "TEST", 31, 43]]], ["It works with the fact that everyone who participates in the life of social grouping quickly acquires a sense of what you have to do to influence people.\u2019", [["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152]]], ["In practice the participants attempt to understand the reason and motive behind the way the \u2018commodities\u2019 are being applied.", [["participants", "SPECIES", 16, 28]]], ["Whilst we acknowledge, as Ryle remarks, \u2018Understanding is still psychological divining\u2026\u2019 (Ryle 1990, p.52), as individuals we call upon our experiences and understanding of the culture of which we are a part, to make sense of interactions between participants.", [["participants", "SPECIES", 247, 259], ["the culture", "TEST", 173, 184]]], ["Commodities of power are both tangible and intangible.", [["power", "OBSERVATION_MODIFIER", 15, 20], ["tangible", "OBSERVATION_MODIFIER", 30, 38], ["intangible", "OBSERVATION_MODIFIER", 43, 53]]], ["The notion of controlling power seems to relate to many different attributes which are as diverse as charisma, physical strength, education, beauty, status, property ownership and as examples of a negative effect, withdrawal of affection, lack of communication, exclusion, physical threat.Metaphor in useIt is important to recognize that \u2018Commodities\u2019 change through time because they are personal, cultural and temporal.", [["withdrawal of affection", "PROBLEM", 214, 237], ["temporal", "ANATOMY_MODIFIER", 412, 420]]], ["A new export contracts manager had been appointed and became involved in the project that had been on-going for several months.", [["new", "OBSERVATION_MODIFIER", 2, 5]]], ["He seemed to be unaware of the culture of his new company\u2019 (ibid, p.268).", [["the culture", "TEST", 27, 38]]], ["His attempts to exercise control over the project could be thought of in terms of commodities of power.", [["exercise control", "TREATMENT", 16, 32]]], ["The staff saw the new manager as attempting to undermine their efforts; he was considered an alien.Metaphor in useThe project provided many instances of the use of commodities in a positive sense as well as being used through veiled threats for those who wished to maintain the status quo.", [["Metaphor", "TREATMENT", 99, 107]]], ["For example, the managing director preferred to use his charms and personality to control the situation rather than use his formal power.", [["his charms", "TREATMENT", 52, 62]]], ["In this case as the memory and influence of the founder fades so too will the \u201cpower\u201d of those who chose to use \u201cKT\u201d as a commodity will find its influence will also have fadedIllustration 3: In two workshops facilitated by Bednar and Stowell, A. in 2011 they found the mnemonic a useful way of helping participants to appreciate the way in which individuals react when they meet for the first time.", [["individuals", "ORGANISM", 347, 358], ["participants", "SPECIES", 303, 315]]], ["In the second of the reported workshops there was no evidence of attempts to exercise control over the other participants during group work, as Bednar reported (July 8th, 2008) \u2018Informal powers were low key and while some may have been used I believe that this was more personality trait than intention.", [["participants", "SPECIES", 109, 121], ["no evidence of", "UNCERTAINTY", 50, 64]]], ["(Interestingly Bednar\u2019s reflection about personality trait is a good example of a commodity of power as, in this instance, someone used their personality to good effect at times).", [["personality trait", "PROBLEM", 41, 58]]], ["On this point it is worth noting that participants might use other ways of trying to influence outcomesIllustration 4: In 2014 Hart set up a series of workshops to help her research \u2018knowledge transfer\u2019.", [["participants", "SPECIES", 38, 50]]], ["This meant that unless the \u2018knowledge\u2019 of the individuals was passed on to their replacement they had to effectively start again.", [["individuals", "ORGANISM", 46, 57], ["their replacement", "TREATMENT", 75, 92]]], ["Staff were willing to take part with many giving up their free time to join the discussions.Metaphor in useThe participants were aware of the relationship between knowledge and its association to personal reputation.", [["participants", "SPECIES", 111, 123]]], ["There seemed a consensus in the group that the hoarding of knowledge was a further expression of implicit knowledge and every possibility that subject experts had.", [["hoarding", "DISEASE", 47, 55]]], ["They \u2018guarded\u2019 their knowledge, consciously or unconsciously, this strategy to \u2018protect\u2019 their knowledge, she commented, could be seen as an example of a commodity of power (Hart 2014, p14).Metaphor in useHarts study coincided with a time of organizational change.", [["p14", "GENE_OR_GENE_PRODUCT", 185, 188], ["p14", "PROTEIN", 185, 188], ["Metaphor in useHarts study", "TEST", 190, 216], ["organizational change", "TREATMENT", 242, 263]]], ["At least one participant, a senior manager of the knowledge services department, did not attend all meetings because he was located in a different part of the country, but importantly, was due to transfer to this establishment within a few months.", [["participant", "SPECIES", 13, 24]]], ["Hart observed that in each session, despite the meetings being set up to explore all aspects of knowledge transfer with no predefined outcome, he seemed to be at pains to ensure that the other participants were aware of his \u2018vast\u2019 experience.", [["pains", "DISEASE", 162, 167], ["participants", "SPECIES", 193, 205]]], ["In a later study exploring how \u2018commodity\u2019 could be applied in virtual team discussions, Cooray observed that \u2018\u2026in this exercise the more technically proficient participants seemed to use their expertise as a way of influencing others.", [["participants", "SPECIES", 161, 173], ["a later study", "TEST", 3, 16]]], ["(N.B. It could also be an example of the use of soft power; the implication being a form of ready-made excuse if things went wrong\u2019 Stowell and Cooray 2017)Authority ::: A useful Mnemonic: PEArLAny process of inquiry within a social organisational setting will be sanctioned by a person, or group concerned with the situation under investigation.", [["person", "SPECIES", 280, 286], ["soft power", "TREATMENT", 48, 58]]], ["\u2018A\u2019 makes clear who has formal control.relationships ::: A useful Mnemonic: PEArLThe models produced during the inquiry process will reflect the intended relationships to be maintained within any proposed intervention.", [["formal control", "TREATMENT", 24, 38], ["any proposed intervention", "TREATMENT", 192, 217], ["clear", "OBSERVATION", 10, 15]]], ["An examination of these relationships may be useful in questioning any undeclared assumptions and worldviews (Weltanschauungen) held by the participants.", [["participants", "SPECIES", 140, 152], ["An examination", "TEST", 0, 14]]], ["These relationships may provide insight into how individual power and control has been dealt with by participants during the inquiry and with their intended intervention.", [["participants", "SPECIES", 101, 113], ["their intended intervention", "TREATMENT", 142, 169]]], ["Reflecting upon the intended relationships, what they are, what is expressed, the context and how \u2018soft power\u2019 is deployed may help to identify potential areas of conflict.relationships ::: A useful Mnemonic: PEArLI have found from the practice that embedding \u2018commodity\u2019 (r) within the mnemonic PEArL it becomes a visual and practical way in which to explore the implications of \u2018soft\u2019 power.", [["conflict", "OBSERVATION", 163, 171]]], ["By surfacing the use of Soft power we can generate an exchange of ideas as a means of gaining an Appreciation of the situation of interest.ConclusionHaving grown up in a world which subscribes to the scientific paradigm many find it difficult to look outside a world described according to a causal model into one where reality is established from subjective experience of relationships within the human environment.", [["human", "ORGANISM", 398, 403], ["human", "SPECIES", 398, 403], ["human", "SPECIES", 398, 403], ["Soft power", "TREATMENT", 24, 34]]], ["What we make of our world is shaped by a series of concrete phenomena and impressions formed from our (subjective) experience of it and through the communities to which we belong.", [["concrete phenomena", "PROBLEM", 51, 69]]], ["If this fails then we set about trying to find new paradigms or new ways to explain something which, frankly, cannot be wrapped up into a package to be used until the next time; it does not answer our question.ConclusionWe are afraid of accepting that our naive insights may be of value.", [["a package", "TREATMENT", 136, 145]]], ["To accept that a simple statement uttered in discussion might have a greater depth for the person uttering may be difficult for those who view the world solely in concrete terms.", [["person", "SPECIES", 91, 97]]], ["But the manner in which individuals interact may ring alarm bells amongst the participants.", [["participants", "SPECIES", 78, 90]]], ["Commodities are part of a transformation process affecting the position held by each participant in a given situation.", [["a transformation process", "PROBLEM", 24, 48], ["transformation", "OBSERVATION", 26, 40], ["position", "OBSERVATION_MODIFIER", 63, 71]]], ["Starting positions are transformed by the trading of commodities and by the strategies chosen by participants.", [["participants", "SPECIES", 97, 109]]], ["By allowing participants \u2018in\u2019 on the way in which people seek to influence outcomes acts as a means of reminding us that we should stop and think \u2018what does this mean\u2019; \u2018why are they reacting in this way?\u2019", [["people", "ORGANISM", 50, 56], ["participants", "SPECIES", 12, 24], ["people", "SPECIES", 50, 56]]], ["The point of the idea is to develop participants\u2019 awareness of the potential impact that some interactions might have on shaping the outcome.", [["participants", "SPECIES", 36, 48]]], ["We can gain insight into the way participants attempt to shape the outcome through their use of language and the nonverbal cues they may use to reinforce their meaning.", [["participants", "SPECIES", 33, 45]]], ["Power is an integral part of political behaviour and its currency is relative to the degree of dependency upon a given \u2018commodity\u2019.", [["political behaviour", "OBSERVATION", 29, 48], ["dependency", "OBSERVATION", 95, 105]]], ["Thinking about power in this way provides a means of articulating it in terms that is appropriate to a given organizational culture, which can be understood by those most affected and for all to reflect upon and used as part of the process of gaining an holistic view of the situation.", [["organizational culture", "TEST", 109, 131]]]], "1116dee4f5048605b10c0d9a947605f341f3d4a1": [["INTRODUCTIONConventionally-housed laboratory rodents commonly sustain infection with one or more viral agents (Foster et al., 1982) .", [["infection", "DISEASE", 70, 79], ["rodents", "ORGANISM", 45, 52], ["infection", "PROBLEM", 70, 79], ["infection", "OBSERVATION", 70, 79]]], ["Since some of these infections are known or thought to affect the outcome of experimental procedures, it is important to understand their pathogenesis and natural history.", [["infections", "DISEASE", 20, 30], ["these infections", "PROBLEM", 14, 30], ["experimental procedures", "TREATMENT", 77, 100], ["infections", "OBSERVATION", 20, 30]]], ["The execution of studies designed to elucidate the biology of rodent virus infections requires the ability to detect and quantify infectious virus in large numbers of clinical specimens.", [["specimens", "ANATOMY", 176, 185], ["infections", "DISEASE", 75, 85], ["rodent virus", "ORGANISM", 62, 74], ["specimens", "CANCER", 176, 185], ["rodent", "SPECIES", 62, 68], ["rodent virus", "SPECIES", 62, 74], ["The execution of studies", "TEST", 0, 24], ["rodent virus infections", "PROBLEM", 62, 85], ["infectious virus", "PROBLEM", 130, 146], ["clinical specimens", "TEST", 167, 185]]], ["Because of the high transmission potential of many of these agents, alternatives to animal inoculation are desirable.", [["these agents", "TREATMENT", 54, 66], ["alternatives", "TREATMENT", 68, 80], ["animal inoculation", "TREATMENT", 84, 102]]], ["Many rodent viruses do not induce morphologic changes in inoculated cell cultures, necessitating the use of immunochemical probes to detect viral antigens.", [["cell cultures", "ANATOMY", 68, 81], ["cell cultures", "CELL", 68, 81], ["inoculated cell cultures", "CELL_LINE", 57, 81], ["viral antigens", "PROTEIN", 140, 154], ["Many rodent viruses", "PROBLEM", 0, 19], ["morphologic changes", "PROBLEM", 34, 53], ["inoculated cell cultures", "TEST", 57, 81], ["immunochemical probes", "TREATMENT", 108, 129], ["viral antigens", "PROBLEM", 140, 154], ["viruses", "OBSERVATION", 12, 19], ["inoculated cell cultures", "OBSERVATION", 57, 81]]], ["We have used the fluorescent focus test for detection and quantification (Smith, 1983; Smith et al., 1984) ; however, the procedure is expensive and labor-intensive.", [["the fluorescent focus test", "TEST", 13, 39], ["the procedure", "TREATMENT", 118, 131], ["labor", "PROBLEM", 149, 154]]], ["It is particularly cumbersome when applied to large numbers of samples.", [["samples", "ANATOMY", 63, 70], ["samples", "CANCER", 63, 70], ["large", "OBSERVATION_MODIFIER", 46, 51]]], ["Smith et al. (1981) reported quantification of herpes, mumps and measles viruses in unfixed cultured cells using the enzyme immunoassay (EIA) .", [["cells", "ANATOMY", 101, 106], ["herpes, mumps and measles viruses", "DISEASE", 47, 80], ["herpes", "ORGANISM", 47, 53], ["mumps", "ORGANISM", 55, 60], ["measles viruses", "ORGANISM", 65, 80], ["cells", "CELL", 101, 106], ["unfixed cultured cells", "CELL_TYPE", 84, 106], ["measles viruses", "SPECIES", 65, 80], ["herpes", "PROBLEM", 47, 53], ["mumps", "PROBLEM", 55, 60], ["measles viruses in unfixed cultured cells", "PROBLEM", 65, 106], ["the enzyme immunoassay", "TEST", 113, 135], ["EIA", "TEST", 137, 140], ["herpes", "OBSERVATION", 47, 53]]], ["Recently, Yong-He et al. (1984) reported the use of EIA to detect several flaviviruses in cultured cells which were formalin-fixed prior to processing.", [["cells", "ANATOMY", 99, 104], ["formalin", "CHEMICAL", 116, 124], ["cells", "CELL", 99, 104], ["cultured cells", "CELL_LINE", 90, 104], ["EIA", "TEST", 52, 55], ["several flaviviruses in cultured cells", "PROBLEM", 66, 104], ["flaviviruses", "OBSERVATION", 74, 86]]], ["In the case of rodent viruses, viral inactivation prior to EIA is desirable to protect animals housed in the vicinity of the laboratory, as well as personnel in the case of zoonotic viruses.INTRODUCTIONIn this paper, we report the application of EIA methodology to detection andVirus strainsThe immunosuppressive (MVM(i)) and prototype (MVM(p)) strains of minute virus of mice were obtained from Dr. Peter Tattersall (Department of Human Genetics, Yale University) and were passaged once in BHK21 cells.", [["BHK21 cells", "ANATOMY", 491, 502], ["zoonotic viruses", "DISEASE", 173, 189], ["Virus strains", "ORGANISM", 278, 291], ["MVM(p)", "GENE_OR_GENE_PRODUCT", 337, 343], ["minute virus", "ORGANISM", 356, 368], ["mice", "ORGANISM", 372, 376], ["Human", "ORGANISM", 432, 437], ["BHK21 cells", "CELL", 491, 502], ["BHK21 cells", "CELL_LINE", 491, 502], ["rodent", "SPECIES", 15, 21], ["mice", "SPECIES", 372, 376], ["Human", "SPECIES", 432, 437], ["Virus strains", "SPECIES", 278, 291], ["mice", "SPECIES", 372, 376], ["rodent viruses", "PROBLEM", 15, 29], ["viral inactivation", "PROBLEM", 31, 49], ["EIA", "TEST", 59, 62], ["zoonotic viruses", "PROBLEM", 173, 189], ["EIA methodology", "TREATMENT", 246, 261], ["Virus strains", "PROBLEM", 278, 291], ["The immunosuppressive (MVM(i)", "TREATMENT", 291, 320], ["prototype (MVM(p)", "TREATMENT", 326, 343], ["viruses", "OBSERVATION", 22, 29], ["viral inactivation", "OBSERVATION", 31, 49], ["zoonotic viruses", "OBSERVATION", 173, 189]]], ["Virus stocks used for tissue culture inoculation were in the form of crude BHK21 celllysates.", [["tissue culture", "ANATOMY", 22, 36], ["Virus", "ORGANISM", 0, 5], ["tissue culture", "CELL", 22, 36], ["BHK21", "GENE_OR_GENE_PRODUCT", 75, 80], ["Virus stocks", "TREATMENT", 0, 12], ["tissue culture inoculation", "TEST", 22, 48], ["crude BHK21 celllysates", "TREATMENT", 69, 92]]], ["Virus obtained from Dr. Tattersall was also used to inoculate neonatal Crl: CFlBr mice intracerebrally to generate clinical material for testing.AntiseraAscitic fluid containing polyclonal antibody to MVM(i) was prepared by injecting multiparous female Crl : CFl Br mice intraperitoneally at weekly intervals with infected infant mouse brain emulsified in Freund's complete adjuvant.", [["brain", "ANATOMY", 336, 341], ["Virus", "ORGANISM", 0, 5], ["CFlBr mice", "ORGANISM", 76, 86], ["MVM", "ORGANISM", 201, 204], ["CFl", "GENE_OR_GENE_PRODUCT", 259, 262], ["Br mice", "ORGANISM", 263, 270], ["mouse", "ORGANISM", 330, 335], ["brain", "ORGAN", 336, 341], ["Freund", "ORGANISM", 356, 362], ["polyclonal antibody", "PROTEIN", 178, 197], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 266, 270], ["infant", "SPECIES", 323, 329], ["mouse", "SPECIES", 330, 335], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 266, 270], ["mouse", "SPECIES", 330, 335], ["Virus", "PROBLEM", 0, 5], ["testing", "TEST", 137, 144], ["AntiseraAscitic fluid containing polyclonal antibody", "TREATMENT", 145, 197], ["infected infant mouse brain emulsified", "TREATMENT", 314, 352], ["polyclonal antibody", "OBSERVATION", 178, 197], ["infected", "OBSERVATION", 314, 322], ["brain", "ANATOMY", 336, 341]]], ["Mouse ascitic fluid containing antibody to a mouse brain-adapted rat coronavirus, sialodacryoadenitis virus (SDAV), was similarly prepared for use as a control reagent.", [["ascitic fluid", "ANATOMY", 6, 19], ["brain", "ANATOMY", 51, 56], ["Mouse", "ORGANISM", 0, 5], ["ascitic fluid", "ORGANISM_SUBSTANCE", 6, 19], ["mouse", "ORGANISM", 45, 50], ["brain", "ORGAN", 51, 56], ["rat", "ORGANISM", 65, 68], ["coronavirus", "ORGANISM", 69, 80], ["sialodacryoadenitis virus", "ORGANISM", 82, 107], ["SDAV", "ORGANISM", 109, 113], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 45, 50], ["rat", "SPECIES", 65, 68], ["coronavirus", "SPECIES", 69, 80], ["sialodacryoadenitis virus", "SPECIES", 82, 107], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 45, 50], ["rat coronavirus", "SPECIES", 65, 80], ["sialodacryoadenitis virus", "SPECIES", 82, 107], ["SDAV", "SPECIES", 109, 113], ["Mouse ascitic fluid containing antibody", "PROBLEM", 0, 39], ["a mouse brain", "PROBLEM", 43, 56], ["rat coronavirus", "PROBLEM", 65, 80], ["sialodacryoadenitis virus (SDAV", "PROBLEM", 82, 113], ["a control reagent", "TREATMENT", 150, 167], ["ascitic fluid", "OBSERVATION", 6, 19], ["brain", "ANATOMY", 51, 56]]], ["Hyperimmune rabbit antiserum to MVM(p) was obtained from Dr. Tattersall.AntiseraCell cultures C6 rat glioma cells were cultured in Dulbecco's modified essential medium containing 5% heat-inactivated fetal bovine serum and antibiotics (DMEM 95-5).", [["glioma cells", "ANATOMY", 101, 113], ["fetal bovine serum", "ANATOMY", 199, 217], ["rabbit", "ORGANISM", 12, 18], ["antiserum", "ORGANISM_SUBSTANCE", 19, 28], ["MVM", "ORGANISM", 32, 35], ["C6 rat glioma cells", "CELL", 94, 113], ["bovine", "ORGANISM", 205, 211], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["AntiseraCell cultures", "CELL_LINE", 72, 93], ["C6 rat glioma cells", "CELL_LINE", 94, 113], ["rabbit", "SPECIES", 12, 18], ["rat", "SPECIES", 97, 100], ["bovine", "SPECIES", 205, 211], ["rabbit", "SPECIES", 12, 18], ["rat", "SPECIES", 97, 100], ["bovine", "SPECIES", 205, 211], ["Hyperimmune rabbit antiserum", "TREATMENT", 0, 28], ["AntiseraCell cultures C6 rat glioma cells", "TEST", 72, 113], ["Dulbecco", "TEST", 131, 139], ["inactivated fetal bovine serum", "TREATMENT", 187, 217], ["antibiotics", "TREATMENT", 222, 233], ["DMEM", "TEST", 235, 239], ["glioma cells", "OBSERVATION", 101, 113]]], ["Cells were added in a volume of 0.1 ml to 96-well cluster dishes (Costar, Cambridge, MA) or in a volume of 0.5 ml to 4-chamber Lab Tek slides (Miles Laboratories, Naperville, IL) at densities of 1-2 X IO3 or 5-10 X 103, respectively.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Culture vessels were maintained in humidified chambers in a 37\u00b0C 5% CO, atmosphere.", [["Culture vessels", "ANATOMY", 0, 15], ["CO", "CHEMICAL", 68, 70], ["Culture vessels", "MULTI-TISSUE_STRUCTURE", 0, 15], ["CO", "SIMPLE_CHEMICAL", 68, 70], ["Culture vessels", "TEST", 0, 15], ["vessels", "ANATOMY", 8, 15], ["humidified chambers", "OBSERVATION", 35, 54]]], ["Cultures were inoculated within 3 h of seeding.Viral infectivity assaysFor the fluorescent focus test, 10% tissue homogenates or IO-fold virus dilutions in volumes of 0.3 ml were added to chambers of Lab Tek slides containing C6 cells.", [["tissue homogenates", "ANATOMY", 107, 125], ["C6 cells", "ANATOMY", 226, 234], ["tissue homogenates", "TISSUE", 107, 125], ["C6 cells", "CELL", 226, 234], ["C6 cells", "CELL_LINE", 226, 234], ["Cultures", "TEST", 0, 8], ["seeding", "PROBLEM", 39, 46], ["Viral infectivity assays", "PROBLEM", 47, 71], ["the fluorescent focus test", "TEST", 75, 101], ["IO-fold virus dilutions", "TREATMENT", 129, 152], ["infectivity", "OBSERVATION", 53, 64], ["C6 cells", "OBSERVATION", 226, 234]]], ["After a 1 h absorption period at 37\"C, the virus inocula were removed, and the cells were washed once with DMEM 95-5.", [["cells", "ANATOMY", 79, 84], ["cells", "CELL", 79, 84], ["the virus inocula", "PROBLEM", 39, 56], ["DMEM", "TEST", 107, 111]]], ["Medium (1 ml per chamber) was added, and the cultures were maintained for periods outlined in the results, Acetone-fixed cells were processed for indirect immunofluorescence using hyperimmune mouse ascitic fluid to MVM(i) diluted 1 : 50 and fluorescein-conjugated goat anti-mouse immunoglobulin (Antibodies Inc., Davis, CA) diluted 1 : 50 and containing 0.01% Evans blue (Roboz Surgical Instruments Co., Washington, DC).", [["cells", "ANATOMY", 121, 126], ["ascitic fluid", "ANATOMY", 198, 211], ["DC", "ANATOMY", 416, 418], ["Acetone", "CHEMICAL", 107, 114], ["fluorescein", "CHEMICAL", 241, 252], ["Evans blue", "CHEMICAL", 360, 370], ["Acetone", "CHEMICAL", 107, 114], ["fluorescein", "CHEMICAL", 241, 252], ["Acetone", "SIMPLE_CHEMICAL", 107, 114], ["cells", "CELL", 121, 126], ["hyperimmune", "ORGANISM", 180, 191], ["mouse", "ORGANISM", 192, 197], ["ascitic fluid", "ORGANISM_SUBSTANCE", 198, 211], ["fluorescein", "SIMPLE_CHEMICAL", 241, 252], ["goat", "ORGANISM", 264, 268], ["anti-mouse immunoglobulin", "SIMPLE_CHEMICAL", 269, 294], ["Evans blue", "SIMPLE_CHEMICAL", 360, 370], ["Acetone-fixed cells", "CELL_LINE", 107, 126], ["goat anti-mouse immunoglobulin", "PROTEIN", 264, 294], ["Antibodies", "PROTEIN", 296, 306], ["mouse", "SPECIES", 192, 197], ["goat", "SPECIES", 264, 268], ["anti-mouse", "SPECIES", 269, 279], ["mouse", "SPECIES", 192, 197], ["goat", "SPECIES", 264, 268], ["the cultures", "TEST", 41, 53], ["Acetone-fixed cells", "TREATMENT", 107, 126], ["indirect immunofluorescence", "TEST", 146, 173], ["hyperimmune mouse ascitic fluid", "TREATMENT", 180, 211], ["fluorescein", "TEST", 241, 252], ["conjugated goat anti-mouse immunoglobulin", "TREATMENT", 253, 294], ["Antibodies", "TEST", 296, 306]]], ["Glycerol-mounted slides were viewed with an Olympus BH-2 transmission fluorescence microscope, and single cells or foci containing viral antigen were counted at 100 or 40 diameters, respectively.Virus neutralizationLog dilutions of hyperimmune rabbit antiserum to MVM(p) were mixed in 96-well transfer plates (Dynatech Laboratories, Inc., Alexandria, VA) with equal volumes of virus suspensions containing either 100 or 1,000 median infectious doses of MVM(p).", [["cells", "ANATOMY", 106, 111], ["foci", "ANATOMY", 115, 119], ["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "SIMPLE_CHEMICAL", 0, 8], ["cells", "CELL", 106, 111], ["foci", "CELL", 115, 119], ["Virus", "ORGANISM", 195, 200], ["hyperimmune", "ORGANISM", 232, 243], ["rabbit", "ORGANISM", 244, 250], ["antiserum", "ORGANISM_SUBSTANCE", 251, 260], ["MVM", "ORGANISM", 264, 267], ["MVM", "ORGANISM", 453, 456], ["viral antigen", "PROTEIN", 131, 144], ["hyperimmune", "SPECIES", 232, 243], ["rabbit", "SPECIES", 244, 250], ["rabbit", "SPECIES", 244, 250], ["Glycerol-mounted slides", "TREATMENT", 0, 23], ["an Olympus BH", "TEST", 41, 54], ["fluorescence microscope", "TEST", 70, 93], ["foci", "PROBLEM", 115, 119], ["viral antigen", "TEST", 131, 144], ["Virus neutralizationLog dilutions", "TREATMENT", 195, 228], ["hyperimmune rabbit antiserum", "TREATMENT", 232, 260], ["virus suspensions", "TREATMENT", 377, 394], ["foci", "OBSERVATION", 115, 119], ["viral", "OBSERVATION_MODIFIER", 131, 136]]], ["After 1 h at 37\u00b0C the mixtures were added to newly seeded C6 cells in cluster dishes.", [["C6 cells", "ANATOMY", 58, 66], ["C6 cells", "CELL", 58, 66], ["C6 cells", "CELL_LINE", 58, 66], ["C the mixtures", "TREATMENT", 16, 30], ["newly seeded C6 cells in cluster dishes", "PROBLEM", 45, 84], ["C6 cells", "OBSERVATION", 58, 66]]], ["After 4 days, the cells were fixed and processed through the EIA protocol outlined above.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["the cells", "TREATMENT", 14, 23], ["the EIA protocol", "TEST", 57, 73]]], ["The hyperimmune rabbit antibody reduced infectivity of MVM(p) or MVM(i) in plaque assays by 90% when diluted 1 : 10,000 (Tattersall and Bratton, 1983) .CalculationsOptical density (O.D.) values were considered significant if they exceeded by 3 SD the mean value for control wells in the same assay.", [["plaque", "ANATOMY", 75, 81], ["hyperimmune", "ORGANISM", 4, 15], ["rabbit", "ORGANISM", 16, 22], ["MVM", "ORGANISM", 55, 58], ["plaque", "PATHOLOGICAL_FORMATION", 75, 81], ["hyperimmune rabbit antibody", "PROTEIN", 4, 31], ["hyperimmune", "SPECIES", 4, 15], ["rabbit", "SPECIES", 16, 22], ["rabbit", "SPECIES", 16, 22], ["The hyperimmune rabbit antibody", "TEST", 0, 31], ["plaque assays", "TEST", 75, 88], ["hyperimmune rabbit", "OBSERVATION", 4, 22], ["density", "OBSERVATION", 172, 179]]], ["Virus titers measured by the EIA were calculated by the method of Reed and Muench (1938) .", [["Virus", "ORGANISM", 0, 5], ["Virus titers", "TEST", 0, 12], ["the EIA", "TEST", 25, 32]]], ["Fluorescent focus titers were calculated by the method described by Lorenz and Bogel (1973) .RESULTSIn an early experiment, C6 cells inoculated with log dilutions of MVM(p) and held for 4 days were treated with ( In the next experiment, cells in cluster dishes and Lab Tek slides were inoculated in paralIe1 with MVM(p) dilutions and fixed for EIA and IFA, respectively, on day 2,4,5 or 6 (cluster dishes only on day 6).", [["C6 cells", "ANATOMY", 124, 132], ["cells", "ANATOMY", 237, 242], ["C6 cells", "CELL", 124, 132], ["MVM", "ORGANISM", 166, 169], ["cells", "CELL", 237, 242], ["C6 cells", "CELL_LINE", 124, 132], ["Fluorescent focus titers", "TEST", 0, 24], ["C6 cells", "PROBLEM", 124, 132], ["MVM", "PROBLEM", 166, 169], ["Lab Tek slides", "TEST", 265, 279], ["EIA", "TEST", 344, 347], ["IFA", "TEST", 352, 355]]], ["The virus titer as determined by fluorescent focus test did not change with time, although the size of countable foci did increase.", [["foci", "ANATOMY", 113, 117], ["The virus titer", "TEST", 0, 15], ["fluorescent focus test", "TEST", 33, 55], ["countable foci", "PROBLEM", 103, 117], ["virus", "OBSERVATION", 4, 9], ["size", "OBSERVATION_MODIFIER", 95, 99], ["foci", "OBSERVATION", 113, 117], ["increase", "OBSERVATION_MODIFIER", 122, 130]]], ["The titer calculated from the EIA increased significantly between day 2 and day 4, plateau&g on day 5 at the same level as the fluorescent focus titer.RESULTSWe next wished to determine whether MVM infectivity was being inactivated by the glutaraldehyde fixation, since processing of large numbers of plates in a biological safety cabinet was cumbersome.RESULTSCells were inoculated with 3,000 or 30,000 ID,, of either MVM(p) or MVMfi) and held for 4 days.", [["glutaraldehyde", "CHEMICAL", 239, 253], ["glutaraldehyde", "CHEMICAL", 239, 253], ["MVM", "ORGANISM", 194, 197], ["glutaraldehyde", "SIMPLE_CHEMICAL", 239, 253], ["MVM", "SPECIES", 194, 197], ["The titer", "TEST", 0, 9], ["the EIA", "TEST", 26, 33], ["MVM infectivity", "PROBLEM", 194, 209], ["the glutaraldehyde fixation", "TREATMENT", 235, 262], ["large numbers of plates", "PROBLEM", 284, 307], ["glutaraldehyde fixation", "OBSERVATION", 239, 262], ["large", "OBSERVATION_MODIFIER", 284, 289], ["numbers", "OBSERVATION_MODIFIER", 290, 297], ["plates", "OBSERVATION_MODIFIER", 301, 307]]], ["Supernatant culture fluid was collected from wells prior to treatment with 0.02% glutaraldehyde and at 2, 6, and 24 h after fixation.", [["culture fluid", "ANATOMY", 12, 25], ["glutaraldehyde", "CHEMICAL", 81, 95], ["glutaraldehyde", "CHEMICAL", 81, 95], ["fluid", "ORGANISM_SUBSTANCE", 20, 25], ["glutaraldehyde", "SIMPLE_CHEMICAL", 81, 95], ["Supernatant culture fluid", "TEST", 0, 25], ["treatment", "TREATMENT", 60, 69], ["0.02% glutaraldehyde", "TREATMENT", 75, 95], ["fixation", "TREATMENT", 124, 132], ["fluid", "OBSERVATION", 20, 25]]], ["Viral infectivity was measured by fluorescent focus assay.", [["Viral", "ORGANISM", 0, 5], ["Viral infectivity", "PROBLEM", 0, 17], ["fluorescent focus assay", "TEST", 34, 57], ["infectivity", "OBSERVATION", 6, 17]]], ["Infectivity of MVM(i) was reduced by about 70% at 24 h post-fixation.", [["MVM", "ORGANISM", 15, 18], ["fixation", "TREATMENT", 60, 68]]], ["Infectivity of MVM(p) was unaltered by treatment with this concentration of glutaraldehyde, even at 24 h.RESULTSSince viral inactivation was not achieved with 0.02% glutaraldehyde and since a higher concentration had resulted in unacceptable background signal, we studied the ability of neutral buffered formalin to inactivate virus in the supernates of wells inoculated with 30,000 ID,, of MVM(p).", [["glutaraldehyde", "CHEMICAL", 76, 90], ["glutaraldehyde", "CHEMICAL", 165, 179], ["formalin", "CHEMICAL", 304, 312], ["glutaraldehyde", "CHEMICAL", 76, 90], ["glutaraldehyde", "CHEMICAL", 165, 179], ["formalin", "CHEMICAL", 304, 312], ["MVM", "ORGANISM", 15, 18], ["glutaraldehyde", "SIMPLE_CHEMICAL", 76, 90], ["glutaraldehyde", "SIMPLE_CHEMICAL", 165, 179], ["formalin", "SIMPLE_CHEMICAL", 304, 312], ["this concentration of glutaraldehyde", "TREATMENT", 54, 90], ["viral inactivation", "PROBLEM", 118, 136], ["0.02% glutaraldehyde", "TREATMENT", 159, 179], ["a higher concentration", "PROBLEM", 190, 212], ["unacceptable background signal", "PROBLEM", 229, 259], ["neutral buffered formalin", "TREATMENT", 287, 312], ["virus", "PROBLEM", 327, 332]]], ["The experiment was performed only with MVM(p), since this strain had been more resistant to inactivation.RESULTSFormalin at final To confirm that the reaction product detected in the EIA was specific for MVM antigen, a neutralization test using rabbit hyperimmune MVM antibody was performed (Table 3) .", [["MVM", "ORGANISM", 39, 42], ["MVM antigen", "GENE_OR_GENE_PRODUCT", 204, 215], ["rabbit", "ORGANISM", 245, 251], ["hyperimmune", "ORGANISM", 252, 263], ["MVM", "ORGANISM", 264, 267], ["MVM antigen", "PROTEIN", 204, 215], ["rabbit hyperimmune MVM antibody", "PROTEIN", 245, 276], ["rabbit", "SPECIES", 245, 251], ["rabbit", "SPECIES", 245, 251], ["MVM", "SPECIES", 264, 267], ["this strain", "PROBLEM", 53, 64], ["the reaction product", "PROBLEM", 146, 166], ["the EIA", "TEST", 179, 186], ["MVM antigen", "PROBLEM", 204, 215], ["a neutralization test", "TEST", 217, 238], ["rabbit hyperimmune MVM antibody", "TEST", 245, 276]]], ["Using a challenge dose of 100 ID,, of MVM(p), a marginal mean O.D. value was obtained only at the highest antibody dilution tested (1: 10,000).", [["MVM", "ORGANISM", 38, 41], ["a marginal mean O.D. value", "TEST", 46, 72], ["the highest antibody dilution", "TEST", 94, 123]]], ["With lo-fold more virus, there was a significant mean O.D. reading (0.97) for this antibody dilution, but the value was lower than the mean for wells inoculated with virus plus diluent (,1.51).RESULTSHaving confirmed the specificity of the EIA results, we wished to determine whether the assay could be applied to clinical material (infected animal tissue).", [["tissue", "ANATOMY", 349, 355], ["tissue", "TISSUE", 349, 355], ["lo-fold more virus", "PROBLEM", 5, 23], ["this antibody dilution", "TEST", 78, 100], ["the value", "TEST", 106, 115], ["virus plus diluent", "TREATMENT", 166, 184], ["the EIA", "TEST", 236, 243], ["the assay", "TEST", 284, 293], ["clinical material (infected animal tissue", "PROBLEM", 314, 355], ["lo-fold", "OBSERVATION_MODIFIER", 5, 12], ["more", "OBSERVATION_MODIFIER", 13, 17], ["virus", "OBSERVATION", 18, 23], ["significant", "OBSERVATION_MODIFIER", 37, 48]]], ["Homogenates of ' Day post-inoculation of brain collections from neonatal mice infected intracerebrally.RESULTSbrains from neonatal mice inoculated intracerebrally with MVM(p~ or MVM(i) and collected on day 3,7 or 10 post-inoculation were assayed by fluorescent focus test and EIA (Table 4 ).", [["Homogenates", "ANATOMY", 0, 11], ["brain", "ANATOMY", 41, 46], ["intracerebrally", "ANATOMY", 147, 162], ["brain", "ORGAN", 41, 46], ["mice", "ORGANISM", 73, 77], ["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 131, 135], ["brain collections", "PROBLEM", 41, 58], ["RESULTSbrains", "TEST", 103, 116], ["MVM", "PROBLEM", 168, 171], ["fluorescent focus test", "TEST", 249, 271], ["EIA", "TEST", 276, 279], ["brain", "ANATOMY", 41, 46], ["collections", "OBSERVATION", 47, 58], ["infected", "OBSERVATION_MODIFIER", 78, 86]]], ["Selected homogenates were assayed repeatedly by EIA to assess reproducibility.RESULTSVirus titers determined from the two types of infectivity assays were generally similar.", [["homogenates", "ANATOMY", 9, 20], ["reproducibility", "TEST", 62, 77], ["RESULTSVirus titers", "TEST", 78, 97], ["infectivity assays", "TEST", 131, 149], ["infectivity", "OBSERVATION", 131, 142], ["similar", "OBSERVATION_MODIFIER", 165, 172]]], ["In some cases, fluorescent focus titers were about ten-foid higher than EIA titers.", [["fluorescent focus titers", "TEST", 15, 39]]], ["The greatest variability among independent assays was 1.0 log,, for a brain sample collected from MVM(p)-infected mice 7 days post-inoculation.DISCUSSIONThe application of EIA methodology to rodent virus quantification as described here has several advantages over previously used techniques.", [["brain sample", "ANATOMY", 70, 82], ["brain", "ORGAN", 70, 75], ["MVM", "ORGANISM", 98, 101], ["mice", "ORGANISM", 114, 118], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["independent assays", "TEST", 31, 49], ["a brain sample", "TEST", 68, 82], ["EIA methodology", "TREATMENT", 172, 187], ["rodent virus quantification", "TREATMENT", 191, 218], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["variability", "OBSERVATION_MODIFIER", 13, 24], ["brain", "ANATOMY", 70, 75]]], ["EIA uses a microtiter format and therefore requires small volumes of reagents and facilitates processing of large numbers of specimens.", [["specimens", "ANATOMY", 125, 134], ["specimens", "CANCER", 125, 134], ["EIA", "TEST", 0, 3], ["a microtiter format", "TEST", 9, 28], ["small volumes of reagents", "TREATMENT", 52, 77], ["specimens", "TEST", 125, 134], ["small", "OBSERVATION_MODIFIER", 52, 57], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["Results may be obtained without the eye fatigue induced by long periods of microscopic examination required for immunofluorescence assays.", [["eye", "ANATOMY", 36, 39], ["eye fatigue", "DISEASE", 36, 47], ["eye", "ORGAN", 36, 39], ["the eye fatigue", "PROBLEM", 32, 47], ["microscopic examination", "TEST", 75, 98], ["immunofluorescence assays", "TEST", 112, 137], ["eye", "ANATOMY", 36, 39]]], ["Formalin fixation prior to assay eliminates the risk of infecting animals which might be housed in the vicinity of the laboratory.DISCUSSIONYong-He et af.", [["Formalin", "CHEMICAL", 0, 8], ["Formalin", "CHEMICAL", 0, 8], ["Formalin", "SIMPLE_CHEMICAL", 0, 8], ["Formalin fixation", "TREATMENT", 0, 17], ["assay", "TEST", 27, 32], ["infecting animals", "PROBLEM", 56, 73], ["fixation", "OBSERVATION", 9, 17], ["infecting", "OBSERVATION", 56, 65]]], ["(1984) reported that mosquito cells fixed with 10% formalin detached during the course of the EIA.", [["cells", "ANATOMY", 30, 35], ["formalin", "CHEMICAL", 51, 59], ["formalin", "CHEMICAL", 51, 59], ["mosquito cells", "CELL", 21, 35], ["formalin", "SIMPLE_CHEMICAL", 51, 59], ["mosquito cells", "CELL_TYPE", 21, 35], ["mosquito cells", "PROBLEM", 21, 35], ["10% formalin", "TREATMENT", 47, 59], ["the EIA", "TEST", 90, 97]]], ["In contrast, we found that C6 rat glioma cells fixed with 3% formalin adhered to the plastic surface, while those fixed with 2% formalin did not.", [["glioma cells", "ANATOMY", 34, 46], ["surface", "ANATOMY", 93, 100], ["glioma", "DISEASE", 34, 40], ["formalin", "CHEMICAL", 61, 69], ["formalin", "CHEMICAL", 128, 136], ["formalin", "CHEMICAL", 61, 69], ["formalin", "CHEMICAL", 128, 136], ["C6", "CELL", 27, 29], ["rat", "ORGANISM", 30, 33], ["glioma cells", "CELL", 34, 46], ["formalin", "SIMPLE_CHEMICAL", 61, 69], ["formalin", "SIMPLE_CHEMICAL", 128, 136], ["C6 rat glioma cells", "CELL_LINE", 27, 46], ["rat", "SPECIES", 30, 33], ["rat", "SPECIES", 30, 33], ["C6 rat glioma cells", "PROBLEM", 27, 46], ["3% formalin", "TREATMENT", 58, 69], ["2% formalin", "TREATMENT", 125, 136], ["glioma cells", "OBSERVATION", 34, 46], ["plastic", "OBSERVATION_MODIFIER", 85, 92], ["surface", "OBSERVATION_MODIFIER", 93, 100]]], ["However, in both studies, viral antigen liberated from the fixed cells and subsequently bound to the solid phase was apparently detected.", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["viral antigen", "PROTEIN", 26, 39], ["fixed cells", "CELL_TYPE", 59, 70], ["viral antigen", "TEST", 26, 39], ["fixed cells", "OBSERVATION", 59, 70], ["solid phase", "OBSERVATION_MODIFIER", 101, 112]]], ["Additionally, we have shown that neutralization tests may be performed using this method.", [["neutralization tests", "TEST", 33, 53], ["this method", "TREATMENT", 77, 88]]], ["Antibody preparations used for neutralization and detection must, of course, each be made in a different species.DISCUSSIONFluorescent focus titers tended to be higher than EIA titers obtained for brain homogenates from infected infant mice.", [["brain homogenates", "ANATOMY", 197, 214], ["brain homogenates", "ORGANISM_SUBSTANCE", 197, 214], ["mice", "ORGANISM", 236, 240], ["infant", "SPECIES", 229, 235], ["mice", "SPECIES", 236, 240], ["mice", "SPECIES", 236, 240], ["Antibody preparations", "TREATMENT", 0, 21], ["neutralization", "TREATMENT", 31, 45], ["detection", "TEST", 50, 59], ["a different species", "PROBLEM", 93, 112], ["DISCUSSIONFluorescent focus titers", "TEST", 113, 147], ["EIA titers", "TEST", 173, 183], ["brain homogenates", "PROBLEM", 197, 214]]], ["The most likely explanation for this observation is that the assays were terminated 4 days post-inoculation of C6 cells.", [["C6 cells", "ANATOMY", 111, 119], ["C6 cells", "CELL", 111, 119], ["C6 cells", "CELL_LINE", 111, 119], ["the assays", "TEST", 57, 67], ["C6 cells", "PROBLEM", 111, 119], ["most likely explanation for", "UNCERTAINTY", 4, 31], ["C6 cells", "OBSERVATION", 111, 119]]], ["This was necessitated by the fact that the cells had reached confluency and could not be held for an additional day.", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["the cells", "PROBLEM", 39, 48]]], ["As shown in Table 2 , optimum virus titers determined by EIA are not reached until day 5.", [["optimum virus titers", "TEST", 22, 42]]], ["Thus, it was not surprising that EIA titers were, in some cases, about lo-fold lower than fluorescent focus titers.", [["EIA titers", "TEST", 33, 43]]], ["This problem may be rectified in the future by the use of cells seeded at lower densities.", [["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["lower densities", "OBSERVATION_MODIFIER", 74, 89]]], ["The absolute association between parvovirus replication and cell division dictates that conditions for an assay such as the one described here be fully standardized.DISCUSSIONSuch standardization may be necessarily incomplete in the clinical setting.", [["cell", "ANATOMY", 60, 64], ["parvovirus", "ORGANISM", 33, 43], ["cell", "CELL", 60, 64], ["parvovirus", "SPECIES", 33, 43], ["parvovirus replication", "TREATMENT", 33, 55], ["an assay", "TEST", 103, 111], ["absolute", "OBSERVATION_MODIFIER", 4, 12], ["parvovirus replication", "OBSERVATION", 33, 55]]], ["Toxicity induced by tissue-associated enzymes may result in the death of a proportion of inoculated cells, and tissue-associated growth factors may induce cell division at a rate faster than that of control, uninoculated cells.", [["tissue", "ANATOMY", 20, 26], ["cells", "ANATOMY", 100, 105], ["tissue", "ANATOMY", 111, 117], ["cell", "ANATOMY", 155, 159], ["cells", "ANATOMY", 221, 226], ["Toxicity", "DISEASE", 0, 8], ["death", "DISEASE", 64, 69], ["tissue", "TISSUE", 20, 26], ["cells", "CELL", 100, 105], ["tissue", "TISSUE", 111, 117], ["cell", "CELL", 155, 159], ["cells", "CELL", 221, 226], ["tissue-associated enzymes", "PROTEIN", 20, 45], ["inoculated cells", "CELL_LINE", 89, 105], ["growth factors", "PROTEIN", 129, 143], ["control, uninoculated cells", "CELL_LINE", 199, 226], ["associated enzymes", "PROBLEM", 27, 45], ["inoculated cells", "PROBLEM", 89, 105], ["tissue-associated growth factors", "PROBLEM", 111, 143], ["cell division", "PROBLEM", 155, 168], ["inoculated cells", "OBSERVATION", 89, 105], ["uninoculated cells", "OBSERVATION", 208, 226]]], ["Based on this experience with EIA applied to a murine parvovirus, we feel that the method is worthy of further development and application to other rodent viruses.", [["murine parvovirus", "DISEASE", 47, 64], ["murine", "ORGANISM", 47, 53], ["parvovirus", "ORGANISM", 54, 64], ["murine", "SPECIES", 47, 53], ["parvovirus", "SPECIES", 54, 64], ["murine parvovirus", "SPECIES", 47, 64], ["EIA", "TREATMENT", 30, 33], ["a murine parvovirus", "TREATMENT", 45, 64], ["other rodent viruses", "PROBLEM", 142, 162]]], ["The ability to assay virus in formalin-fixed cells renders the method especially attractive for the assay of agents which are known to be zoonotic, such as lymphocytic choriomeningitis virus and Hantaviruses.", [["cells", "ANATOMY", 45, 50], ["lymphocytic choriomeningitis virus", "DISEASE", 156, 190], ["formalin", "CHEMICAL", 30, 38], ["cells", "CELL", 45, 50], ["lymphocytic choriomeningitis virus", "ORGANISM", 156, 190], ["Hantaviruses", "CANCER", 195, 207], ["formalin-fixed cells", "CELL_TYPE", 30, 50], ["lymphocytic choriomeningitis virus", "SPECIES", 156, 190], ["lymphocytic choriomeningitis virus", "SPECIES", 156, 190], ["assay virus in formalin", "TEST", 15, 38], ["fixed cells", "PROBLEM", 39, 50], ["agents", "TREATMENT", 109, 115], ["zoonotic", "PROBLEM", 138, 146], ["lymphocytic choriomeningitis virus", "PROBLEM", 156, 190], ["Hantaviruses", "PROBLEM", 195, 207], ["lymphocytic choriomeningitis", "OBSERVATION", 156, 184]]]], "PMC7102524": [], "e6a89069788780dbd00f63852998a58a3eeb6e5c": [["INTRODUCTIONThe World Health Organization declared the novel coronavirus disease 2019 (COVID-19) as a pandemic in March 2020, with rising infection rates around the world and within the United States.", [["coronavirus disease", "DISEASE", 61, 80], ["COVID-19", "CHEMICAL", 87, 95], ["infection", "DISEASE", 138, 147], ["coronavirus", "ORGANISM", 61, 72], ["the novel coronavirus disease", "PROBLEM", 51, 80], ["COVID", "TEST", 87, 92], ["rising infection rates", "PROBLEM", 131, 153], ["coronavirus disease", "OBSERVATION", 61, 80], ["rising", "OBSERVATION_MODIFIER", 131, 137], ["infection", "OBSERVATION", 138, 147]]], ["1 This outbreak has radically altered delivery of care in emergency departments (ED), as efforts continue to prevent transmission and combat the disease.", [["the disease", "PROBLEM", 141, 152], ["radically", "OBSERVATION_MODIFIER", 20, 29], ["altered", "OBSERVATION_MODIFIER", 30, 37], ["disease", "OBSERVATION", 145, 152]]], ["2 Although attention has appropriately been focused on clinical management and emergency preparedness during COVID-19, this historic event has also had significant consequences for mental health that mayINTRODUCTIONThe coronavirus disease 2019 (COVID-19) pandemic caused by the coronavirus SARS-CoV-2 has radically altered delivery of care in emergency settings.", [["coronavirus disease", "DISEASE", 219, 238], ["COVID-19", "CHEMICAL", 245, 253], ["SARS", "DISEASE", 290, 294], ["coronavirus SARS-CoV-2", "ORGANISM", 278, 300], ["coronavirus", "SPECIES", 278, 289], ["clinical management", "TREATMENT", 55, 74], ["COVID", "TEST", 109, 114], ["mayINTRODUCTIONThe coronavirus disease", "PROBLEM", 200, 238], ["COVID", "TEST", 245, 250], ["pandemic", "PROBLEM", 255, 263], ["the coronavirus SARS", "PROBLEM", 274, 294]]], ["Unprecedented hardship due to ongoing fears of exposure and threats to personal safety, along with societal measures enacted to curb disease transmission, have had broad psychosocial impact on patients and healthcare workers alike.", [["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["societal measures", "TREATMENT", 99, 116]]], ["These changes can significantly affect diagnosing and managing behavioral emergencies such as agitation in the emergency department.", [["agitation", "DISEASE", 94, 103], ["behavioral emergencies", "PROBLEM", 63, 85], ["agitation", "PROBLEM", 94, 103]]], ["On behalf of the American Association for Emergency Psychiatry, we highlight unique considerations for patients with severe behavioral symptoms and staff members managing symptoms of agitation during COVID-19.", [["agitation", "DISEASE", 183, 192], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["severe behavioral symptoms", "PROBLEM", 117, 143], ["symptoms", "PROBLEM", 171, 179], ["agitation", "PROBLEM", 183, 192], ["COVID", "TEST", 200, 205]]], ["Early detection and treatment of agitation, precautions to minimize staff hazards, coordination with security personnel and psychiatric services, and avoidance of coercive strategies that cause respiratory depression will help mitigate heightened risks to safety caused by this outbreak.", [["respiratory", "ANATOMY", 194, 205], ["agitation", "DISEASE", 33, 42], ["psychiatric", "DISEASE", 124, 135], ["respiratory depression", "DISEASE", 194, 216], ["Early detection", "TEST", 0, 15], ["agitation", "PROBLEM", 33, 42], ["precautions", "TREATMENT", 44, 55], ["psychiatric services", "TREATMENT", 124, 144], ["coercive strategies", "TREATMENT", 163, 182], ["respiratory depression", "PROBLEM", 194, 216], ["this outbreak", "PROBLEM", 273, 286]]], ["Unprecedented hardship due to ongoing fears of exposure, threats to personal safety, and limited access to resources have broad psychosocial impact on patients and healthcare workers alike.", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159]]], ["3 These changes can significantly affect how individuals with behavioral symptoms may present and what management strategies are most appropriate during the care of behavioral emergencies.INTRODUCTIONAgitation is one of the most common behavioral emergencies in the ED, with 1.7 million episodes 4 annually in emergency settings and a recent estimated overall ED prevalence of 2.6%.", [["behavioral symptoms", "PROBLEM", 62, 81]]], ["5 Agitated patients are among the most challenging to evaluate and manage by emergency physicians, as their excessive psychomotor activity can escalate quickly into violent acts and physically aggressive behavior.", [["aggressive behavior", "DISEASE", 193, 212], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["their excessive psychomotor activity", "PROBLEM", 102, 138], ["physically aggressive behavior", "PROBLEM", 182, 212]]], ["6 Nationwide, 78% of emergency physicians reported being targets of workplace violence in the previous 12 months.", [["violence", "DISEASE", 78, 86]]], ["7 In 2012, the American Association for Management of Agitation During the COVID-19 Pandemic Wong et al.INTRODUCTIONEmergency Psychiatry (AAEP) published Project BETA (Best practices in Evaluation and Treatment of Agitation), consisting of a landmark series of consensus guidelines to provide effective and safety-minded strategies for agitation management with the best interests of the patient in mind while ensuring the safety of healthcare workers.", [["Agitation", "DISEASE", 54, 63], ["Agitation", "DISEASE", 214, 223], ["agitation", "DISEASE", 336, 345], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 388, 395], ["Agitation", "PROBLEM", 54, 63], ["Evaluation", "TEST", 186, 196], ["Agitation", "PROBLEM", 214, 223], ["consensus guidelines", "TREATMENT", 261, 281], ["safety-minded strategies", "TREATMENT", 307, 331], ["agitation management", "TREATMENT", 336, 356]]], ["4 The Project BETA guidelines focus on a noncoercive approach to manage these patients with an emphasis on de-escalation, safety and risk assessment, and addressing potentially life-threatening medical concerns.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["a noncoercive approach", "TREATMENT", 39, 61], ["de-escalation", "TREATMENT", 107, 120], ["risk assessment", "TEST", 133, 148]]], ["8, 9 Forced medication and physical restraint are reserved as the last resort to control agitation symptoms, given that their use is associated with elevated risk for both patients and staff.", [["agitation", "DISEASE", 89, 98], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["Forced medication", "TREATMENT", 5, 22], ["physical restraint", "TREATMENT", 27, 45], ["agitation symptoms", "PROBLEM", 89, 107]]], ["10 The management principles encapsulated within Project BETA remain applicable in the COVID-19 era, but adaptations are needed in light of the unique circumstances and environmental conditions due to the pandemic.", [["The management principles", "TREATMENT", 3, 28], ["Project BETA", "TREATMENT", 49, 61], ["the pandemic", "PROBLEM", 201, 213]]], ["Given the possibility of a projected lengthy timeline before this outbreak abates, 11 awareness of its effects on the management of agitation is needed now to ensure safety of both patients with behavioral symptoms and frontline healthcare workers caring for them.", [["agitation", "DISEASE", 132, 141], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["the management", "TREATMENT", 114, 128], ["agitation", "PROBLEM", 132, 141], ["behavioral symptoms", "PROBLEM", 195, 214]]], ["On behalf of AAEP, we aim to highlight in this work some important unique considerations for the management of agitation in the ED during COVID-19 (Table 1) .COVID-19 EFFECTS ON PATIENT VISITS AND PRESENTATIONS Psychosocial FactorsThe COVID-19 pandemic is occurring during a time of unprecedented digital interconnectedness.", [["agitation", "DISEASE", 111, 120], ["the management", "TREATMENT", 93, 107], ["agitation", "PROBLEM", 111, 120], ["COVID", "TEST", 138, 143], ["The COVID", "TEST", 231, 240], ["19 EFFECTS", "OBSERVATION_MODIFIER", 164, 174]]], ["12 Advancements in digital platforms and intense media coverage have amplified the intensity of associated psychological fear, creating a novel \"digital pandemic\" that significantly exacerbates symptoms of anxiety and stress.", [["anxiety", "DISEASE", 206, 213], ["digital platforms", "TREATMENT", 19, 36], ["intense media coverage", "TREATMENT", 41, 63], ["anxiety", "PROBLEM", 206, 213], ["stress", "PROBLEM", 218, 224]]], ["13 The large-scale public lockdown efforts to implement social distancing has secondarily forced many individuals to stay indoors for prolonged periods of time, increasing the risk of social isolation, tensions within the home, and disruption of positive adaptive behaviors to relieve symptoms of mental illness.", [["positive adaptive behaviors", "PROBLEM", 246, 273], ["symptoms", "PROBLEM", 285, 293], ["mental illness", "PROBLEM", 297, 311], ["large", "OBSERVATION_MODIFIER", 7, 12], ["social isolation", "OBSERVATION", 184, 200]]], ["14 In addition, COVID-19 may directly affect workflow and slow down assessments in the ED, leading to escalation of agitation symptoms for those who require immediate attention.COVID-19 EFFECTS ON PATIENT VISITS AND PRESENTATIONS Psychosocial FactorsHospital visitor restrictions reduce risk of transmission 15 but also remove vital links of social and family support for individuals during times of crisis.", [["agitation", "DISEASE", 116, 125], ["COVID-19", "CHEMICAL", 16, 24], ["COVID-19", "DNA", 16, 24], ["COVID", "TEST", 16, 21], ["slow down assessments", "TEST", 58, 79], ["agitation symptoms", "PROBLEM", 116, 134], ["crisis", "PROBLEM", 400, 406], ["19 EFFECTS", "OBSERVATION_MODIFIER", 183, 193]]], ["Since asymptomatic carriers can silently transmit the virus, 16 some patients are fearful that they may unknowingly contract COVID-19 during their time in the ED.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["asymptomatic carriers", "PROBLEM", 6, 27]]], ["Others with symptoms concerning for COVID-19 may escalate their behavior if their expectations for testing or disposition are not met due to limited capacity for EDs to widely test or hospitalize members of the community they serve.", [["symptoms", "PROBLEM", 12, 20], ["COVID", "TEST", 36, 41], ["testing", "TEST", 99, 106], ["limited capacity", "PROBLEM", 141, 157]]], ["17 These added pressures can increase the risk of agitation even for visits that may not be associated with a behavioral chief complaint.", [["agitation", "DISEASE", 50, 59], ["These added pressures", "TREATMENT", 3, 24], ["agitation", "PROBLEM", 50, 59], ["pressures", "OBSERVATION_MODIFIER", 15, 24]]], ["With reports of recent surges in firearm sales across the US, 18 extra vigilance is needed regarding potential dangers due to weapons both in the healthcare setting and at home, especially for patients with elevated risk of self-harm or violence.", [["self-harm", "DISEASE", 224, 233], ["violence", "DISEASE", 237, 245], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201]]], ["19Access to ServicesPatients presenting with agitation often represent socioeconomically disadvantaged populations with significant health disparities.", [["agitation", "DISEASE", 45, 54], ["agitation", "PROBLEM", 45, 54]]], ["20 Unfortunately, individuals with homelessness, mental illness, and substance use disorders face additional potential problems with screening, quarantine, and symptom treatment during pandemics.", [["homelessness, mental illness", "DISEASE", 35, 63], ["substance use disorders", "DISEASE", 69, 92], ["mental illness", "PROBLEM", 49, 63], ["substance use disorders", "PROBLEM", 69, 92], ["screening", "TEST", 133, 142], ["quarantine", "TREATMENT", 144, 154], ["symptom treatment", "TREATMENT", 160, 177], ["pandemics", "PROBLEM", 185, 194]]], ["21 Preliminary data demonstrating associations between mortality and challenges in accessing healthcare resources have already surfaced during COVID-19.", [["Preliminary data", "TEST", 3, 19], ["COVID", "TEST", 143, 148]]], ["22 Economic hardship and disruption of outpatient mental health services may limit the ability for these individuals to refill their maintenance medications for psychiatric and/or substance use conditions, causing exacerbation or decompensation of their illnesses.", [["psychiatric", "DISEASE", 161, 172], ["maintenance medications", "TREATMENT", 133, 156], ["exacerbation", "PROBLEM", 214, 226], ["decompensation of their illnesses", "PROBLEM", 230, 263]]], ["This is compounded by closure of shelters, detoxification units, and other high-density communal settings (eg, drop-in centers and soup kitchens) which may reduce their access to critical social services and increase their likelihood to present to the ED in need.", [["closure of shelters", "TREATMENT", 22, 41], ["detoxification units", "TREATMENT", 43, 63], ["closure", "OBSERVATION", 22, 29], ["high-density", "OBSERVATION_MODIFIER", 75, 87]]], ["As the support systems and outpatient services deteriorate for these patients, the likelihood that they develop decompensation of their underlying mental illness may increase, leading to ED visits and agitated behaviors during their stay.Clinical PresentationsAlthough it may seem that increased stress and anxiety would inherently increase the volume of behavioral visits during natural disasters and pandemics, experiences from past events have demonstrated that the effects are quite complex and even counterintuitive.", [["decompensation", "DISEASE", 112, 126], ["anxiety", "DISEASE", 307, 314], ["pandemics", "DISEASE", 402, 411], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["outpatient services", "TREATMENT", 27, 46], ["decompensation of their underlying mental illness", "PROBLEM", 112, 161], ["agitated behaviors", "PROBLEM", 201, 219], ["increased stress", "PROBLEM", 286, 302], ["anxiety", "PROBLEM", 307, 314], ["pandemics", "PROBLEM", 402, 411], ["increased", "OBSERVATION_MODIFIER", 286, 295], ["stress", "OBSERVATION", 296, 302]]], ["23 Total mental health-related visits may actually initially decrease as individuals focus on immediate survival and self-protection, 24 but those who do seek care appear to have more severe symptoms.", [["more severe symptoms", "PROBLEM", 179, 199]]], ["25 For example, inpatient psychiatric admissions fell by 20% for the first 30 days following the devastating earthquake in Christchurch, New Zealand.", [["psychiatric", "DISEASE", 26, 37], ["earthquake", "DISEASE", 109, 119]]], ["26 New psychiatric presentations following the 2011 Fukushima nuclear plant disaster also decreased, but those admitted had high rates of confusional, manic, and delirious states.", [["psychiatric", "DISEASE", 7, 18], ["confusional", "DISEASE", 138, 149], ["manic", "DISEASE", 151, 156], ["delirious", "DISEASE", 162, 171], ["manic", "PROBLEM", 151, 156], ["delirious states", "PROBLEM", 162, 178]]], ["27 Given the public perceptions of fear and mistrust around the government's response to the pandemic, 28 individuals with chronic psychotic disorders may incorporate those perceptions into their delusional content and manifest as themes of contamination, persecution, and conspiracy theories.", [["psychotic disorders", "DISEASE", 131, 150], ["delusional", "DISEASE", 196, 206], ["fear", "PROBLEM", 35, 39], ["mistrust", "PROBLEM", 44, 52], ["chronic psychotic disorders", "PROBLEM", 123, 150]]], ["Particular sensitivity and extra efforts to counteract and redirect these sentiments may be needed as part of the management of agitation.Clinical PresentationsIn addition, there are increasing reports of neuropsychiatric symptoms due to COVID-19.", [["agitation", "DISEASE", 128, 137], ["neuropsychiatric symptoms", "DISEASE", 205, 230], ["COVID-19", "CHEMICAL", 238, 246], ["Particular sensitivity", "PROBLEM", 0, 22], ["the management", "TREATMENT", 110, 124], ["agitation", "PROBLEM", 128, 137], ["neuropsychiatric symptoms", "PROBLEM", 205, 230], ["COVID", "TEST", 238, 243], ["increasing", "OBSERVATION_MODIFIER", 183, 193]]], ["Several case reports have documented encephalopathy and delirium as the presenting syndrome for the disease rather than the more common respiratory or gastrointestinal complaints.", [["respiratory", "ANATOMY", 136, 147], ["gastrointestinal", "ANATOMY", 151, 167], ["encephalopathy", "DISEASE", 37, 51], ["delirium", "DISEASE", 56, 64], ["respiratory or gastrointestinal complaints", "DISEASE", 136, 178], ["gastrointestinal", "ORGAN", 151, 167], ["encephalopathy", "PROBLEM", 37, 51], ["delirium", "PROBLEM", 56, 64], ["the presenting syndrome", "PROBLEM", 68, 91], ["the disease", "PROBLEM", 96, 107], ["gastrointestinal complaints", "PROBLEM", 151, 178], ["encephalopathy", "OBSERVATION", 37, 51], ["delirium", "OBSERVATION", 56, 64], ["gastrointestinal", "ANATOMY", 151, 167]]], ["29, 30 The Centers for Disease Control and Prevention also found that 6% of hospitalized patients with confirmed COVID-19 had associated symptoms of altered mental status and confusion.", [["COVID", "DISEASE", 113, 118], ["confusion", "DISEASE", 175, 184], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Disease Control", "TREATMENT", 23, 38], ["COVID", "TEST", 113, 118], ["associated symptoms", "PROBLEM", 126, 145], ["altered mental status", "PROBLEM", 149, 170], ["confusion", "PROBLEM", 175, 184]]], ["31 Elderly patients are at the highest risk for morbidity and mortality related to the disease.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["morbidity", "PROBLEM", 48, 57], ["mortality", "PROBLEM", 62, 71], ["the disease", "PROBLEM", 83, 94], ["disease", "OBSERVATION", 87, 94]]], ["32 Acute agitation in patients with delirium caused by hypoxia, a prominent clinical feature of patients infected with COVID-19, complicates the presentation of dementia and psychiatric illness, particularly in the older population.", [["agitation", "DISEASE", 9, 18], ["delirium", "DISEASE", 36, 44], ["hypoxia", "DISEASE", 55, 62], ["COVID-19", "CHEMICAL", 119, 127], ["dementia", "DISEASE", 161, 169], ["psychiatric illness", "DISEASE", 174, 193], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 96, 104], ["Acute agitation", "PROBLEM", 3, 18], ["delirium", "PROBLEM", 36, 44], ["hypoxia", "PROBLEM", 55, 62], ["COVID", "TEST", 119, 124], ["dementia", "PROBLEM", 161, 169], ["psychiatric illness", "PROBLEM", 174, 193], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["agitation", "OBSERVATION", 9, 18], ["hypoxia", "OBSERVATION", 55, 62], ["prominent", "OBSERVATION_MODIFIER", 66, 75], ["infected", "OBSERVATION", 105, 113], ["dementia", "OBSERVATION", 161, 169]]], ["33 Given the elevated rates of clinical and adverse events associated with delirium and the various neuropsychiatric symptoms that may be associated with COVID-19, 34 emergency physicians need to be mindful of these potential complications when evaluating these patients.", [["delirium", "DISEASE", 75, 83], ["neuropsychiatric symptoms", "DISEASE", 100, 125], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["the elevated rates of clinical and adverse events", "PROBLEM", 9, 58], ["delirium", "PROBLEM", 75, 83], ["the various neuropsychiatric symptoms", "PROBLEM", 88, 125], ["COVID", "TEST", 154, 159], ["these potential complications", "PROBLEM", 210, 239]]], ["A thorough mental status exam 35 will also help clinicians evaluate the diverse etiologies of any acute behavioral presentation that may be present in this cohort of patients.COVID-19 EFFECTS ON CARE DELIVERY Individual Staff FactorsCOVID-19 has taken its toll on healthcare workers amidst multiple additional stressors imposed upon them.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["A thorough mental status exam", "TEST", 0, 29], ["any acute behavioral presentation", "PROBLEM", 94, 127], ["FactorsCOVID", "TEST", 226, 238], ["19 EFFECTS", "OBSERVATION_MODIFIER", 181, 191]]], ["36 These include rapid changes in clinical roles and responsibilities, extra workload, disrupted supplies in personal protective equipment (PPE), rationing of resources, and valid fears regarding potential exposure to the disease.", [["rapid changes in clinical roles", "PROBLEM", 17, 48], ["the disease", "PROBLEM", 218, 229], ["rapid", "OBSERVATION_MODIFIER", 17, 22], ["disease", "OBSERVATION", 222, 229]]], ["3 In particular, those on the front lines in the ED may have increased feelings of anxiety, frustration, and resentment due to these added stressors in a dynamic and high-stress clinical environment.", [["front lines", "ANATOMY", 30, 41], ["anxiety", "DISEASE", 83, 90], ["front lines", "CELL_LINE", 30, 41], ["anxiety", "PROBLEM", 83, 90], ["frustration", "PROBLEM", 92, 103], ["these added stressors", "PROBLEM", 127, 148], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["37 Given that de-escalation requires clinicians to remain calm and compassionate despite displays of aggression or violence, these negative emotions due to COVID-19 can significantly undermine efforts to use patientcentered approaches during management of agitation.", [["aggression", "DISEASE", 101, 111], ["violence", "DISEASE", 115, 123], ["COVID-19", "CHEMICAL", 156, 164], ["agitation", "DISEASE", 256, 265], ["COVID-19", "CHEMICAL", 156, 164], ["COVID", "TEST", 156, 161], ["patientcentered approaches", "TREATMENT", 208, 234], ["management", "TREATMENT", 242, 252], ["agitation", "PROBLEM", 256, 265]]], ["38 As emergency healthcare workers care for rising volumes of infected patients presenting in extremis, they work at an elevated risk to personal safety from potential occupational exposure to COVID-19.", [["COVID-19", "CHEMICAL", 193, 201], ["COVID-19", "CHEMICAL", 193, 201], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["COVID", "TEST", 193, 198], ["infected", "OBSERVATION", 62, 70]]], ["39, 40 This risk increases further during episodes of patient agitation.", [["agitation", "DISEASE", 62, 71], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["patient agitation", "PROBLEM", 54, 71], ["increases", "OBSERVATION_MODIFIER", 17, 26]]], ["Clinicians may come into close physical contact with COVID-19 positive patients to de-escalate, provide physical control of disruptive behavior, and perform diagnostic and therapeutic procedures.", [["disruptive behavior", "DISEASE", 124, 143], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["disruptive behavior", "PROBLEM", 124, 143], ["therapeutic procedures", "TREATMENT", 172, 194]]], ["As a result, professional societies recommend that emergency clinicians continuously wear PPE during their entire shift in the ED.", [["PPE", "TREATMENT", 90, 93]]], ["They also note that close contact during procedures or processes, including a physical examination, can generate potentially infectious aerosols and requires a higher level of PPE that includes an N95 respirator.", [["a physical examination", "TEST", 76, 98], ["potentially infectious aerosols", "PROBLEM", 113, 144], ["a higher level of PPE", "TREATMENT", 158, 179], ["an N95 respirator", "TREATMENT", 194, 211]]], ["41 However, use of PPE may compromise the emergency clinician's spatial orientation, maneuverability, and awareness of personal safety, which are all vital skills to safely evaluate and manage the agitated patient.", [["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213], ["PPE", "TREATMENT", 19, 22]]], ["42, 43 PPE also adds physical limitations to recognizing facial features and body language, removing key aspects of nonverbal communication that support successful deescalation and rapport with agitated patients.Clinical Resource LimitationsIn some geographic areas, EDs are overwhelmed by the volume of COVID-19 infected patients combined with critical shortages of supplies, staffing, and physical space.", [["facial", "ANATOMY", 57, 63], ["body", "ANATOMY", 77, 81], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 322, 330], ["COVID", "TEST", 304, 309], ["facial", "ANATOMY", 57, 63], ["some", "OBSERVATION_MODIFIER", 244, 248], ["geographic", "OBSERVATION_MODIFIER", 249, 259]]], ["44 Other EDs anecdotally report lower census levels, likely due to a combination of fewer accidental injuries during public lockdown efforts and ED avoidance behaviors by patients fearing exposure to the virus.", [["injuries", "DISEASE", 101, 109], ["ED avoidance behaviors", "DISEASE", 145, 167], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["fewer accidental injuries", "PROBLEM", 84, 109], ["public lockdown efforts", "TREATMENT", 117, 140], ["the virus", "PROBLEM", 200, 209], ["likely due to", "UNCERTAINTY", 53, 66], ["injuries", "OBSERVATION", 101, 109]]], ["As a result, staffing models have either decreased or adjusted to focus attention on the surges of COVID-19 cases 45 and there may be fewer staff available to handle agitated patients in many EDs.", [["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["COVID", "TEST", 99, 104], ["decreased", "OBSERVATION_MODIFIER", 41, 50]]], ["In addition, security personnel may have extra responsibilities related to COVID-19 (eg, visitor restrictions, minimizing traffic), impacting the ability for rapid and timely responses to episodes of agitation in the ED.", [["agitation", "DISEASE", 200, 209], ["COVID", "TEST", 75, 80], ["agitation", "PROBLEM", 200, 209]]], ["Requirements to ration use of PPE 46 may further limit the time, attention, and resources normally needed to safely respond to agitation.", [["agitation", "DISEASE", 127, 136], ["PPE", "TREATMENT", 30, 33], ["agitation", "PROBLEM", 127, 136]]], ["The increased number of COVID-19 patients with critical care needs has disrupted and limited supplies of sedative medications in the ED.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["COVID", "TEST", 24, 29], ["sedative medications", "TREATMENT", 105, 125], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["47 Ancillary services and psychiatric consultation are also less readily available as they are either furloughed to minimize exposure or deployed to other clinical units with more urgent needs related to the pandemic.", [["psychiatric", "DISEASE", 26, 37], ["psychiatric consultation", "TEST", 26, 50], ["the pandemic", "PROBLEM", 204, 216]]], ["17 Clinicians need to pre-emptively consider these limitations when managing patients at risk for agitation before behavior escalates and resources are needed rapidly.EVALUATION AND MANAGEMENT RECOMMENDATIONSIn a healthcare system that is already taxed with additional stressors on multiple levels, these factors unique to the COVID-19 era discussed above need to be taken into consideration to mitigate escalation to violent behavior and address potential threats to safety associated with agitation.", [["agitation", "DISEASE", 98, 107], ["agitation", "DISEASE", 491, 500], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["agitation", "PROBLEM", 98, 107], ["EVALUATION", "TEST", 167, 177], ["agitation", "PROBLEM", 491, 500]]], ["In light of this elevated occupational hazard, extra measures are needed to continually protect the safety of ED personnel and effectively combat an anticipated lengthy battle with this pandemic, regardless of the clinical concerns or level of agitation.", [["agitation", "DISEASE", 244, 253], ["this elevated occupational hazard", "PROBLEM", 12, 45], ["extra measures", "TREATMENT", 47, 61], ["agitation", "PROBLEM", 244, 253]]], ["48 We highlight specific recommendations on the evaluation and management of the agitated patient in the setting of COVID-19.EVALUATION AND MANAGEMENT RECOMMENDATIONSThe medical and psychiatric evaluation should proceed in a manner that minimizes COVID-19 exposure risk while effectively detecting dangerous and reversible causes of agitation.", [["psychiatric", "DISEASE", 182, 193], ["agitation", "DISEASE", 333, 342], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["the evaluation", "TEST", 44, 58], ["management", "TREATMENT", 63, 73], ["COVID", "TEST", 116, 121], ["EVALUATION", "TEST", 125, 135], ["psychiatric evaluation", "TEST", 182, 204], ["agitation", "PROBLEM", 333, 342]]], ["Collateral information should be obtained early to counteract limitations of history taking due to social distancing and PPE requirements.", [["social distancing and PPE requirements", "PROBLEM", 99, 137]]], ["The Joint Statement for Care of Patients with Behavioral Health Emergencies and Suspected or Confirmed COVID-19 supports the use of telehealth for screening, 49 which may not be applicable in every situation but can significantly reduce exposure.", [["Patients", "ORGANISM", 32, 40], ["Patients", "SPECIES", 32, 40], ["screening", "TEST", 147, 156], ["Joint", "ANATOMY", 4, 9]]], ["If direct contact is required, donning of appropriate PPE, limiting the amount of time clinicians are less than six feet away from the patient, and minimizing the number of staff members at the bedside will reduce any exposure risk.", [["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142]]], ["3 The virus has been detected in the saliva of infected patients, 50, 51 and precautions must be taken to minimize aerosol and droplet exposure, which may be magnified in those agitated patients who present with pressured speech or spit at ED personnel.", [["saliva", "ORGANISM_SUBSTANCE", 37, 43], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 186, 194], ["The virus", "PROBLEM", 2, 11], ["precautions", "TREATMENT", 77, 88], ["aerosol and droplet exposure", "TREATMENT", 115, 143], ["virus", "OBSERVATION", 6, 11], ["infected", "OBSERVATION", 47, 55], ["droplet exposure", "OBSERVATION", 127, 143]]], ["52 Judicious use and careful consideration of the utility in diagnostic studies are needed to safely evaluate for potentially life-threatening causes of the patient's agitation.", [["agitation", "DISEASE", 167, 176], ["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["diagnostic studies", "TEST", 61, 79], ["the patient's agitation", "PROBLEM", 153, 176]]], ["Finally, given known asymptomatic transmission of COVID-19, 53 there should be a lower threshold to test these patients for the presence of the virus before admission for medical causes of their agitation or transferring them to definitive psychiatric care.EVALUATION AND MANAGEMENT RECOMMENDATIONSProject BETA strongly encourages early de-escalation, which combines targeted verbal and nonverbal strategies to assist the patient with calming down and reducing aggressive behavior.", [["agitation", "DISEASE", 195, 204], ["psychiatric", "DISEASE", 240, 251], ["aggressive behavior", "DISEASE", 461, 480], ["patients", "ORGANISM", 111, 119], ["patient", "ORGANISM", 422, 429], ["patients", "SPECIES", 111, 119], ["patient", "SPECIES", 422, 429], ["COVID", "TEST", 50, 55], ["a lower threshold", "PROBLEM", 79, 96], ["the virus", "PROBLEM", 140, 149], ["their agitation", "PROBLEM", 189, 204], ["definitive psychiatric care", "TREATMENT", 229, 256], ["EVALUATION", "TEST", 257, 267], ["early de-escalation", "TREATMENT", 331, 350], ["nonverbal strategies", "TREATMENT", 387, 407], ["asymptomatic", "OBSERVATION_MODIFIER", 21, 33]]], ["8 In light of COVID-19, extra vigilance and early pre-emptive action are needed to detect and treat any signs of agitation, including use of objective scales to assess the level of agitation and prompt de-escalation by qualified ED personnel.", [["agitation", "DISEASE", 113, 122], ["agitation", "DISEASE", 181, 190], ["COVID", "TEST", 14, 19], ["extra vigilance", "TREATMENT", 24, 39], ["early pre-emptive action", "TREATMENT", 44, 68], ["agitation", "PROBLEM", 113, 122], ["objective scales", "TREATMENT", 141, 157], ["agitation", "PROBLEM", 181, 190]]], ["Extra investment in time and effort to develop a therapeutic relationship and establish trust may be needed to overcome additional patient stressors and physical barriers to create rapport.", [["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138]]], ["Clinical personnel should communicate early with hospital security if there is any concern about escalation or violent behaviors to allow for lengthier response times and higher potential for escalation, even in milder forms of agitation.", [["agitation", "DISEASE", 228, 237], ["violent behaviors", "PROBLEM", 111, 128], ["agitation", "PROBLEM", 228, 237]]], ["Care coordination with psychiatric services is critical in light of limitations to outpatient mental health and social services.EVALUATION AND MANAGEMENT RECOMMENDATIONSPatients who are delirious and acutely agitated with concomitant COVID-19 infection deserve special attention given elevated patient risks associated with the viral illness.", [["psychiatric", "DISEASE", 23, 34], ["COVID-19", "CHEMICAL", 234, 242], ["infection", "DISEASE", 243, 252], ["viral illness", "DISEASE", 328, 341], ["patient", "ORGANISM", 294, 301], ["patient", "SPECIES", 294, 301], ["EVALUATION", "TEST", 128, 138], ["delirious", "PROBLEM", 186, 195], ["acutely agitated", "PROBLEM", 200, 216], ["concomitant COVID-19 infection", "PROBLEM", 222, 252], ["elevated patient risks", "PROBLEM", 285, 307], ["the viral illness", "PROBLEM", 324, 341]]], ["Unfortunately, the ability to implement non-coercive techniques 10 and reorientation strategies 54 in treatment of agitation and delirium is compromised by social distancing and isolation measures to minimize COVID-19 spread.", [["agitation", "DISEASE", 115, 124], ["delirium", "DISEASE", 129, 137], ["non-coercive techniques", "TREATMENT", 40, 63], ["reorientation strategies", "TREATMENT", 71, 95], ["agitation", "PROBLEM", 115, 124], ["delirium", "PROBLEM", 129, 137], ["isolation measures", "TREATMENT", 178, 196], ["COVID", "TEST", 209, 214]]], ["Patients who experience persistent and severe agitation or delirium despite de-escalation and attempts to treat underlying causes or precipitants may require physical restraint and use of sedative medication therapy.", [["agitation", "DISEASE", 46, 55], ["delirium", "DISEASE", 59, 67], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["persistent and severe agitation", "PROBLEM", 24, 55], ["delirium", "PROBLEM", 59, 67], ["de-escalation", "TREATMENT", 76, 89], ["underlying causes", "PROBLEM", 112, 129], ["physical restraint", "TREATMENT", 158, 176], ["sedative medication therapy", "TREATMENT", 188, 215], ["persistent", "OBSERVATION_MODIFIER", 24, 34], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["agitation", "OBSERVATION", 46, 55]]], ["It is possible that the threshold to use pharmacotherapy may be lower during this pandemic given the elevated risk to both patients and staff caring for them.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["pharmacotherapy", "TREATMENT", 41, 56]]], ["Low doses of first-generation antipsychotics such as haloperidol or second-generation antipsychotics such as olanzapine and risperidone have been found to be equally effective in patients with delirium, but have differing onset and side-effect profiles.", [["haloperidol", "CHEMICAL", 53, 64], ["olanzapine", "CHEMICAL", 109, 119], ["risperidone", "CHEMICAL", 124, 135], ["delirium", "DISEASE", 193, 201], ["haloperidol", "CHEMICAL", 53, 64], ["olanzapine", "CHEMICAL", 109, 119], ["risperidone", "CHEMICAL", 124, 135], ["haloperidol", "SIMPLE_CHEMICAL", 53, 64], ["olanzapine", "SIMPLE_CHEMICAL", 109, 119], ["risperidone", "SIMPLE_CHEMICAL", 124, 135], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["first-generation antipsychotics", "TREATMENT", 13, 44], ["haloperidol", "TREATMENT", 53, 64], ["second-generation antipsychotics", "TREATMENT", 68, 100], ["olanzapine", "TREATMENT", 109, 119], ["risperidone", "TREATMENT", 124, 135], ["delirium", "PROBLEM", 193, 201], ["side-effect profiles", "PROBLEM", 232, 252]]], ["55 Extrapyramidal symptoms are most common with haloperidol, and sedation occurs most frequently with olanzapine.", [["haloperidol", "CHEMICAL", 48, 59], ["olanzapine", "CHEMICAL", 102, 112], ["haloperidol", "CHEMICAL", 48, 59], ["olanzapine", "CHEMICAL", 102, 112], ["haloperidol", "SIMPLE_CHEMICAL", 48, 59], ["olanzapine", "SIMPLE_CHEMICAL", 102, 112], ["Extrapyramidal symptoms", "PROBLEM", 3, 26], ["haloperidol", "TREATMENT", 48, 59], ["sedation", "TREATMENT", 65, 73], ["olanzapine", "TREATMENT", 102, 112]]], ["56 Adverse events associated with restraints and sedatives, including apnea and respiratory depression, will be significantly more dangerous in light of discordance between clinical and imaging evidence for degree of pulmonary involvement, rapid deterioration in the clinical course, and profound hypoxia associated with COVID-19.", [["respiratory", "ANATOMY", 80, 91], ["pulmonary", "ANATOMY", 217, 226], ["apnea", "DISEASE", 70, 75], ["respiratory depression", "DISEASE", 80, 102], ["hypoxia", "DISEASE", 297, 304], ["COVID-19", "CHEMICAL", 321, 329], ["COVID-19", "CHEMICAL", 321, 329], ["pulmonary", "ORGAN", 217, 226], ["Adverse events", "PROBLEM", 3, 17], ["restraints", "TREATMENT", 34, 44], ["sedatives", "TREATMENT", 49, 58], ["apnea", "PROBLEM", 70, 75], ["respiratory depression", "PROBLEM", 80, 102], ["clinical and imaging", "TEST", 173, 193], ["pulmonary involvement", "PROBLEM", 217, 238], ["rapid deterioration", "PROBLEM", 240, 259], ["profound hypoxia", "PROBLEM", 288, 304], ["COVID", "TEST", 321, 326], ["respiratory depression", "OBSERVATION", 80, 102], ["pulmonary", "ANATOMY", 217, 226], ["involvement", "OBSERVATION", 227, 238], ["rapid", "OBSERVATION_MODIFIER", 240, 245], ["deterioration", "OBSERVATION_MODIFIER", 246, 259], ["profound", "OBSERVATION_MODIFIER", 288, 296], ["hypoxia", "OBSERVATION", 297, 304]]], ["57 If these pharmacologic measures are required, the patient should be closely monitored with frequent vital signs and continuous cardiac, pulse oximetry, and capnometry monitoring.CONCLUSIONThe COVID-19 pandemic has created unique stressors that may contribute to agitation symptoms.", [["cardiac", "ANATOMY", 130, 137], ["agitation", "DISEASE", 265, 274], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["frequent vital signs", "TEST", 94, 114], ["continuous cardiac, pulse oximetry", "TEST", 119, 153], ["capnometry monitoring", "TEST", 159, 180], ["agitation symptoms", "PROBLEM", 265, 283], ["may contribute to", "UNCERTAINTY", 247, 264]]], ["It has also increased personal risks for healthcare staff working in the ED, while adding new limitations to appropriately and effectively manage agitation due to measures needed to combat viral transmission.", [["agitation", "DISEASE", 146, 155], ["agitation", "PROBLEM", 146, 155], ["combat viral transmission", "PROBLEM", 182, 207], ["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["Extra measures for early detection, treatment of underlying causes for agitation, precautions to minimize staff hazards, coordination with security and psychiatric services, and avoidance of coercive strategies that cause respiratory depression will help mitigate heightened risks to safety caused by this outbreak.", [["respiratory", "ANATOMY", 222, 233], ["agitation", "DISEASE", 71, 80], ["psychiatric", "DISEASE", 152, 163], ["respiratory depression", "DISEASE", 222, 244], ["Extra measures", "TREATMENT", 0, 14], ["early detection", "TEST", 19, 34], ["underlying causes", "PROBLEM", 49, 66], ["agitation", "PROBLEM", 71, 80], ["precautions", "TREATMENT", 82, 93], ["psychiatric services", "TREATMENT", 152, 172], ["coercive strategies", "TREATMENT", 191, 210], ["respiratory depression", "PROBLEM", 222, 244], ["this outbreak", "PROBLEM", 301, 314]]]], "b9eda6deb70fba0c25dda160f7afc8887b3484c7": [["IntroductionAny insult to the vertebral column and spinal cord can lead to alterations of its function and vertebral column destruction.", [["vertebral column", "ANATOMY", 30, 46], ["spinal cord", "ANATOMY", 51, 62], ["vertebral column", "ANATOMY", 107, 123], ["vertebral column", "MULTI-TISSUE_STRUCTURE", 30, 46], ["spinal cord", "ORGAN", 51, 62], ["vertebral column", "MULTI-TISSUE_STRUCTURE", 107, 123], ["Any insult to the vertebral column and spinal cord", "PROBLEM", 12, 62], ["vertebral column destruction", "PROBLEM", 107, 135], ["insult", "OBSERVATION", 16, 22], ["vertebral", "ANATOMY", 30, 39], ["column", "ANATOMY_MODIFIER", 40, 46], ["spinal cord", "ANATOMY", 51, 62], ["vertebral", "ANATOMY", 107, 116], ["column", "ANATOMY_MODIFIER", 117, 123], ["destruction", "OBSERVATION", 124, 135]]], ["Pathologies such as Parkinson's Disease, diabetic neuropathy, syringomyelia, and neural tube defects have been shown to cause neuroarthropathy as a long-term sequela [1, 2] .", [["neural tube", "ANATOMY", 81, 92], ["Parkinson's Disease", "DISEASE", 20, 39], ["diabetic neuropathy", "DISEASE", 41, 60], ["syringomyelia", "DISEASE", 62, 75], ["neural tube defects", "DISEASE", 81, 100], ["neuroarthropathy", "DISEASE", 126, 142], ["neural tube", "TISSUE", 81, 92], ["Pathologies", "PROBLEM", 0, 11], ["Parkinson's Disease", "PROBLEM", 20, 39], ["diabetic neuropathy", "PROBLEM", 41, 60], ["syringomyelia", "PROBLEM", 62, 75], ["neural tube defects", "PROBLEM", 81, 100], ["neuroarthropathy", "PROBLEM", 126, 142], ["a long-term sequela", "PROBLEM", 146, 165], ["Parkinson's Disease", "OBSERVATION", 20, 39], ["diabetic", "OBSERVATION_MODIFIER", 41, 49], ["neuropathy", "OBSERVATION", 50, 60], ["syringomyelia", "OBSERVATION", 62, 75], ["neural", "ANATOMY_MODIFIER", 81, 87], ["tube defects", "OBSERVATION", 88, 100], ["neuroarthropathy", "OBSERVATION", 126, 142], ["long-term sequela", "OBSERVATION_MODIFIER", 148, 165]]], ["Jean-Marie Charcot first described Charcot arthropathy in a patient in the 1800's.", [["Charcot", "DISEASE", 11, 18], ["Charcot arthropathy", "DISEASE", 35, 54], ["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["Charcot arthropathy", "PROBLEM", 35, 54], ["Charcot first", "OBSERVATION_MODIFIER", 11, 24], ["Charcot", "OBSERVATION_MODIFIER", 35, 42], ["arthropathy", "OBSERVATION", 43, 54]]], ["The first report of CAS was published in 1884 in a patient with tabes dorsalis, but with the advent of antibiotic treatments, CAS as a sequela of syphilis is rare [3, 4] .", [["CAS", "CHEMICAL", 126, 129], ["syphilis", "DISEASE", 146, 154], ["patient", "ORGANISM", 51, 58], ["tabes dorsalis", "ORGANISM", 64, 78], ["patient", "SPECIES", 51, 58], ["tabes dorsalis", "TREATMENT", 64, 78], ["antibiotic treatments", "TREATMENT", 103, 124], ["CAS", "TREATMENT", 126, 129], ["syphilis", "PROBLEM", 146, 154], ["dorsalis", "ANATOMY", 70, 78]]], ["CAS is now a well-defined long-term complication following traumatic spinal cord injury (SCI), developing on average 17 years after injury.IntroductionThe pathophysiology is not well understood, but believed to be a combination of neuro-trauma due to loss of sensation at the joint and neurovascular abnormalities due to inflammation [5] .", [["spinal cord", "ANATOMY", 69, 80], ["joint", "ANATOMY", 276, 281], ["neurovascular", "ANATOMY", 286, 299], ["CAS", "CHEMICAL", 0, 3], ["cord injury", "DISEASE", 76, 87], ["SCI", "DISEASE", 89, 92], ["neuro-trauma", "DISEASE", 231, 243], ["loss of sensation", "DISEASE", 251, 268], ["neurovascular abnormalities", "DISEASE", 286, 313], ["inflammation", "DISEASE", 321, 333], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 69, 80], ["joint", "MULTI-TISSUE_STRUCTURE", 276, 281], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 286, 299], ["a well-defined long-term complication", "PROBLEM", 11, 48], ["traumatic spinal cord injury", "PROBLEM", 59, 87], ["injury", "PROBLEM", 132, 138], ["neuro-trauma", "PROBLEM", 231, 243], ["loss of sensation at the joint", "PROBLEM", 251, 281], ["neurovascular abnormalities", "PROBLEM", 286, 313], ["inflammation", "PROBLEM", 321, 333], ["well-defined", "OBSERVATION_MODIFIER", 13, 25], ["long-term", "OBSERVATION_MODIFIER", 26, 35], ["complication", "OBSERVATION", 36, 48], ["traumatic", "OBSERVATION_MODIFIER", 59, 68], ["spinal cord", "ANATOMY", 69, 80], ["injury", "OBSERVATION", 81, 87], ["SCI", "ANATOMY", 89, 92], ["joint", "ANATOMY", 276, 281], ["neurovascular", "ANATOMY", 286, 299], ["inflammation", "OBSERVATION", 321, 333]]], ["Recurrent infections increase joint destruction, and therefore more prevalent in wheelchairbound patients with poor nursing care [6] .", [["joint", "ANATOMY", 30, 35], ["infections", "DISEASE", 10, 20], ["joint", "MULTI-TISSUE_STRUCTURE", 30, 35], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Recurrent infections", "PROBLEM", 0, 20], ["joint destruction", "PROBLEM", 30, 47], ["infections", "OBSERVATION", 10, 20], ["joint", "ANATOMY", 30, 35], ["destruction", "OBSERVATION", 36, 47], ["more prevalent", "OBSERVATION_MODIFIER", 63, 77]]], ["Currently, no consensus exists on neurosurgical management of CAS.IntroductionHere we describe the case of a patient with paraplegia who developed CAS following a traumatic SCI complicated by a complex hospital course.History and examinationA 55-year-old male with T10 complete paraplegia was transferred to our institution on broad-spectrum antibiotics from another facility after presenting with 2 days of emesis and productive cough.", [["CAS", "DISEASE", 62, 65], ["paraplegia", "DISEASE", 122, 132], ["CAS", "DISEASE", 147, 150], ["SCI", "DISEASE", 173, 176], ["paraplegia", "DISEASE", 278, 288], ["emesis", "DISEASE", 408, 414], ["cough", "DISEASE", 430, 435], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["neurosurgical management", "TREATMENT", 34, 58], ["paraplegia", "PROBLEM", 122, 132], ["CAS", "PROBLEM", 147, 150], ["a traumatic SCI", "PROBLEM", 161, 176], ["T10 complete paraplegia", "PROBLEM", 265, 288], ["broad-spectrum antibiotics", "TREATMENT", 327, 353], ["emesis", "PROBLEM", 408, 414], ["productive cough", "PROBLEM", 419, 435], ["no", "UNCERTAINTY", 11, 13], ["CAS", "OBSERVATION", 62, 65], ["T10", "ANATOMY", 265, 268], ["paraplegia", "OBSERVATION", 278, 288], ["emesis", "OBSERVATION", 408, 414], ["productive", "OBSERVATION_MODIFIER", 419, 429], ["cough", "OBSERVATION", 430, 435]]], ["He was being treated for a \"bone infection\" and lateral abdominal wall abscess with drain placement, which was mal-positioned on radiologic imaging.", [["bone", "ANATOMY", 28, 32], ["lateral abdominal wall abscess", "ANATOMY", 48, 78], ["bone infection", "DISEASE", 28, 42], ["abscess", "DISEASE", 71, 78], ["He", "ORGANISM", 0, 2], ["bone", "TISSUE", 28, 32], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 56, 70], ["a \"bone infection\"", "PROBLEM", 25, 43], ["lateral abdominal wall abscess", "PROBLEM", 48, 78], ["drain placement", "TREATMENT", 84, 99], ["radiologic imaging", "TEST", 129, 147], ["bone", "ANATOMY", 28, 32], ["infection", "OBSERVATION", 33, 42], ["lateral", "ANATOMY_MODIFIER", 48, 55], ["abdominal", "ANATOMY", 56, 65], ["wall", "ANATOMY_MODIFIER", 66, 70], ["abscess", "OBSERVATION", 71, 78], ["drain", "OBSERVATION", 84, 89]]], ["Eleven years ago, the patient was injured from a gunshot wound leaving him with paraplegia.", [["wound", "ANATOMY", 57, 62], ["gunshot", "DISEASE", 49, 56], ["paraplegia", "DISEASE", 80, 90], ["patient", "ORGANISM", 22, 29], ["wound", "PATHOLOGICAL_FORMATION", 57, 62], ["patient", "SPECIES", 22, 29], ["a gunshot wound", "PROBLEM", 47, 62], ["paraplegia", "PROBLEM", 80, 90], ["wound", "OBSERVATION", 57, 62], ["paraplegia", "OBSERVATION", 80, 90]]], ["He had neurogenic bowel and bladder dysfunction managed with an indwelling urethral catheter and sigmoid colostomy.", [["neurogenic bowel", "ANATOMY", 7, 23], ["bladder", "ANATOMY", 28, 35], ["urethral", "ANATOMY", 75, 83], ["neurogenic bowel and bladder dysfunction", "DISEASE", 7, 47], ["bowel", "ORGAN", 18, 23], ["bladder", "ORGAN", 28, 35], ["urethral", "ORGANISM_SUBDIVISION", 75, 83], ["neurogenic bowel", "PROBLEM", 7, 23], ["bladder dysfunction", "PROBLEM", 28, 47], ["an indwelling urethral catheter", "TREATMENT", 61, 92], ["sigmoid colostomy", "TREATMENT", 97, 114], ["neurogenic", "ANATOMY_MODIFIER", 7, 17], ["bowel", "ANATOMY", 18, 23], ["bladder", "ANATOMY", 28, 35], ["dysfunction", "OBSERVATION", 36, 47], ["indwelling", "OBSERVATION", 64, 74], ["urethral", "ANATOMY", 75, 83], ["catheter", "OBSERVATION", 84, 92], ["sigmoid colostomy", "OBSERVATION", 97, 114]]], ["Additionally, the patient had poor skilled nursing care, resulting in non-healing sacral and lower extremity ulcers.History and examinationPhysical exam on transfer was remarkable for inability to sit upright in his wheelchair, minimal expiratory wheezing, increased green/brown watery ostomy output, multiple ulcers, sacral wound with significant depth beyond the spinal column, tenderness to palpation on the thoracic spine, and exposed wound on the lumbar spine with an overlying hard palpable mass.", [["sacral", "ANATOMY", 82, 88], ["lower extremity ulcers", "ANATOMY", 93, 115], ["ulcers", "ANATOMY", 310, 316], ["sacral wound", "ANATOMY", 318, 330], ["spinal column", "ANATOMY", 365, 378], ["thoracic spine", "ANATOMY", 411, 425], ["wound", "ANATOMY", 439, 444], ["lumbar spine", "ANATOMY", 452, 464], ["palpable mass", "ANATOMY", 488, 501], ["ulcers", "DISEASE", 109, 115], ["expiratory wheezing", "DISEASE", 236, 255], ["ulcers", "DISEASE", 310, 316], ["tenderness", "DISEASE", 380, 390], ["patient", "ORGANISM", 18, 25], ["sacral", "ORGANISM_SUBDIVISION", 82, 88], ["lower extremity", "ORGANISM_SUBDIVISION", 93, 108], ["ulcers", "PATHOLOGICAL_FORMATION", 109, 115], ["watery", "ORGANISM_SUBDIVISION", 279, 285], ["ulcers", "PATHOLOGICAL_FORMATION", 310, 316], ["wound", "PATHOLOGICAL_FORMATION", 325, 330], ["thoracic spine", "MULTI-TISSUE_STRUCTURE", 411, 425], ["wound", "PATHOLOGICAL_FORMATION", 439, 444], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 452, 464], ["patient", "SPECIES", 18, 25], ["non-healing sacral and lower extremity ulcers", "PROBLEM", 70, 115], ["examinationPhysical exam", "TEST", 128, 152], ["minimal expiratory wheezing", "PROBLEM", 228, 255], ["increased green/brown watery ostomy output", "PROBLEM", 257, 299], ["multiple ulcers", "PROBLEM", 301, 316], ["sacral wound", "PROBLEM", 318, 330], ["significant depth beyond the spinal column", "PROBLEM", 336, 378], ["tenderness", "PROBLEM", 380, 390], ["palpation", "TEST", 394, 403], ["exposed wound on the lumbar spine", "PROBLEM", 431, 464], ["an overlying hard palpable mass", "PROBLEM", 470, 501], ["non-healing", "OBSERVATION_MODIFIER", 70, 81], ["sacral", "ANATOMY", 82, 88], ["lower", "ANATOMY_MODIFIER", 93, 98], ["extremity", "ANATOMY", 99, 108], ["ulcers", "OBSERVATION", 109, 115], ["minimal", "OBSERVATION_MODIFIER", 228, 235], ["expiratory wheezing", "OBSERVATION", 236, 255], ["increased", "OBSERVATION_MODIFIER", 257, 266], ["green", "OBSERVATION_MODIFIER", 267, 272], ["ostomy output", "OBSERVATION", 286, 299], ["multiple", "OBSERVATION_MODIFIER", 301, 309], ["ulcers", "OBSERVATION", 310, 316], ["sacral", "ANATOMY", 318, 324], ["wound", "OBSERVATION", 325, 330], ["significant", "OBSERVATION_MODIFIER", 336, 347], ["depth", "OBSERVATION_MODIFIER", 348, 353], ["spinal", "ANATOMY", 365, 371], ["column", "ANATOMY_MODIFIER", 372, 378], ["tenderness", "OBSERVATION", 380, 390], ["palpation", "OBSERVATION", 394, 403], ["thoracic spine", "ANATOMY", 411, 425], ["exposed", "OBSERVATION_MODIFIER", 431, 438], ["wound", "OBSERVATION", 439, 444], ["lumbar spine", "ANATOMY", 452, 464], ["overlying", "OBSERVATION_MODIFIER", 473, 482], ["hard", "OBSERVATION_MODIFIER", 483, 487], ["palpable", "OBSERVATION_MODIFIER", 488, 496], ["mass", "OBSERVATION", 497, 501]]], ["Neurologic exam was notable for flaccid paralysis in the bilateral lower extremities and a T10 sensory level at the umbilicus.", [["flaccid", "ANATOMY", 32, 39], ["lower extremities", "ANATOMY", 67, 84], ["umbilicus", "ANATOMY", 116, 125], ["paralysis", "DISEASE", 40, 49], ["lower extremities", "ORGANISM_SUBDIVISION", 67, 84], ["umbilicus", "ORGAN", 116, 125], ["Neurologic exam", "TEST", 0, 15], ["flaccid paralysis in the bilateral lower extremities", "PROBLEM", 32, 84], ["paralysis", "OBSERVATION", 40, 49], ["bilateral", "ANATOMY_MODIFIER", 57, 66], ["lower extremities", "ANATOMY", 67, 84], ["T10", "ANATOMY", 91, 94], ["umbilicus", "ANATOMY", 116, 125]]], ["Medical history was notable for COPD, left lower extremity osteomyelitis, Clostridium difficle colitis, MRSA and IV drug use.", [["left lower extremity", "ANATOMY", 38, 58], ["COPD", "DISEASE", 32, 36], ["osteomyelitis", "DISEASE", 59, 72], ["Clostridium difficle colitis", "DISEASE", 74, 102], ["MRSA", "DISEASE", 104, 108], ["lower extremity", "ORGANISM_SUBDIVISION", 43, 58], ["Clostridium difficle", "SPECIES", 74, 94], ["MRSA", "SPECIES", 104, 108], ["Clostridium difficle", "SPECIES", 74, 94], ["COPD", "PROBLEM", 32, 36], ["left lower extremity osteomyelitis", "PROBLEM", 38, 72], ["Clostridium difficle colitis", "PROBLEM", 74, 102], ["MRSA", "PROBLEM", 104, 108], ["COPD", "OBSERVATION", 32, 36], ["left", "ANATOMY_MODIFIER", 38, 42], ["lower extremity", "ANATOMY", 43, 58], ["osteomyelitis", "OBSERVATION", 59, 72], ["Clostridium difficle colitis", "OBSERVATION", 74, 102], ["MRSA", "OBSERVATION", 104, 108]]], ["Lab values were notable for elevated inflammatory markers (ESR/CRP), leukocytosis, and hypoalbuminemia.Initial imagingOutside CT abdominal/pelvis with contrast demonstrated a large sacral pressure ulcer with underlying fragmentation and destruction of the bilateral lumbosacral junctions; osteomyelitis of the left ischium and right iliac bone; and 6cm left lateral wall abscess with osteomyelitis at the left eleventh rib and dislodged drainage catheter outside of the fluid collection (Fig. 1) .Initial imagingSubsequent non-contrast CT demonstrated severe T11 vertebral body deformity, a ballistic tract extending into the spinal canal and articular process of T12 and retained ballistic fragment in the left T12 paraspinal soft tissue.", [["abdominal/pelvis", "ANATOMY", 129, 145], ["sacral", "ANATOMY", 181, 187], ["ulcer", "ANATOMY", 197, 202], ["lumbosacral junctions", "ANATOMY", 266, 287], ["left ischium", "ANATOMY", 310, 322], ["right iliac bone", "ANATOMY", 327, 343], ["left lateral wall abscess", "ANATOMY", 353, 378], ["fluid", "ANATOMY", 470, 475], ["T11 vertebral body", "ANATOMY", 559, 577], ["tract", "ANATOMY", 601, 606], ["spinal canal", "ANATOMY", 626, 638], ["articular", "ANATOMY", 643, 652], ["left T12 paraspinal soft tissue", "ANATOMY", 707, 738], ["leukocytosis", "DISEASE", 69, 81], ["hypoalbuminemia", "DISEASE", 87, 102], ["ulcer", "DISEASE", 197, 202], ["osteomyelitis", "DISEASE", 289, 302], ["abscess", "DISEASE", 371, 378], ["osteomyelitis", "DISEASE", 384, 397], ["vertebral body deformity", "DISEASE", 563, 587], ["CRP", "GENE_OR_GENE_PRODUCT", 63, 66], ["pelvis", "ORGAN", 139, 145], ["lumbosacral junctions", "MULTI-TISSUE_STRUCTURE", 266, 287], ["ischium", "ORGAN", 315, 322], ["iliac bone", "MULTI-TISSUE_STRUCTURE", 333, 343], ["rib", "ORGAN", 419, 422], ["tract", "ORGANISM_SUBDIVISION", 601, 606], ["spinal canal", "MULTI-TISSUE_STRUCTURE", 626, 638], ["articular", "TISSUE", 643, 652], ["T12 paraspinal soft tissue", "TISSUE", 712, 738], ["inflammatory markers", "PROTEIN", 37, 57], ["ESR", "PROTEIN", 59, 62], ["CRP", "PROTEIN", 63, 66], ["Lab values", "TEST", 0, 10], ["elevated inflammatory markers", "PROBLEM", 28, 57], ["ESR", "TEST", 59, 62], ["CRP", "TEST", 63, 66], ["leukocytosis", "PROBLEM", 69, 81], ["hypoalbuminemia", "PROBLEM", 87, 102], ["Initial imagingOutside CT abdominal/pelvis with contrast", "TEST", 103, 159], ["a large sacral pressure ulcer", "PROBLEM", 173, 202], ["underlying fragmentation", "PROBLEM", 208, 232], ["destruction of the bilateral lumbosacral junctions", "PROBLEM", 237, 287], ["osteomyelitis of the left ischium and right iliac bone", "PROBLEM", 289, 343], ["6cm left lateral wall abscess", "PROBLEM", 349, 378], ["osteomyelitis at the left eleventh rib", "PROBLEM", 384, 422], ["dislodged drainage catheter", "TREATMENT", 427, 454], ["the fluid collection", "PROBLEM", 466, 486], ["Initial imaging", "TEST", 497, 512], ["Subsequent non-contrast CT", "TEST", 512, 538], ["severe T11 vertebral body deformity", "PROBLEM", 552, 587], ["a ballistic tract", "PROBLEM", 589, 606], ["retained ballistic fragment", "PROBLEM", 672, 699], ["inflammatory markers", "OBSERVATION", 37, 57], ["leukocytosis", "OBSERVATION", 69, 81], ["hypoalbuminemia", "OBSERVATION", 87, 102], ["abdominal", "ANATOMY", 129, 138], ["pelvis", "ANATOMY", 139, 145], ["large", "OBSERVATION_MODIFIER", 175, 180], ["sacral", "ANATOMY", 181, 187], ["pressure ulcer", "OBSERVATION", 188, 202], ["fragmentation", "OBSERVATION", 219, 232], ["destruction", "OBSERVATION", 237, 248], ["bilateral", "ANATOMY_MODIFIER", 256, 265], ["lumbosacral junctions", "ANATOMY", 266, 287], ["osteomyelitis", "OBSERVATION", 289, 302], ["left", "ANATOMY_MODIFIER", 310, 314], ["ischium", "ANATOMY", 315, 322], ["right", "ANATOMY_MODIFIER", 327, 332], ["iliac", "ANATOMY_MODIFIER", 333, 338], ["bone", "ANATOMY", 339, 343], ["6cm", "OBSERVATION_MODIFIER", 349, 352], ["left", "ANATOMY_MODIFIER", 353, 357], ["lateral", "ANATOMY_MODIFIER", 358, 365], ["wall", "ANATOMY_MODIFIER", 366, 370], ["abscess", "OBSERVATION", 371, 378], ["osteomyelitis", "OBSERVATION", 384, 397], ["left", "ANATOMY_MODIFIER", 405, 409], ["eleventh rib", "ANATOMY", 410, 422], ["dislodged", "OBSERVATION_MODIFIER", 427, 436], ["drainage catheter", "OBSERVATION", 437, 454], ["fluid collection", "OBSERVATION", 470, 486], ["Fig", "OBSERVATION_MODIFIER", 488, 491], ["severe", "OBSERVATION_MODIFIER", 552, 558], ["T11", "ANATOMY_MODIFIER", 559, 562], ["vertebral", "ANATOMY", 563, 572], ["body", "ANATOMY_MODIFIER", 573, 577], ["deformity", "OBSERVATION", 578, 587], ["ballistic tract", "OBSERVATION", 591, 606], ["spinal canal", "ANATOMY", 626, 638], ["articular", "ANATOMY_MODIFIER", 643, 652], ["T12", "ANATOMY", 664, 667], ["retained", "OBSERVATION_MODIFIER", 672, 680], ["ballistic fragment", "OBSERVATION", 681, 699], ["left", "ANATOMY_MODIFIER", 707, 711], ["T12", "ANATOMY_MODIFIER", 712, 715], ["paraspinal", "ANATOMY_MODIFIER", 716, 726], ["soft tissue", "ANATOMY", 727, 738]]], ["A sacral pressure ulcer extended into the lumbosacral junction causing osteomyelitis of the right iliac crest, L2/L3 vertebral bodies, and sacrum ( Fig. 1) .", [["sacral pressure ulcer", "ANATOMY", 2, 23], ["lumbosacral junction", "ANATOMY", 42, 62], ["right iliac crest", "ANATOMY", 92, 109], ["L2/L3 vertebral bodies", "ANATOMY", 111, 133], ["sacrum", "ANATOMY", 139, 145], ["ulcer", "DISEASE", 18, 23], ["osteomyelitis", "DISEASE", 71, 84], ["lumbosacral junction", "MULTI-TISSUE_STRUCTURE", 42, 62], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 98, 109], ["sacrum", "ORGAN", 139, 145], ["A sacral pressure ulcer", "PROBLEM", 0, 23], ["osteomyelitis of the right iliac crest", "PROBLEM", 71, 109], ["sacral", "ANATOMY", 2, 8], ["pressure", "OBSERVATION_MODIFIER", 9, 17], ["ulcer", "OBSERVATION", 18, 23], ["lumbosacral junction", "ANATOMY", 42, 62], ["osteomyelitis", "OBSERVATION", 71, 84], ["right", "ANATOMY_MODIFIER", 92, 97], ["iliac", "ANATOMY", 98, 103], ["crest", "ANATOMY_MODIFIER", 104, 109], ["L2", "ANATOMY_MODIFIER", 111, 113], ["L3", "ANATOMY_MODIFIER", 114, 116], ["vertebral", "ANATOMY", 117, 126], ["bodies", "ANATOMY_MODIFIER", 127, 133], ["sacrum", "ANATOMY", 139, 145], ["Fig", "OBSERVATION_MODIFIER", 148, 151]]], ["Imaging was also notable for complete destruction of the L4 and L5 vertebral bodies, periosteal destruction, and sclerosis of the L3 vertebral body extending into the L2-3 disc space (Fig. 1 ).Index surgical treatmentOn hospital day (HOD) 10, the patient underwent an index surgery of L4 and L5 vertebral column resection, posterior L3-S1 interbody fusion utilizing cage and bone graft, T2iliac posterior spinal fusion with instrumentation and bone graft, and L1-L2 and L2-L3 osteotomy.", [["L4", "ANATOMY", 57, 59], ["L5 vertebral bodies", "ANATOMY", 64, 83], ["periosteal", "ANATOMY", 85, 95], ["L3 vertebral body", "ANATOMY", 130, 147], ["L4", "ANATOMY", 285, 287], ["L5 vertebral column", "ANATOMY", 292, 311], ["bone", "ANATOMY", 375, 379], ["spinal", "ANATOMY", 405, 411], ["bone", "ANATOMY", 444, 448], ["periosteal destruction", "DISEASE", 85, 107], ["sclerosis", "DISEASE", 113, 122], ["periosteal", "TISSUE", 85, 95], ["vertebral body", "MULTI-TISSUE_STRUCTURE", 133, 147], ["patient", "ORGANISM", 247, 254], ["bone", "TISSUE", 375, 379], ["bone graft", "MULTI-TISSUE_STRUCTURE", 444, 454], ["patient", "SPECIES", 247, 254], ["Imaging", "TEST", 0, 7], ["complete destruction of the L4 and L5 vertebral bodies", "PROBLEM", 29, 83], ["periosteal destruction", "PROBLEM", 85, 107], ["sclerosis of the L3 vertebral body", "PROBLEM", 113, 147], ["an index surgery of L4 and L5 vertebral column resection", "TREATMENT", 265, 321], ["posterior L3-S1 interbody fusion utilizing cage", "TREATMENT", 323, 370], ["bone graft", "TREATMENT", 375, 385], ["T2iliac posterior spinal fusion", "TREATMENT", 387, 418], ["instrumentation and bone graft", "TREATMENT", 424, 454], ["L1-L2 and L2-L3 osteotomy", "TREATMENT", 460, 485], ["destruction", "OBSERVATION", 38, 49], ["L4", "ANATOMY_MODIFIER", 57, 59], ["L5", "ANATOMY_MODIFIER", 64, 66], ["vertebral", "ANATOMY", 67, 76], ["bodies", "ANATOMY_MODIFIER", 77, 83], ["periosteal", "ANATOMY_MODIFIER", 85, 95], ["destruction", "OBSERVATION", 96, 107], ["sclerosis", "OBSERVATION", 113, 122], ["L3", "ANATOMY_MODIFIER", 130, 132], ["vertebral", "ANATOMY", 133, 142], ["body", "ANATOMY_MODIFIER", 143, 147], ["L2", "ANATOMY_MODIFIER", 167, 169], ["3 disc", "ANATOMY_MODIFIER", 170, 176], ["space", "ANATOMY_MODIFIER", 177, 182], ["L4", "ANATOMY", 285, 287], ["L5", "ANATOMY_MODIFIER", 292, 294], ["vertebral", "ANATOMY", 295, 304], ["column", "ANATOMY_MODIFIER", 305, 311], ["resection", "OBSERVATION", 312, 321], ["posterior", "ANATOMY_MODIFIER", 323, 332], ["L3", "ANATOMY", 333, 335], ["S1", "ANATOMY_MODIFIER", 336, 338], ["interbody fusion", "OBSERVATION", 339, 355], ["cage", "ANATOMY", 366, 370], ["bone", "ANATOMY", 375, 379], ["graft", "OBSERVATION", 380, 385], ["posterior", "ANATOMY_MODIFIER", 395, 404], ["spinal", "ANATOMY", 405, 411], ["fusion", "OBSERVATION", 412, 418], ["instrumentation", "OBSERVATION", 424, 439], ["bone", "ANATOMY", 444, 448], ["graft", "OBSERVATION", 449, 454], ["L1", "ANATOMY_MODIFIER", 460, 462], ["L2", "ANATOMY_MODIFIER", 463, 465], ["L2", "ANATOMY_MODIFIER", 470, 472], ["L3", "ANATOMY_MODIFIER", 473, 475], ["osteotomy", "OBSERVATION", 476, 485]]], ["As patient was wheelchair bound, fusion to T2 was done to optimize upright positioning.", [["patient", "ORGANISM", 3, 10], ["T2", "DNA", 43, 45], ["patient", "SPECIES", 3, 10], ["wheelchair bound", "PROBLEM", 15, 31], ["fusion to T2", "TREATMENT", 33, 45]]], ["A wound VAC was placed inferiorly over the sacral region and iliac crest bilaterally up to L3.", [["wound", "ANATOMY", 2, 7], ["sacral region", "ANATOMY", 43, 56], ["iliac crest", "ANATOMY", 61, 72], ["wound", "PATHOLOGICAL_FORMATION", 2, 7], ["sacral region", "MULTI-TISSUE_STRUCTURE", 43, 56], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 61, 72], ["L3", "DNA", 91, 93], ["A wound VAC", "TREATMENT", 0, 11], ["wound", "ANATOMY", 2, 7], ["VAC", "OBSERVATION", 8, 11], ["inferiorly", "ANATOMY_MODIFIER", 23, 33], ["sacral", "ANATOMY", 43, 49], ["region", "ANATOMY_MODIFIER", 50, 56], ["iliac", "ANATOMY", 61, 66], ["crest", "ANATOMY_MODIFIER", 67, 72], ["bilaterally", "ANATOMY_MODIFIER", 73, 84], ["L3", "ANATOMY", 91, 93]]], ["The top three-quarter portion of the wound was closed in the usual fashion.", [["wound", "ANATOMY", 37, 42], ["wound", "PATHOLOGICAL_FORMATION", 37, 42], ["the wound", "PROBLEM", 33, 42], ["top", "OBSERVATION_MODIFIER", 4, 7], ["three", "OBSERVATION_MODIFIER", 8, 13], ["quarter", "OBSERVATION_MODIFIER", 14, 21], ["portion", "OBSERVATION_MODIFIER", 22, 29], ["wound", "OBSERVATION", 37, 42], ["closed", "OBSERVATION", 47, 53]]], ["Per patients request, the retained bullet in the paraspinal musculature was removed.", [["paraspinal musculature", "ANATOMY", 49, 71], ["patients", "ORGANISM", 4, 12], ["bullet", "ORGANISM_SUBDIVISION", 35, 41], ["paraspinal musculature", "ORGAN", 49, 71], ["patients", "SPECIES", 4, 12], ["the retained bullet in the paraspinal musculature", "PROBLEM", 22, 71], ["retained", "OBSERVATION_MODIFIER", 26, 34], ["bullet", "OBSERVATION", 35, 41], ["paraspinal musculature", "ANATOMY", 49, 71], ["removed", "OBSERVATION", 76, 83]]], ["Upper extremity somatosensory and motor evoked potentials performed throughout the case showed no changes from baseline.", [["Upper extremity somatosensory", "ANATOMY", 0, 29], ["Upper extremity somatosensory", "TEST", 0, 29], ["motor evoked potentials", "TEST", 34, 57], ["extremity somatosensory", "ANATOMY", 6, 29]]], ["All thoracic screws showed greater than 8 mAs and intraoperative O-arm demonstrated appropriate positioning of implants and screws (Fig. 2) .", [["thoracic", "ANATOMY", 4, 12], ["thoracic screws", "MULTI-TISSUE_STRUCTURE", 4, 19], ["All thoracic screws", "TREATMENT", 0, 19], ["appropriate positioning of implants and screws (Fig", "TREATMENT", 84, 135], ["thoracic", "ANATOMY", 4, 12], ["screws", "OBSERVATION", 13, 19], ["greater", "OBSERVATION_MODIFIER", 27, 34], ["arm", "ANATOMY", 67, 70], ["implants", "OBSERVATION", 111, 119], ["screws", "OBSERVATION", 124, 130]]], ["1 Radiographic images from outside hospital.", [["Radiographic images", "TEST", 2, 21]]], ["Imaging on presentation from OSH showed a Axial CT imaging demonstrating a large penetrating decubitus ulcer extending into the lumbosacral junction and along the right iliac crest with associated osteomyelitis involving the right iliac crest and sacrum.", [["decubitus ulcer", "ANATOMY", 93, 108], ["lumbosacral junction", "ANATOMY", 128, 148], ["right iliac crest", "ANATOMY", 163, 180], ["right iliac crest", "ANATOMY", 225, 242], ["sacrum", "ANATOMY", 247, 253], ["ulcer", "DISEASE", 103, 108], ["osteomyelitis", "DISEASE", 197, 210], ["OSH", "CANCER", 29, 32], ["decubitus ulcer", "PATHOLOGICAL_FORMATION", 93, 108], ["lumbosacral junction", "MULTI-TISSUE_STRUCTURE", 128, 148], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 169, 180], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 231, 242], ["sacrum", "ORGAN", 247, 253], ["Imaging", "TEST", 0, 7], ["a Axial CT imaging", "TEST", 40, 58], ["a large penetrating decubitus ulcer", "PROBLEM", 73, 108], ["associated osteomyelitis involving the right iliac crest and sacrum", "PROBLEM", 186, 253], ["large", "OBSERVATION_MODIFIER", 75, 80], ["penetrating", "OBSERVATION_MODIFIER", 81, 92], ["decubitus", "ANATOMY", 93, 102], ["ulcer", "OBSERVATION", 103, 108], ["lumbosacral junction", "ANATOMY", 128, 148], ["right", "ANATOMY_MODIFIER", 163, 168], ["iliac", "ANATOMY", 169, 174], ["crest", "ANATOMY_MODIFIER", 175, 180], ["osteomyelitis", "OBSERVATION", 197, 210], ["right", "ANATOMY_MODIFIER", 225, 230], ["iliac", "ANATOMY", 231, 236], ["crest", "ANATOMY_MODIFIER", 237, 242], ["sacrum", "ANATOMY", 247, 253]]], ["Additionally, there was evidence of a left ischial ulcer with associated left hip effusion. b Sagittal CT imaging demonstrating complete dissociation of the lumbosacral junction with heterotopic ossification.", [["left ischial ulcer", "ANATOMY", 38, 56], ["left hip effusion", "ANATOMY", 73, 90], ["lumbosacral junction", "ANATOMY", 157, 177], ["ulcer", "DISEASE", 51, 56], ["left hip effusion", "DISEASE", 73, 90], ["heterotopic ossification", "DISEASE", 183, 207], ["ischial", "ORGANISM_SUBDIVISION", 43, 50], ["ulcer", "PATHOLOGICAL_FORMATION", 51, 56], ["hip", "ORGANISM_SUBDIVISION", 78, 81], ["lumbosacral junction", "MULTI-TISSUE_STRUCTURE", 157, 177], ["a left ischial ulcer", "PROBLEM", 36, 56], ["associated left hip effusion", "PROBLEM", 62, 90], ["b Sagittal CT imaging", "TEST", 92, 113], ["complete dissociation of the lumbosacral junction", "PROBLEM", 128, 177], ["heterotopic ossification", "PROBLEM", 183, 207], ["left", "ANATOMY_MODIFIER", 38, 42], ["ischial", "ANATOMY", 43, 50], ["ulcer", "OBSERVATION", 51, 56], ["left", "ANATOMY_MODIFIER", 73, 77], ["hip", "ANATOMY", 78, 81], ["effusion", "OBSERVATION", 82, 90], ["dissociation", "OBSERVATION", 137, 149], ["lumbosacral junction", "ANATOMY", 157, 177], ["heterotopic ossification", "OBSERVATION", 183, 207]]], ["There is also evidence of complete destruction and collapse of the L4 and L5 vertebrae with partial destruction of L3. c Sagittal CT imaging revealed ballistic bony changes involving T9 -T11 vertebral bodies with a retained ballistic fragment at the T12 soft tissues. d Sagittal 3dimensional reconstruction of the thoracolumbar spine demonstrating a Charcot joint at the L1-L2 vertebral level with an associated dextroconvexity centered at the destroyed L4-L5 vertebraePost-operative coursePost-operatively, the patient remained intubated due to respiratory insufficiency secondary to prolonged anesthesia time and persistent hypotension requiring pressure support and transfusion.", [["L4", "ANATOMY", 67, 69], ["L5 vertebrae", "ANATOMY", 74, 86], ["bony", "ANATOMY", 160, 164], ["T9 -T11 vertebral bodies", "ANATOMY", 183, 207], ["fragment", "ANATOMY", 234, 242], ["T12 soft tissues", "ANATOMY", 250, 266], ["thoracolumbar spine", "ANATOMY", 314, 333], ["joint", "ANATOMY", 358, 363], ["vertebral", "ANATOMY", 377, 386], ["respiratory", "ANATOMY", 546, 557], ["respiratory insufficiency", "DISEASE", 546, 571], ["hypotension", "DISEASE", 626, 637], ["L4", "ORGAN", 67, 69], ["L5 vertebrae", "MULTI-TISSUE_STRUCTURE", 74, 86], ["T12 soft tissues", "TISSUE", 250, 266], ["thoracolumbar spine", "MULTI-TISSUE_STRUCTURE", 314, 333], ["Charcot joint", "MULTI-TISSUE_STRUCTURE", 350, 363], ["vertebral", "ORGAN", 377, 386], ["patient", "ORGANISM", 512, 519], ["L3", "DNA", 115, 117], ["patient", "SPECIES", 512, 519], ["complete destruction", "PROBLEM", 26, 46], ["collapse of the L4 and L5 vertebrae", "PROBLEM", 51, 86], ["partial destruction of L3", "PROBLEM", 92, 117], ["c", "TEST", 119, 120], ["Sagittal CT imaging", "TEST", 121, 140], ["ballistic bony changes", "PROBLEM", 150, 172], ["a retained ballistic fragment", "PROBLEM", 213, 242], ["Sagittal 3dimensional reconstruction of the thoracolumbar spine", "TREATMENT", 270, 333], ["a Charcot joint", "PROBLEM", 348, 363], ["an associated dextroconvexity", "PROBLEM", 398, 427], ["intubated", "TREATMENT", 529, 538], ["respiratory insufficiency", "PROBLEM", 546, 571], ["prolonged anesthesia", "TREATMENT", 585, 605], ["persistent hypotension", "PROBLEM", 615, 637], ["pressure support", "TREATMENT", 648, 664], ["transfusion", "TREATMENT", 669, 680], ["evidence of", "UNCERTAINTY", 14, 25], ["complete", "OBSERVATION_MODIFIER", 26, 34], ["destruction", "OBSERVATION", 35, 46], ["collapse", "OBSERVATION", 51, 59], ["L4", "ANATOMY_MODIFIER", 67, 69], ["L5", "ANATOMY_MODIFIER", 74, 76], ["vertebrae", "ANATOMY", 77, 86], ["partial", "OBSERVATION_MODIFIER", 92, 99], ["destruction", "OBSERVATION", 100, 111], ["L3", "ANATOMY", 115, 117], ["ballistic", "OBSERVATION", 150, 159], ["bony", "ANATOMY", 160, 164], ["changes", "OBSERVATION", 165, 172], ["T9", "ANATOMY_MODIFIER", 183, 185], ["T11", "ANATOMY_MODIFIER", 187, 190], ["vertebral", "ANATOMY", 191, 200], ["bodies", "ANATOMY_MODIFIER", 201, 207], ["retained", "OBSERVATION_MODIFIER", 215, 223], ["ballistic fragment", "OBSERVATION", 224, 242], ["T12", "ANATOMY_MODIFIER", 250, 253], ["soft tissues", "ANATOMY", 254, 266], ["thoracolumbar spine", "ANATOMY", 314, 333], ["Charcot joint", "ANATOMY", 350, 363], ["L1", "ANATOMY_MODIFIER", 371, 373], ["L2", "ANATOMY_MODIFIER", 374, 376], ["vertebral", "ANATOMY", 377, 386], ["level", "ANATOMY_MODIFIER", 387, 392], ["L4", "ANATOMY_MODIFIER", 454, 456], ["L5", "ANATOMY_MODIFIER", 457, 459], ["respiratory insufficiency", "OBSERVATION", 546, 571], ["persistent", "OBSERVATION_MODIFIER", 615, 625], ["hypotension", "OBSERVATION", 626, 637], ["pressure support", "OBSERVATION", 648, 664]]], ["Intraoperative estimated blood loss was 700cc and the patient received 2.7L crystalloid, 6 units of packed red blood cells (PRBCs), and 2 units of fresh frozen plasma (FFP).", [["blood", "ANATOMY", 25, 30], ["red blood cells", "ANATOMY", 107, 122], ["PRBCs", "ANATOMY", 124, 129], ["plasma", "ANATOMY", 160, 166], ["blood loss", "DISEASE", 25, 35], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["patient", "ORGANISM", 54, 61], ["red blood cells", "CELL", 107, 122], ["PRBCs", "CELL", 124, 129], ["plasma", "ORGANISM_SUBSTANCE", 160, 166], ["packed red blood cells", "CELL_TYPE", 100, 122], ["PRBCs", "CELL_TYPE", 124, 129], ["patient", "SPECIES", 54, 61], ["Intraoperative estimated blood loss", "PROBLEM", 0, 35], ["2.7L crystalloid", "TREATMENT", 71, 87], ["packed red blood cells", "TREATMENT", 100, 122], ["PRBCs", "TREATMENT", 124, 129], ["fresh frozen plasma", "TREATMENT", 147, 166], ["FFP", "TREATMENT", 168, 171], ["blood loss", "OBSERVATION", 25, 35]]], ["The patient was extubated on post-operative day (POD) 1 but remained persistently hypotensive and tachycardic.", [["hypotensive", "DISEASE", 82, 93], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["persistently hypotensive", "PROBLEM", 69, 93], ["tachycardic", "PROBLEM", 98, 109], ["persistently", "OBSERVATION_MODIFIER", 69, 81], ["hypotensive", "OBSERVATION", 82, 93]]], ["Patient had a complicated and difficult post-operative course.", [["Patient", "SPECIES", 0, 7]]], ["Due to nephrotoxicity from vancomycin while hypotensive, the patient developed a non-oliguric acute kidney injury and hydronephrosis from a malpositioned indwelling catheter.", [["kidney", "ANATOMY", 100, 106], ["nephrotoxicity", "DISEASE", 7, 21], ["vancomycin", "CHEMICAL", 27, 37], ["hypotensive", "DISEASE", 44, 55], ["acute kidney injury", "DISEASE", 94, 113], ["hydronephrosis", "DISEASE", 118, 132], ["vancomycin", "CHEMICAL", 27, 37], ["vancomycin", "SIMPLE_CHEMICAL", 27, 37], ["patient", "ORGANISM", 61, 68], ["kidney", "ORGAN", 100, 106], ["patient", "SPECIES", 61, 68], ["nephrotoxicity", "PROBLEM", 7, 21], ["vancomycin", "TREATMENT", 27, 37], ["hypotensive", "PROBLEM", 44, 55], ["a non-oliguric acute kidney injury", "PROBLEM", 79, 113], ["hydronephrosis", "PROBLEM", 118, 132], ["a malpositioned indwelling catheter", "TREATMENT", 138, 173], ["nephrotoxicity", "OBSERVATION", 7, 21], ["non-oliguric", "OBSERVATION_MODIFIER", 81, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["kidney", "ANATOMY", 100, 106], ["injury", "OBSERVATION", 107, 113], ["hydronephrosis", "OBSERVATION", 118, 132], ["malpositioned", "OBSERVATION_MODIFIER", 140, 153], ["indwelling", "OBSERVATION_MODIFIER", 154, 164], ["catheter", "OBSERVATION", 165, 173]]], ["During a routine wound VAC change on POD 20, the patient felt a \"pop\" and noticed his distal fixation present.", [["wound", "ANATOMY", 17, 22], ["wound", "PATHOLOGICAL_FORMATION", 17, 22], ["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["a routine wound VAC change", "TREATMENT", 7, 33], ["his distal fixation", "TREATMENT", 82, 101], ["wound", "ANATOMY", 17, 22], ["VAC", "OBSERVATION", 23, 26], ["distal", "ANATOMY_MODIFIER", 86, 92], ["fixation", "OBSERVATION", 93, 101]]], ["Imaging revealed pullout of the iliac screw fixation and loss of distraction with the interbody cage (Fig. 3) .Post-operative courseOn HOD 30/POD21, the patient returned to the operating room for a revision T2-iliac posterior spinal fusion with instrumentation, L3-S1 anterior interbody fixation, demonstrating the right-sided iliac screws situated in the subcutaneous soft tissue overlying the right gluteus maximus. c Axial CT imaging re-demonstrating the pulled-out right-sided iliac screws implantation of new bilateral iliac screw, iliac crest cortoss fixation, and transiliac bar cross link fixation (Fig. 3) .", [["iliac", "ANATOMY", 32, 37], ["spinal", "ANATOMY", 226, 232], ["subcutaneous soft tissue", "ANATOMY", 356, 380], ["right gluteus maximus", "ANATOMY", 395, 416], ["iliac", "ANATOMY", 481, 486], ["iliac", "ANATOMY", 524, 529], ["iliac crest", "ANATOMY", 537, 548], ["iliac", "MULTI-TISSUE_STRUCTURE", 32, 37], ["patient", "ORGANISM", 153, 160], ["iliac screws", "MULTI-TISSUE_STRUCTURE", 327, 339], ["subcutaneous soft tissue", "TISSUE", 356, 380], ["gluteus maximus", "TISSUE", 401, 416], ["iliac screws", "MULTI-TISSUE_STRUCTURE", 481, 493], ["iliac screw", "MULTI-TISSUE_STRUCTURE", 524, 535], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 537, 548], ["patient", "SPECIES", 153, 160], ["Imaging", "TEST", 0, 7], ["pullout of the iliac screw fixation", "TREATMENT", 17, 52], ["loss of distraction", "PROBLEM", 57, 76], ["the interbody cage", "TREATMENT", 82, 100], ["a revision T2-iliac posterior spinal fusion", "TREATMENT", 196, 239], ["instrumentation", "TREATMENT", 245, 260], ["L3-S1 anterior interbody fixation", "TREATMENT", 262, 295], ["the right-sided iliac screws", "TREATMENT", 311, 339], ["Axial CT imaging", "TEST", 420, 436], ["right-sided iliac screws implantation", "TREATMENT", 469, 506], ["new bilateral iliac screw", "TREATMENT", 510, 535], ["iliac crest cortoss fixation", "TREATMENT", 537, 565], ["transiliac bar cross link fixation", "TREATMENT", 571, 605], ["pullout", "OBSERVATION", 17, 24], ["iliac", "ANATOMY", 32, 37], ["screw fixation", "OBSERVATION", 38, 52], ["loss", "OBSERVATION_MODIFIER", 57, 61], ["distraction", "OBSERVATION", 65, 76], ["interbody cage", "OBSERVATION", 86, 100], ["revision", "OBSERVATION", 198, 206], ["iliac", "ANATOMY", 210, 215], ["posterior", "ANATOMY_MODIFIER", 216, 225], ["spinal", "ANATOMY", 226, 232], ["fusion", "OBSERVATION", 233, 239], ["instrumentation", "OBSERVATION", 245, 260], ["L3", "ANATOMY", 262, 264], ["S1", "ANATOMY_MODIFIER", 265, 267], ["anterior", "ANATOMY_MODIFIER", 268, 276], ["interbody fixation", "OBSERVATION", 277, 295], ["right", "ANATOMY_MODIFIER", 315, 320], ["sided", "ANATOMY_MODIFIER", 321, 326], ["iliac", "ANATOMY", 327, 332], ["screws", "OBSERVATION", 333, 339], ["subcutaneous", "ANATOMY_MODIFIER", 356, 368], ["soft tissue", "ANATOMY", 369, 380], ["right", "ANATOMY_MODIFIER", 395, 400], ["gluteus maximus", "ANATOMY", 401, 416], ["right", "ANATOMY_MODIFIER", 469, 474], ["sided", "ANATOMY_MODIFIER", 475, 480], ["iliac", "ANATOMY", 481, 486], ["screws implantation", "OBSERVATION", 487, 506], ["new", "OBSERVATION_MODIFIER", 510, 513], ["bilateral", "ANATOMY_MODIFIER", 514, 523], ["iliac", "ANATOMY", 524, 529], ["screw", "OBSERVATION", 530, 535], ["iliac", "ANATOMY", 537, 542], ["crest", "ANATOMY_MODIFIER", 543, 548], ["cortoss fixation", "OBSERVATION", 549, 565], ["transiliac", "ANATOMY", 571, 581], ["fixation", "OBSERVATION", 597, 605]]], ["A wound VAC was placed over the entire surgical field.Post-operative coursePatient remained in the hospital for IV broad-spectrum antibiotics in consultation with infectious disease service and bi-weekly wound VAC changes.", [["wound", "ANATOMY", 2, 7], ["wound", "ANATOMY", 204, 209], ["infectious disease", "DISEASE", 163, 181], ["wound", "PATHOLOGICAL_FORMATION", 2, 7], ["wound", "PATHOLOGICAL_FORMATION", 204, 209], ["A wound VAC", "TREATMENT", 0, 11], ["IV broad-spectrum antibiotics", "TREATMENT", 112, 141], ["infectious disease service", "TREATMENT", 163, 189], ["bi-weekly wound VAC changes", "TREATMENT", 194, 221], ["wound", "ANATOMY", 2, 7], ["VAC", "OBSERVATION", 8, 11], ["entire", "OBSERVATION_MODIFIER", 32, 38], ["surgical", "OBSERVATION", 39, 47], ["wound VAC", "OBSERVATION", 204, 213]]], ["Despite his co-morbidities, the surgical site healed well.", [["site", "ANATOMY", 41, 45], ["his co-morbidities", "PROBLEM", 8, 26], ["the surgical site", "PROBLEM", 28, 45], ["surgical", "OBSERVATION_MODIFIER", 32, 40], ["site", "OBSERVATION_MODIFIER", 41, 45], ["healed", "OBSERVATION", 46, 52]]], ["However, was deemed a non-optimal candidate for debridement and skin flap closure of his sacral pressure ulcer.", [["skin", "ANATOMY", 64, 68], ["sacral", "ANATOMY", 89, 95], ["ulcer", "DISEASE", 105, 110], ["skin", "ORGAN", 64, 68], ["sacral", "ORGANISM_SUBDIVISION", 89, 95], ["ulcer", "PATHOLOGICAL_FORMATION", 105, 110], ["debridement", "TREATMENT", 48, 59], ["skin flap closure", "TREATMENT", 64, 81], ["his sacral pressure ulcer", "PROBLEM", 85, 110], ["debridement", "OBSERVATION", 48, 59], ["skin", "ANATOMY", 64, 68], ["flap", "OBSERVATION", 69, 73], ["sacral", "ANATOMY", 89, 95], ["pressure ulcer", "OBSERVATION", 96, 110]]], ["The patient was discharged home 5 months from initial presentation with home health care and indefinite IV and oral antibiotics.DiscussionPatients who develop CAS often present with back pain, wheelchair instability, or autonomic dysreflexia inferior to the level of injury [7, 8] .", [["oral", "ANATOMY", 111, 115], ["back", "ANATOMY", 182, 186], ["CAS", "DISEASE", 159, 162], ["back pain", "DISEASE", 182, 191], ["wheelchair instability", "DISEASE", 193, 215], ["autonomic dysreflexia", "DISEASE", 220, 241], ["patient", "ORGANISM", 4, 11], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["patient", "SPECIES", 4, 11], ["home health care", "TREATMENT", 72, 88], ["indefinite IV", "TREATMENT", 93, 106], ["oral antibiotics", "TREATMENT", 111, 127], ["back pain", "PROBLEM", 182, 191], ["wheelchair instability", "PROBLEM", 193, 215], ["autonomic dysreflexia", "PROBLEM", 220, 241], ["injury", "PROBLEM", 267, 273], ["back", "ANATOMY", 182, 186], ["injury", "OBSERVATION", 267, 273]]], ["Signs of CAS development often do not manifest for decades after injury and may be overlooked [9] .DiscussionAebli et al. has investigated the clinical presentation and early detection of CAS in high risk patients and recommends radiological screening in patients with paraplegia to identify disc space narrowing [9, 10] .", [["disc space", "ANATOMY", 292, 302], ["CAS", "DISEASE", 188, 191], ["paraplegia", "DISEASE", 269, 279], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 255, 263], ["injury", "PROBLEM", 65, 71], ["CAS", "PROBLEM", 188, 191], ["radiological screening", "TEST", 229, 251], ["paraplegia", "PROBLEM", 269, 279], ["disc space narrowing", "PROBLEM", 292, 312], ["CAS", "OBSERVATION", 9, 12], ["disc", "ANATOMY", 292, 296], ["space", "ANATOMY_MODIFIER", 297, 302], ["narrowing", "OBSERVATION", 303, 312]]], ["Surgical fusion and instrumentation has been reported to provide positive outcomes and allow patients to return to their previous level of activity; however, the risk of re-occurrence in patients with paraplegia warrants careful consideration prior to intervention [11] [12] [13] .DiscussionSurgical treatment is known to have a high rate of complications and there are no established recommendations for optimal surgical approach [14] .", [["paraplegia", "DISEASE", 201, 211], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 187, 195], ["Surgical fusion", "TREATMENT", 0, 15], ["instrumentation", "TREATMENT", 20, 35], ["paraplegia", "PROBLEM", 201, 211], ["intervention", "TREATMENT", 252, 264], ["a high rate of complications", "PROBLEM", 327, 355], ["optimal surgical approach", "TREATMENT", 405, 430], ["fusion", "OBSERVATION", 9, 15]]], ["Recent case series recommend circumferential fixation for patients with multiple level involvement, whether performed as a single-stage or multistage operation [5, 15] .", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Recent case series", "TEST", 0, 18], ["circumferential fixation", "TREATMENT", 29, 53], ["multiple level involvement", "PROBLEM", 72, 98], ["a single-stage or multistage operation", "TREATMENT", 121, 159]]], ["Use of bone morphogenetic protein and four-rod lumbopelvic fixation showed favorable outcomes in 23 patients [16] .", [["bone", "ANATOMY", 7, 11], ["bone", "TISSUE", 7, 11], ["patients", "ORGANISM", 100, 108], ["bone morphogenetic protein", "PROTEIN", 7, 33], ["patients", "SPECIES", 100, 108], ["bone morphogenetic protein", "TREATMENT", 7, 33], ["four-rod lumbopelvic fixation", "TREATMENT", 38, 67], ["bone", "ANATOMY", 7, 11]]], ["Zyck et al. reports relief of autonomic dysreflexia symptoms after four-rod thoracolumbar posterior fusion in a patient with C6 quadriplegia [17] .DiscussionA case series of nine patients demonstrated successful fusion in all patients, eight of which underwent circumferential fusion, with an improvement in functional status in all patients [18] .", [["autonomic dysreflexia", "DISEASE", 30, 51], ["quadriplegia", "DISEASE", 128, 140], ["patient", "ORGANISM", 112, 119], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 333, 341], ["patient", "SPECIES", 112, 119], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 333, 341], ["autonomic dysreflexia symptoms", "PROBLEM", 30, 60], ["four-rod thoracolumbar posterior fusion", "TREATMENT", 67, 106], ["C6 quadriplegia", "PROBLEM", 125, 140], ["successful fusion", "TREATMENT", 201, 218], ["circumferential fusion", "TREATMENT", 261, 283], ["autonomic dysreflexia", "OBSERVATION", 30, 51], ["thoracolumbar", "ANATOMY", 76, 89], ["posterior", "ANATOMY_MODIFIER", 90, 99], ["fusion", "OBSERVATION", 100, 106], ["fusion", "OBSERVATION", 212, 218], ["circumferential", "OBSERVATION_MODIFIER", 261, 276], ["fusion", "OBSERVATION", 277, 283], ["improvement", "OBSERVATION_MODIFIER", 293, 304]]], ["However, successful posterior fusions have been observed in patients with only mild bone destruction [19] .", [["bone", "ANATOMY", 84, 88], ["bone destruction", "DISEASE", 84, 100], ["patients", "ORGANISM", 60, 68], ["bone", "TISSUE", 84, 88], ["patients", "SPECIES", 60, 68], ["successful posterior fusions", "TREATMENT", 9, 37], ["mild bone destruction", "PROBLEM", 79, 100], ["posterior", "ANATOMY_MODIFIER", 20, 29], ["fusions", "OBSERVATION", 30, 37], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["bone", "ANATOMY", 84, 88], ["destruction", "OBSERVATION", 89, 100]]], ["Although one-staged anterior and posterior fusion has shown the most favorable outcomes, two-staged fusion in posterior instrumentation followed by anterior bone graft can be used in patients with extensive co-morbidities who cannot tolerate prolonged operative times [19] .", [["anterior bone", "ANATOMY", 148, 161], ["anterior", "MULTI-TISSUE_STRUCTURE", 20, 28], ["anterior bone graft", "MULTI-TISSUE_STRUCTURE", 148, 167], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["one-staged anterior and posterior fusion", "TREATMENT", 9, 49], ["two-staged fusion in posterior instrumentation", "TREATMENT", 89, 135], ["anterior bone graft", "TREATMENT", 148, 167], ["extensive co-morbidities", "PROBLEM", 197, 221], ["anterior", "ANATOMY_MODIFIER", 20, 28], ["posterior", "ANATOMY_MODIFIER", 33, 42], ["fusion", "OBSERVATION", 43, 49], ["posterior", "ANATOMY_MODIFIER", 110, 119], ["instrumentation", "OBSERVATION", 120, 135], ["anterior", "ANATOMY_MODIFIER", 148, 156], ["bone", "ANATOMY", 157, 161], ["graft", "OBSERVATION", 162, 167]]], ["Few studies have reported long-term follow-up.DiscussionHaus et al., demonstrated an average follow-up of 14.3 years and noted that 75% of patients who received a fusion developed another Charcot joint requiring revision surgery [20] .", [["joint", "ANATOMY", 196, 201], ["Charcot joint", "DISEASE", 188, 201], ["patients", "ORGANISM", 139, 147], ["joint", "MULTI-TISSUE_STRUCTURE", 196, 201], ["patients", "SPECIES", 139, 147], ["Few studies", "TEST", 0, 11], ["a fusion", "TREATMENT", 161, 169], ["another Charcot joint", "PROBLEM", 180, 201], ["revision surgery", "TREATMENT", 212, 228], ["Charcot", "OBSERVATION", 188, 195], ["joint", "ANATOMY", 196, 201]]], ["Thus, the authors recommended conservative treatment in those whose dysreflexia symptoms can be managed non-surgically [21] .", [["dysreflexia", "DISEASE", 68, 79], ["conservative treatment", "TREATMENT", 30, 52], ["dysreflexia symptoms", "PROBLEM", 68, 88]]], ["In contrast, Grassner et al., advises against posterior-only fusions due to a high rate of pseudoarthrosis, as seen in our patient, and wound healing delays [22] .", [["wound", "ANATOMY", 136, 141], ["pseudoarthrosis", "DISEASE", 91, 106], ["patient", "ORGANISM", 123, 130], ["wound", "PATHOLOGICAL_FORMATION", 136, 141], ["patient", "SPECIES", 123, 130], ["posterior-only fusions", "TREATMENT", 46, 68], ["a high rate of pseudoarthrosis", "PROBLEM", 76, 106], ["wound healing delays", "PROBLEM", 136, 156], ["pseudoarthrosis", "OBSERVATION", 91, 106], ["wound", "ANATOMY", 136, 141], ["healing", "OBSERVATION_MODIFIER", 142, 149]]], ["Unique to our patient, Suda et al., recommends percutaneous external spinal fixation and wound irrigation for unstable spine lesions with infection, followed by definitive surgical management when infection resolves [23] .DiscussionPrevention is centered around decreasing the force applied to bony elements of the spine.", [["percutaneous", "ANATOMY", 47, 59], ["spinal", "ANATOMY", 69, 75], ["wound", "ANATOMY", 89, 94], ["spine lesions", "ANATOMY", 119, 132], ["bony", "ANATOMY", 294, 298], ["spine", "ANATOMY", 315, 320], ["infection", "DISEASE", 138, 147], ["infection", "DISEASE", 197, 206], ["patient", "ORGANISM", 14, 21], ["wound", "PATHOLOGICAL_FORMATION", 89, 94], ["spine lesions", "PATHOLOGICAL_FORMATION", 119, 132], ["spine", "ORGAN", 315, 320], ["patient", "SPECIES", 14, 21], ["percutaneous external spinal fixation", "TREATMENT", 47, 84], ["wound irrigation", "TREATMENT", 89, 105], ["unstable spine lesions", "PROBLEM", 110, 132], ["infection", "PROBLEM", 138, 147], ["definitive surgical management", "TREATMENT", 161, 191], ["infection", "PROBLEM", 197, 206], ["DiscussionPrevention", "TREATMENT", 222, 242], ["spinal", "ANATOMY", 69, 75], ["fixation", "OBSERVATION", 76, 84], ["spine", "ANATOMY", 119, 124], ["lesions", "OBSERVATION", 125, 132], ["infection", "OBSERVATION", 138, 147], ["bony", "ANATOMY", 294, 298], ["spine", "ANATOMY", 315, 320]]], ["Standaert et al., cautions against long fusions that end at the thoracolumbar junction, or procedures that increase upper trunk mobility as these increase stress on the lower spine [24] .", [["thoracolumbar junction", "ANATOMY", 64, 86], ["trunk", "ANATOMY", 122, 127], ["lower spine", "ANATOMY", 169, 180], ["thoracolumbar junction", "MULTI-TISSUE_STRUCTURE", 64, 86], ["upper", "ORGANISM_SUBDIVISION", 116, 121], ["trunk", "ORGANISM_SUBDIVISION", 122, 127], ["long fusions", "TREATMENT", 35, 47], ["procedures", "TREATMENT", 91, 101], ["increase upper trunk mobility", "PROBLEM", 107, 136], ["thoracolumbar junction", "ANATOMY", 64, 86], ["upper", "ANATOMY_MODIFIER", 116, 121], ["trunk", "ANATOMY", 122, 127], ["lower spine", "ANATOMY", 169, 180]]], ["Post-operatively, positioning and turning patients should be centered around decreasing the stress on the spine and the patient should be turned every 2-3 h.", [["spine", "ANATOMY", 106, 111], ["patients", "ORGANISM", 42, 50], ["spine", "ORGAN", 106, 111], ["patient", "ORGANISM", 120, 127], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 120, 127], ["positioning and turning patients", "TREATMENT", 18, 50], ["spine", "ANATOMY", 106, 111]]], ["Initially, turning is restricted to 30 degrees on each side with the two-person logrolling technique, one supporting the shoulders and buttocks, while the other supports the knees and waist; this reduces twisting of the spine [25] .DiscussionProper patient turning is often neglected as the techniques are resource heavy, but minimizing twisting, lifting and bending can drastically improve outcomes [26, 27] .DiscussionCAS is a long-term complication in patients with traumatic SCI.", [["shoulders", "ANATOMY", 121, 130], ["buttocks", "ANATOMY", 135, 143], ["knees", "ANATOMY", 174, 179], ["spine", "ANATOMY", 220, 225], ["traumatic SCI", "DISEASE", 469, 482], ["shoulders", "ORGANISM_SUBDIVISION", 121, 130], ["buttocks", "ORGANISM_SUBDIVISION", 135, 143], ["knees", "ORGANISM_SUBDIVISION", 174, 179], ["patient", "ORGANISM", 249, 256], ["patients", "ORGANISM", 455, 463], ["patient", "SPECIES", 249, 256], ["patients", "SPECIES", 455, 463], ["the two-person logrolling technique", "TREATMENT", 65, 100], ["a long-term complication", "PROBLEM", 427, 451], ["traumatic SCI", "PROBLEM", 469, 482], ["shoulders", "ANATOMY", 121, 130], ["buttocks", "ANATOMY", 135, 143], ["knees", "ANATOMY", 174, 179], ["waist", "ANATOMY", 184, 189], ["spine", "ANATOMY", 220, 225], ["long-term", "OBSERVATION_MODIFIER", 429, 438], ["traumatic", "OBSERVATION_MODIFIER", 469, 478], ["SCI", "OBSERVATION", 479, 482]]], ["Surgical management is complex with a high level of complications.", [["Surgical management", "TREATMENT", 0, 19], ["a high level of complications", "PROBLEM", 36, 65]]], ["A multi-modal treatment approach is necessary as patients often have multiple co-morbidities limiting wound healing and successful arthrodesis.", [["wound", "ANATOMY", 102, 107], ["patients", "ORGANISM", 49, 57], ["wound", "PATHOLOGICAL_FORMATION", 102, 107], ["patients", "SPECIES", 49, 57], ["A multi-modal treatment approach", "TREATMENT", 0, 32], ["multiple co-morbidities", "PROBLEM", 69, 92], ["wound healing", "PROBLEM", 102, 115], ["successful arthrodesis", "TREATMENT", 120, 142], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["co-morbidities", "OBSERVATION", 78, 92], ["healing", "OBSERVATION_MODIFIER", 108, 115], ["successful", "OBSERVATION_MODIFIER", 120, 130], ["arthrodesis", "OBSERVATION", 131, 142]]], ["Prevention of CAS by appropriate nursing care and early mobilization is crucial.", [["CAS", "CHEMICAL", 14, 17], ["CAS", "PROBLEM", 14, 17], ["appropriate nursing care", "TREATMENT", 21, 45], ["CAS", "OBSERVATION", 14, 17]]], ["Surgeons report favorable outcomes following one-staged circumferential fusion in good surgical candidates.", [["one-staged circumferential fusion", "TREATMENT", 45, 78], ["circumferential", "OBSERVATION_MODIFIER", 56, 71], ["fusion", "OBSERVATION", 72, 78], ["good surgical", "OBSERVATION", 82, 95]]], ["Our patient did not undergo initial circumferential fusion.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["initial circumferential fusion", "TREATMENT", 28, 58], ["circumferential", "OBSERVATION_MODIFIER", 36, 51], ["fusion", "OBSERVATION", 52, 58]]], ["In hindsight, he may have benefited from this approach due to extensive spinal disease and co-morbidities.", [["spinal", "ANATOMY", 72, 78], ["spinal disease", "DISEASE", 72, 86], ["spinal", "ORGAN", 72, 78], ["this approach", "TREATMENT", 41, 54], ["extensive spinal disease", "PROBLEM", 62, 86], ["co-morbidities", "PROBLEM", 91, 105], ["spinal", "ANATOMY", 72, 78], ["disease", "OBSERVATION", 79, 86]]], ["Further research is necessary to decrease morbidity in CAS patients and establish a consensus for surgical management.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["surgical management", "TREATMENT", 98, 117]]]], "32c78d459b21773d5dc8cd438f77b8b02d9e18e9": [["Accepted ArticleMicroglia are the resident immune cells of the brain; they play a major role in the neuroinfilammatory process with a high phagocytic capacity 10 .", [["immune cells", "ANATOMY", 43, 55], ["brain", "ANATOMY", 63, 68], ["ArticleMicroglia", "GENE_OR_GENE_PRODUCT", 9, 25], ["immune cells", "CELL", 43, 55], ["brain", "ORGAN", 63, 68], ["resident immune cells", "CELL_TYPE", 34, 55], ["a high phagocytic capacity", "PROBLEM", 132, 158], ["immune cells", "OBSERVATION", 43, 55], ["brain", "ANATOMY", 63, 68], ["high phagocytic capacity", "OBSERVATION", 134, 158]]], ["It has been shown that reduction of \u03b1-syn expression level in microglia highly increases their response to lipopolysaccharides, while it decreases their phagocytic ability 11 .", [["microglia", "ANATOMY", 62, 71], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 36, 41], ["microglia", "CELL", 62, 71], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 107, 126], ["\u03b1-syn", "PROTEIN", 36, 41], ["microglia", "CELL_TYPE", 62, 71], ["\u03b1-syn expression level in microglia", "PROBLEM", 36, 71], ["lipopolysaccharides", "TREATMENT", 107, 126], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["\u03b1-syn expression", "OBSERVATION", 36, 52]]], ["This is a consequence of overactivation of phospholipase D2 and COX-2, which suggests that \u03b1-syn is implicated in lipid-mediated signaling by microglia 12 .", [["phospholipase D2", "GENE_OR_GENE_PRODUCT", 43, 59], ["COX-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 91, 96], ["lipid", "SIMPLE_CHEMICAL", 114, 119], ["microglia", "CELL", 142, 151], ["phospholipase D2", "PROTEIN", 43, 59], ["COX-2", "PROTEIN", 64, 69], ["\u03b1-syn", "PROTEIN", 91, 96], ["overactivation of phospholipase D2", "PROBLEM", 25, 59], ["COX", "TEST", 64, 67]]], ["Moreover, \u03b1-syn may be an activating extracellular ligand for microglia 12 .", [["extracellular", "ANATOMY", 37, 50], ["microglia", "ANATOMY", 62, 71], ["\u03b1-syn", "CHEMICAL", 10, 15], ["\u03b1-syn", "GENE_OR_GENE_PRODUCT", 10, 15], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["microglia", "CELL", 62, 71], ["\u03b1-syn", "PROTEIN", 10, 15], ["extracellular ligand", "OBSERVATION", 37, 57]]], ["This support the findings mentioned above in relation to its neuroprotective effect 3 .Accepted ArticleThe COVID-19 can infect neurons and cause disease 13 .", [["neurons", "ANATOMY", 127, 134], ["COVID-19", "CHEMICAL", 107, 115], ["COVID-19", "GENE_OR_GENE_PRODUCT", 107, 115], ["neurons", "CELL", 127, 134], ["COVID-19", "DNA", 107, 115], ["The COVID", "TEST", 103, 112], ["disease", "PROBLEM", 145, 152]]], ["It has been shown that it induce neurological diseases such as polyneuropathy,encephalitis, aortic ischemic stroke, and other neurological diseases 14, 15 .", [["neurological", "ANATOMY", 33, 45], ["aortic", "ANATOMY", 92, 98], ["neurological", "ANATOMY", 126, 138], ["neurological diseases", "DISEASE", 33, 54], ["polyneuropathy", "DISEASE", 63, 77], ["encephalitis", "DISEASE", 78, 90], ["aortic ischemic stroke", "DISEASE", 92, 114], ["neurological diseases", "DISEASE", 126, 147], ["aortic", "MULTI-TISSUE_STRUCTURE", 92, 98], ["neurological diseases", "PROBLEM", 33, 54], ["polyneuropathy", "PROBLEM", 63, 77], ["encephalitis", "PROBLEM", 78, 90], ["aortic ischemic stroke", "PROBLEM", 92, 114], ["other neurological diseases", "PROBLEM", 120, 147], ["polyneuropathy", "OBSERVATION", 63, 77], ["encephalitis", "OBSERVATION", 78, 90], ["aortic", "ANATOMY", 92, 98], ["ischemic", "OBSERVATION_MODIFIER", 99, 107], ["stroke", "OBSERVATION", 108, 114]]], ["Neurological manifestations of COVID-19 infection have been classified into two categories: CNS and PNS manifestations.Accepted ArticleCNS symptoms include dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and epilepsy.", [["Neurological", "ANATOMY", 0, 12], ["CNS", "ANATOMY", 92, 95], ["PNS", "ANATOMY", 100, 103], ["cerebrovascular", "ANATOMY", 207, 222], ["infection", "DISEASE", 40, 49], ["dizziness", "DISEASE", 156, 165], ["headache", "DISEASE", 167, 175], ["impaired consciousness", "DISEASE", 177, 199], ["acute cerebrovascular disease", "DISEASE", 201, 230], ["ataxia", "DISEASE", 232, 238], ["epilepsy", "DISEASE", 244, 252], ["CNS", "ANATOMICAL_SYSTEM", 92, 95], ["PNS", "ANATOMICAL_SYSTEM", 100, 103], ["COVID-19 infection", "PROBLEM", 31, 49], ["PNS manifestations", "PROBLEM", 100, 118], ["ArticleCNS symptoms", "PROBLEM", 128, 147], ["dizziness", "PROBLEM", 156, 165], ["headache", "PROBLEM", 167, 175], ["impaired consciousness", "PROBLEM", 177, 199], ["acute cerebrovascular disease", "PROBLEM", 201, 230], ["ataxia", "PROBLEM", 232, 238], ["epilepsy", "PROBLEM", 244, 252], ["CNS", "ANATOMY", 92, 95], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["cerebrovascular disease", "OBSERVATION", 207, 230], ["ataxia", "OBSERVATION", 232, 238], ["epilepsy", "OBSERVATION", 244, 252]]], ["However, PNS symptoms are less severe and include hyposmia, hypoplasia, neuralgia, and hypogeusia 16 .Accepted ArticleTaken together, the evidence shown above suggests that overexpression of \u03b1syn in patients suffering from PD might prevent neuroinvasion by the coronavirus, possibly by inhibiting the spread of the virus from the PNS to the CNS.", [["PNS", "ANATOMY", 9, 12], ["PNS", "ANATOMY", 330, 333], ["CNS", "ANATOMY", 341, 344], ["hyposmia", "DISEASE", 50, 58], ["hypoplasia", "DISEASE", 60, 70], ["neuralgia", "DISEASE", 72, 81], ["hypogeusia", "DISEASE", 87, 97], ["\u03b1syn", "CHEMICAL", 191, 195], ["PD", "DISEASE", 223, 225], ["neuroinvasion", "DISEASE", 240, 253], ["coronavirus", "DISEASE", 261, 272], ["\u03b1syn", "GENE_OR_GENE_PRODUCT", 191, 195], ["patients", "ORGANISM", 199, 207], ["coronavirus", "ORGANISM", 261, 272], ["PNS", "ANATOMICAL_SYSTEM", 330, 333], ["CNS", "ANATOMICAL_SYSTEM", 341, 344], ["\u03b1syn", "PROTEIN", 191, 195], ["patients", "SPECIES", 199, 207], ["PNS symptoms", "PROBLEM", 9, 21], ["hyposmia", "PROBLEM", 50, 58], ["hypoplasia", "PROBLEM", 60, 70], ["neuralgia", "PROBLEM", 72, 81], ["hypogeusia", "PROBLEM", 87, 97], ["overexpression of \u03b1syn", "PROBLEM", 173, 195], ["PD", "PROBLEM", 223, 225], ["neuroinvasion", "PROBLEM", 240, 253], ["the coronavirus", "PROBLEM", 257, 272], ["the virus", "PROBLEM", 311, 320], ["hyposmia", "OBSERVATION", 50, 58], ["hypoplasia", "OBSERVATION", 60, 70], ["neuralgia", "OBSERVATION", 72, 81], ["coronavirus", "OBSERVATION", 261, 272], ["CNS", "ANATOMY", 341, 344]]], ["Consistent with this hypothesis, a retrospective cohort study conducted in Japan showed that patients with Parkinsonism hospitalized for pneumonia had a lower rate of in-hospital mortality 17 .", [["Parkinsonism", "DISEASE", 107, 119], ["pneumonia", "DISEASE", 137, 146], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["this hypothesis", "PROBLEM", 16, 31], ["a retrospective cohort study", "TEST", 33, 61], ["Parkinsonism", "PROBLEM", 107, 119], ["pneumonia", "PROBLEM", 137, 146], ["pneumonia", "OBSERVATION", 137, 146]]], ["This hypothesis can be confirmed by using a large cohort of PD patients experiencing a severe acute respiratory syndrome due to infection with the coronavirus.Accepted ArticleThis article is protected by copyright.", [["PD", "DISEASE", 60, 62], ["acute respiratory syndrome", "DISEASE", 94, 120], ["infection", "DISEASE", 128, 137], ["coronavirus", "DISEASE", 147, 158], ["patients", "ORGANISM", 63, 71], ["coronavirus", "ORGANISM", 147, 158], ["patients", "SPECIES", 63, 71], ["a large cohort of PD", "TREATMENT", 42, 62], ["a severe acute respiratory syndrome", "PROBLEM", 85, 120], ["infection", "PROBLEM", 128, 137], ["the coronavirus", "PROBLEM", 143, 158], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory syndrome", "OBSERVATION", 100, 120], ["infection", "OBSERVATION", 128, 137]]]]}